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Background: Owing to the increasing prevalence of diabetes, the workload related to diabetic macular
oedema and proliferative diabetic retinopathy is rising, making it difficult for hospital eye services to
meet demands.
Objective: The objective was to evaluate the diagnostic performance, cost-effectiveness and
acceptability of a new pathway using multimodal imaging interpreted by ophthalmic graders to detect
reactivation of diabetic macular oedema/proliferative diabetic retinopathy in previously treated patients.
Design: This was a prospective, case-referent, cross-sectional diagnostic study.
Setting: The setting was ophthalmic clinics in 13 NHS hospitals.
Participants: Adults with type 1 or type 2 diabetes with previously successfully treated diabetic
macular oedema/proliferative diabetic retinopathy in one/both eyes in whom, at the time of enrolment,
diabetic macular oedema/proliferative diabetic retinopathy could be active or inactive.
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Methods: For the ophthalmic grader pathway, review of the spectral domain optical coherence tomography
scans to detect diabetic macular oedema, and seven-field Early Treatment Diabetic Retinopathy Study/ultra-
wide field fundus images to detect proliferative diabetic retinopathy, by trained ophthalmic graders. For the
current standard care pathway (reference standard), ophthalmologists examined patients face to face by
slit-lamp biomicroscopy for proliferative diabetic retinopathy and, in addition, spectral domain optical
coherence tomography imaging for diabetic macular oedema.
Outcome measures: The primary outcome measure was sensitivity of the ophthalmic grader pathway
to detect active diabetic macular oedema/proliferative diabetic retinopathy. The secondary outcomes
were specificity, agreement between pathways, cost–consequences, acceptability and the proportion
of patients requiring subsequent ophthalmologist assessment, unable to undergo imaging and with
inadequate quality images/indeterminate findings. It was assumed for the main analysis that all patients
in whom graders diagnosed active disease or were ‘unsure’ or images were ‘ungradable’ required
examination by an ophthalmologist.
Results: Eligible participants with active and inactive diabetic macular oedema (152 and 120 participants,
respectively) and active and inactive proliferative diabetic retinopathy (111 and 170 participants,
respectively) were recruited. Under the main analysis, graders had a sensitivity of 97% (142/147)
(95% confidence interval 92% to 99%) and specificity of 31% (35/113) (95% confidence interval 23%
to 40%) to detect diabetic macular oedema. For proliferative diabetic retinopathy, graders had a similar
sensitivity and specificity using seven-field Early Treatment Diabetic Retinopathy Study [sensitivity 85%
(87/102), 95% confidence interval 77% to 91%; specificity 48% (77/160), 95% confidence interval 41%
to 56%] or ultra-wide field imaging [sensitivity 83% (87/105), 95% confidence interval 75% to 89%;
specificity 54% (86/160), 95% confidence interval 46% to 61%]. Participants attending focus groups
expressed preference for face-to-face evaluations by ophthalmologists. In the ophthalmologists’ absence,
patients voiced the need for immediate feedback following grader’s assessments, maintaining periodic
evaluations by ophthalmologists. Graders and ophthalmologists were supportive of the new pathway.
When compared with the reference standard (current standard pathway), the new grader pathway
could save £1390 per 100 patients in the review of people with diabetic macular oedema and, depending
on the imaging modality used, between £461 and £1189 per 100 patients in the review of people with
proliferative diabetic retinopathy.
Conclusions: For people with diabetic macular oedema, the ophthalmic grader pathway appears safe
and cost saving. The sensitivity of the new pathway to detect active proliferative diabetic retinopathy
was lower, but may still be considered acceptable for patients with proliferative diabetic retinopathy
previously treated with laser. Suggestions from focus group discussions should be taken into consideration
if the new pathway is introduced to ensure its acceptability to users.
Limitations: Lack of fundus fluorescein angiography to confirm diagnosis of active proliferative diabetic
retinopathy.
Future work: Could refinement of the new pathway increase its sensitivity to detect proliferative
diabetic retinopathy? Could artificial intelligence be used for automated reading of images in this
previously treated population?
Trial registration: Current Controlled Trials ISRCTN10856638 and ClinicalTrials.gov NCT03490318.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment
Vol. 25, No. 32. See the NIHR Journals Library website for further project information.
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More and more people are developing diabetes. Diabetic macular oedema and proliferativediabetic retinopathy are complications of diabetes, which could cause blindness. Thus, people
with diabetic macular oedema and proliferative diabetic retinopathy need to be treated in a timely
manner and reviewed in clinic for life.
The population in the world is ageing. As a result, there are more people with eye diseases. There are
also more treatments now for people with eye diseases. The workload in hospitals is increasing, making
it difficult for the NHS to cope with the demand. There are not enough ophthalmologists (eye doctors)
to look after patients. Delayed appointments and treatment mean that patients may lose sight.
The goal of EMERALD (Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And
new vesseLs in Diabetic retinopathy) was to see if patients with treated and stable diabetic macular
oedema or proliferative diabetic retinopathy could be followed by ‘ophthalmic graders’, who are not
doctors but are trained to diagnose diabetic macular oedema and proliferative diabetic retinopathy.
In EMERALD, trained ophthalmic graders examined photographs of the back of the eye of people with
diabetic macular oedema and proliferative diabetic retinopathy. They checked if diabetic macular
oedema and proliferative diabetic retinopathy remain inactive. If so, patients could continue follow-up
with the ophthalmic graders. If diabetic macular oedema or proliferative diabetic retinopathy were
active, graders would immediately refer patients to ophthalmologists.
EMERALD found that graders were excellent at detecting diabetic macular oedema, and this could
give ophthalmologists time to see other patients. Graders were not quite as good at detecting active
proliferative diabetic retinopathy. However, considering that patients had already had treatment, this
may still be safe. Patients participating in focus group discussions mentioned that they would prefer
to see ophthalmologists, so they could ask questions about their eye condition. If this was not possible,
they would like to have immediate results from graders and still see the ophthalmologist from time
to time.
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Diabetic retinopathy is a leading cause of sight loss in people of working age. Patients with diabetic
retinopathy may lose sight from diabetic macular oedema and/or proliferative diabetic retinopathy.
In diabetic macular oedema fluid accumulates at the macula, the retinal area responsible for central sight,
with subsequent central visual loss (e.g. that required for reading). In proliferative diabetic retinopathy
abnormal ‘new vessels’ grow in the retina and may rupture causing a vitreous haemorrhage or scarring
that could lead to a tractional retinal detachment. Vitreous haemorrhage and tractional retinal detachment
cause loss of central and peripheral vision. Owing to increasing numbers of people with diabetes,
it is expected that the burden of diabetic retinopathy will continue to rise, despite improvements
in glycaemic control and screening for retinopathy having reduced the risk of advanced retinopathy.
The estimated prevalence of diabetic macular oedema and proliferative diabetic retinopathy is
similar, at ≈ 7%. Considering the prevalence of diabetes in UK (≈ 3.9 million in 2019), a minimum of
273,000 people have diabetic macular oedema and proliferative diabetic retinopathy in the UK.
Diabetic macular oedema is treated with macular laser photocoagulation (when the central retinal
thickness, measured by spectral domain optical coherence tomography, is < 400 µm) or intravitreal
injections of antivascular endothelial growth factor therapies (when the central retinal thickness is
≥ 400 µm). Patients should be followed up every 3–4 months after laser treatment. After antivascular
endothelial growth factors, patients should usually be followed up monthly during the first year of
treatment and every 1–3 months thereafter, as diabetic macular oedema can recur.
Proliferative diabetic retinopathy is currently treated with laser panretinal photocoagulation.
After treatment, patients are followed up at 4- to 6-month intervals for life, as proliferative diabetic
retinopathy can recur and vitreous haemorrhage/tractional retinal detachment could still occur. A high
proportion of patients followed up in Hospital Eye Services have treated and inactive proliferative
diabetic retinopathy.
Currently in the NHS, ophthalmologists assess patients during follow-up visits. At each visit, patients with
diabetic macular oedema/proliferative diabetic retinopathy receive a visual acuity test, often undertaken
by a nurse; Spectral Domain Optical Coherence Tomography obtained by a photographer/imaging technician;
and fundus examination by slit-lamp biomicroscopy by an ophthalmologist. Based on slit-lamp biomicroscopy
and Spectral Domain Optical Coherence Tomography, the ophthalmologist determines whether or not
diabetic macular oedema is present; based on slit-lamp biomicroscopy the ophthalmologist determines
if there is active proliferative diabetic retinopathy. Spectral Domain Optical Coherence Tomography is
non-invasive, safe and fast, obtaining scans of the macula. Fundus (retinal) photographs or fundus fluorescein
angiography are not routinely carried out to determine the activity of proliferative diabetic retinopathy, but
they are used in selected patients. Fundus fluorescein angiography requires injection of a dye into a
peripheral vein. Images are taken as the dye circulates in the retina. Standard cameras used to obtain
fundus photographs and fundus fluorescein angiography cannot image the retinal periphery, but newer
ultra-wide field imaging captures nearly the entire retina in a single image.
The large number of people with diabetic macular oedema/proliferative diabetic retinopathy and the
need for patients to be followed up at short intervals is making it difficult for the NHS to cope, especially
because of a shortage of ophthalmologists. Difficulties will increase given the increasing prevalence of
diabetes. Identifying new ways to increase NHS capacity/efficiency without compromising quality of care
is essential. EMERALD (Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And
new vesseLs in Diabetic retinopathy) was planned with this in mind.
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Objective
The objective was to determine whether or not patients with successfully treated diabetic macular
oedema/proliferative diabetic retinopathy could be followed through a new care pathway involving
multimodal retinal imaging and image assessment by trained ophthalmic graders. Diagnostic accuracy,
cost-effectiveness and acceptability of this new pathway to patients and health-care professionals were
evaluated against the current standard of care.
Methods
Design
This was a prospective, case-referent, cross-sectional diagnostic study.
Setting
This was carried out in specialist Hospital Eye Services.
Participants
Adults with diabetes, with previously successfully treated diabetic macular oedema/proliferative
diabetic retinopathy in one/both eyes; at the time of enrolment, diabetic macular oedema/proliferative
diabetic retinopathy could be active or inactive.
Clinical pathways assessed
New pathway: multimodal imaging (Spectral Domain Optical Coherence Tomography to detect diabetic
macular oedema; seven-field Early Treatment Diabetic Retinopathy Study and ultra-wide field fundus
images to detect proliferative diabetic retinopathy) with subsequent review by trained, tested and
certified ophthalmic graders.
Standard care pathway: ophthalmologist examining patients in clinic as per current standard practice
(for diabetic macular oedema slit-lamp biomicroscopy examination and Spectral Domain Optical
Coherence Tomography; for proliferative diabetic retinopathy slit-lamp biomicroscopy examination).
Outcomes
The primary outcome was sensitivity of the new pathway to detect active diabetic macular oedema/
proliferative diabetic retinopathy.
The secondary outcomes were specificity, concordance, cost-effectiveness, acceptability of the new
pathway to patients and health-care professionals, proportions of patients requiring subsequent
assessment by ophthalmologist, unable to undergo imaging and with images of inadequate quality for
interpretation.
EMERALD patient flow
Patients with previously treated diabetic macular oedema/proliferative diabetic retinopathy were
identified from clinical records, electronic databases or in clinic. At their review appointment, an
ophthalmologist confirmed patient eligibility, obtained informed consent and determined whether or
not active/inactive diabetic macular oedema/proliferative diabetic retinopathy was present (reference
standard). Visual acuity, Spectral Domain Optical Coherence Tomography and fundus examination were
carried out as per routine standard practice. In some participating sites patients were evaluated in
‘research’ clinics, and in others they were evaluated in usual NHS clinics.
Non-stereoscopic seven-field Early Treatment Diabetic Retinopathy Study and ultra-wide angle fundus
images were obtained, anonymised, uploaded to a central facility and allocated randomly to ophthalmic
graders. Graders did not grade images from their own centre (to ensure masking to the reference standard).
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Graders did not grade both seven-field Early Treatment Diabetic Retinopathy Study and ultra-wide fundus
images from the same patient (to prevent the grading of one technology influencing the grading of the
other). Graders judged whether there was active/inactive diabetic macular oedema/proliferative diabetic
retinopathy or if they were uncertain.
Given the possibility of new vessels not being seen by the ophthalmologist on slit-lamp biomicroscopy
but detected on photographs, EMERALD also evaluated an ‘enhanced’ reference standard for
proliferative diabetic retinopathy consisting of the reference standard supplemented by evaluation of
seven-field Early Treatment Diabetic Retinopathy Study and ultra-wide field fundus images reviewed
by an ophthalmologist expert in diabetic retinopathy. If active proliferative diabetic retinopathy was
detected by one of these three methods, it was considered that the enhanced reference standard
identified active proliferative diabetic retinopathy. Seven-field Early Treatment Diabetic Retinopathy
Study and ultra-wide field images of the same participant were reviewed by different ophthalmologists,
who did not grade images from their own centre.
Focus groups
To determine acceptability of the new pathway to patients and health professionals, focus group
discussions were undertaken.
Sample size and statistical analysis
The sample size was based on the number of patients with reactivated (active) diabetic macular
oedema and proliferative diabetic retinopathy which would enable sensitivity to be tested against a
pre-specified target level of 80%, considered the minimum acceptable level for the ophthalmic grader’s
pathway. A lower specificity was thought acceptable; a target of 65% was used to confirm sufficiency
of the sample size for assessing specificity. To detect sensitivity of the new pathway with 80% and
90% power (10% and 12% higher than the 80% minimal target set) required 89 participants with
each diabetic macular oedema and PDR that had reactivated, with two-sided 5% significance level.
Ninety-three participants whose disease had not reactivated would enable a specificity of 80% to be
detected with 90% power. A 95% confidence interval for photographer sensitivity and specificity would
have a confidence interval (Wilson method) with a width of 10–20%, depending on the observed level.
Allowing for 10% missing/indeterminate results, 104 individuals with each active and inactive diabetic
macular oedema and active and inactive proliferative diabetic retinopathy were required.
Separate analyses were planned for diabetic macular oedema and proliferative diabetic retinopathy.
Participants were categorised as having active or inactive diabetic macular oedema/proliferative diabetic
retinopathy according to the reference standard, at the person level. Those with previously successfully
treated diabetic macular oedema/proliferative diabetic retinopathy constitute ‘eligible’ participants for
each analysis (diabetic macular oedema/proliferative diabetic retinopathy) for the new pathway. This
person-based assessment reflects the consequences of the clinical decision. The diagnostic performance
of the new pathway was quantified against the reference standard. Reflecting how the new pathway
would function in practice, ‘unsure’, ‘ungradable’ and ‘active’ classifications required ‘referral’ and
examination by an ophthalmologist under the main analyses.
Planned sensitivity analyses included (1) assessment of the impact of ‘unsure’ and ‘ungradable’ on
the diagnostic performance of the ophthalmic grader; (2) using the ophthalmologist’s decision to do
further treatment, rather than presence of active disease; (3) detection of more severe disease
(central-involving diabetic macular oedema, pre-retinal or vitreous haemorrhage in proliferative
diabetic retinopathy); (4) diagnostic performance within routine NHS clinics (vs. ‘research’ clinics);
and (5) for proliferative diabetic retinopathy only, diagnostic performance of the ophthalmic grader
against the ‘enhanced’ reference standard. The impact of using ultra-wide field versus seven-field
Early Treatment Diabetic Retinopathy Study images on the diagnostic performance of the new pathway
was assessed under the principal analyses for proliferative diabetic retinopathy using both reference
standard and enhanced reference standard. Additional analyses were carried out in the proliferative
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diabetic retinopathy group to aid understanding findings from pre-planned analyses. Agreement
between proliferative diabetic retinopathy assessment methods was quantified.
Secondary analyses included evaluation of eye level data; analysis including all patients (with or without
diabetic macular oedema/proliferative diabetic retinopathy); assessment of the overall referral (diabetic
macular oedema and proliferative diabetic retinopathy); and use of visual acuity as a proxy to detect
active disease.
Analyses were carried out using Stata® version 15 (StataCorp LP, College Station, TX, USA). A statistical
analysis plan was agreed and made accessible on the EMERALD website and the EMERALD protocol
published prior to data analysis.
Health economic evaluation
Costs of ophthalmic grader and standard pathways were prospectively obtained, including collection
of time costs for each procedure. It was hypothesised that the new pathway would have the same
sensitivity as the standard care pathway but at lower cost, making the analysis a cost–consequences
one, including assessment of ophthalmologist time released by the new pathway. Diabetic macular
oedema and proliferative diabetic retinopathy were assessed separately. If there was marginal loss in
sensitivity in the new pathway, a cost-effectiveness analysis was planned in which the disutility of the
visual impact of the marginal loss would be assessed against costs saved. If there was an unacceptably
low sensitivity for proliferative diabetic retinopathy, no modelling would be done.
Results
Three-hundred and ninety-seven participants, 272 eligible with diabetic macular oedema (152 active
diabetic macular oedema and 120 inactive diabetic macular oedema) and 281 eligible with proliferative
diabetic retinopathy (111 active proliferative diabetic retinopathy and 170 inactive proliferative diabetic
retinopathy) were recruited. Most eligible participants with diabetic macular oedema were white
(n = 240, 88%), male (n = 175, 64%) and over half were aged ≥ 60 years (n = 159, 58%). Most eligible
participants with proliferative diabetic retinopathy were white (n = 234, 83%), male (n = 185, 66%) and
slightly less than half (n = 133, 47%) were aged ≥ 60 years.
Under the main analysis of diabetic macular oedema (grader referring patient to ophthalmologists
due to presence of active diabetic macular oedema or unsure or ungradable), graders had a sensitivity
of 97% (142/147; 95% confidence interval 92% to 99%) with a specificity of 31% (35/113; 95%
confidence interval 23% to 40%) when compared with the reference standard. Similar results were
obtained for analysis evaluating people with diabetic macular oedema requiring further treatment
(sensitivity 95%; 81/85, 95% confidence interval 89% to 98%; specificity 21%; 36/175, 95% confidence
interval 15% to 27%) and those with central-involving diabetic macular oedema (sensitivity 94%;
121/129, 95% confidence interval 88% to 97%; specificity 56%; 72/128, 95% confidence interval
48% to 65%). Results were similar to those of the main analysis when only referral for active diabetic
macular oedema was considered (i.e. excluding the ‘unsure’ and ‘ungradable’) and when patients were
assessed in NHS clinics (vs. ‘research’ clinics).
Under the main analysis of proliferative diabetic retinopathy (grader referring patients to ophthalmologists
due to presence of active proliferative diabetic retinopathy or unsure or ungradable), graders had similar
sensitivity and specificity whether they used seven-field Early Treatment Diabetic Retinopathy Study
(sensitivity 85%; 87/102, 95% confidence interval 77% to 91%; specificity 48%; 77/160, 95% CI 41% to
56%) or ultra-wide field (sensitivity 83%; 87/105, 95% confidence interval 75% to 89%; specificity 54%;
86/160, 95% CI 46% to 61%) images. Sensitivity and specificity were similar when grading patients
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requiring further treatment (for seven-field Early Treatment Diabetic Retinopathy Study images: sensitivity
of 88%; 74/84, 95% confidence interval 79% to 93%; specificity 46%; 82/178, 95% confidence interval
39% to 53%; for ultra-wide field images sensitivity of 86%; 77/90, 95% confidence interval 77% to 91%;
specificity 52%; 91/175, 95% confidence interval 45% to 59%). Sensitivity and specificity of the graders to
detect more severe disease (proliferative diabetic retinopathy with pre-retinal or vitreous haemorrhage)
were slightly higher when using ultra-wide field imaging (sensitivity 87%; 62/71, 95% confidence interval
78% to 93%; specificity 49%; 95/193, 95% confidence interval 42% to 56%; for seven-field Early Treatment
Diabetic Retinopathy Study sensitivity 80%; 53/66, 95% confidence interval 69% to 88%; specificity 40%;
79/196, 95% confidence interval 34% to 47%). Results against the enhanced reference standard were
similar to those against the reference standard (for seven-field Early Treatment Diabetic Retinopathy
Study images, sensitivity of 82%; 111/135, 95% confidence interval 75% to 88%; specificity 54%; 68/127,
95% confidence interval 45% to 62%; for ultra-wide field images sensitivity 80%; 110/138, 95% confidence
interval 72% to 86%; specificity 60%; 76/127, 95% confidence interval 51% to 68%). Findings were similar
whether patients were assessed in NHS or ‘research’ clinics. Sensitivity and specificity, however, were
lower when considering referrals due to active proliferative diabetic retinopathy only (i.e. excluding
‘unsure’ and ‘ungradable’).
Thirty-six participants attended ten focus groups in Northern Ireland (n = 4), Scotland (n = 2) and England
(n = 4). Participants preferred face-to-face evaluations by ophthalmologists, where information about their
eye condition could be received and anxieties assuaged. In the absence of ophthalmologists, participants
voiced the need for immediate results from the grader’s reading of images. Patients wanted periodic
evaluation by ophthalmologists, even if at longer intervals. Patients are uncertain of the professional
identity, training and performance of graders. Graders and ophthalmologists were supportive of the new
pathway, but graders expressed caution about their ability to answer potential questions from patients
unrelated to the activity of their disease.
The cost–consequences analysis, in monetary terms, showed that for diabetic macular oedema, where
sensitivity was very good, the cost-difference (savings) for the grader’s pathway would be £1390 per
100 patients. For proliferative diabetic retinopathy, if sensitivity was considered acceptable, the cost
would be reduced by £461 for seven-field Early Treatment Diabetic Retinopathy Study images and by
£1889 for ultra-wide field images, per 100 patients. The difference arises because ultra-wide images
require less time to be obtained and read than seven-field Early Treatment Diabetic Retinopathy Study.
Conclusions
The sensitivity of the new grader’s pathway to determine diabetic macular oedema was 94% or above
in all analyses suggesting that, for diabetic macular oedema, the new ophthalmic grader pathway would
be safe. The sensitivity to determine proliferative diabetic retinopathy was 80% or above in all planned
analyses with one exception (referrals for active proliferative diabetic retinopathy only, excluding
‘unsure’ and ‘ungradable’). This level of sensitivity, although potentially less than ideal, may be acceptable
for patients previously treated with laser panretinal photocoagulation, for whom this new pathway is
being proposed. Where waiting targets are not achieved and people with serious eye conditions are
waiting longer than acceptable, this new pathway would be reasonable and justified. Ultra-wide field
imaging had slightly higher sensitivity to detect proliferative diabetic retinopathy with pre-retinal/
vitreous haemorrhage (i.e. high-risk) and was less costly than seven-field Early Treatment Diabetic
Retinopathy Study, thus, would be the preferred option. Despite the relatively low specificity of the
new ophthalmic grader pathway, this pathway would save ophthalmologists’ time that could then be
redirected to a more timely evaluation and treatment of patients requiring urgent care, which would
likely be sight-saving for many patients. Recommendations from the focus groups should be followed
if the new pathway is to be introduced to ensure acceptability to users.
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Recommendations for future research
For proliferative diabetic retinopathy, a pilot study could be run prior to its widespread implementation
in the NHS, to further ensure its safety. Measures to further improve the sensitivity of this pathway
(e.g. providing continuous feedback to graders, selecting patients entering the pathway, enhancing
resolution of screens used to view images) could be introduced and evaluated.
Could artificial intelligence be used for automated reading of images in this previously treated
population?
Trial registration
This trial is registered as ISRCTN10856638 and ClinicalTrials.gov NCT03490318.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment Vol. 25, No. 32.
See the NIHR Journals Library website for further project information.
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Chapter 1 Background
Parts of this report have been reproduced with permission from our published protocol: Lois et al.1This is an open access article distributed in accordance with the Creative Commons Attribution 4.0
Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build
upon this work for any purpose, provided the original work is properly cited, a link to the licence is
given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
The text includes minor additions and formatting changes to the original text.
Parts of this report have been reproduced from Lois et al.2 This is an open access article distributed in
accordance with the terms of the Creative Commons Attribution 4.0 (CC BY-NC-ND 4.0) license, which
permits others to copy and redistribute the material in any medium or format, provided the original
work is properly cited. See: https://creativecommons.org/licenses/by/4.0/
Diabetic retinopathy (DR) is the most common microvascular complication of diabetes and a leading cause
of sight loss in people of working age.3 Patients with DR may lose their vision as a result of the development
of diabetic macular oedema (DMO) and/or proliferative diabetic retinopathy (PDR), which are the major
complications of DR. DMO and PDR can happen in the same person and even in the same eye.
Diabetic macular oedema
Diabetic macular oedema is caused by the accumulation of fluid, often accompanied by lipid (and occasionally
blood), in the central part of the retina, the macula, which is responsible for the generation of detailed central
vision.Thus, DMO results in people progressively losing central sight and experiencing difficulties reading,
recognising faces and doing any work for which detailed central vision is required (Figure 1).
In 2010, the prevalence of DMO in England was estimated to be 7% of all people with diabetes.4 An
individual participant data meta-analysis that included 22,896 individuals from 35 studies conducted in
Asia, Australia, Europe and the USA found a very similar estimate of prevalence of DMO, with an overall
age-standardised prevalence of 6.8%.5 Based on these estimates and considering the prevalence of diabetes
in the UK,6 it can be presumed that there are a minimum of 273,000 people in the UK affected by DMO.
In the UK, treatments for DMO include focal or grid macular laser, eye injections of anti-vascular
endothelial growth factor (anti-VEGF) therapies and eye injections of steroids. All treatments aim to dry
the macula and improve or maintain vision. Macular laser is advised and offered when the central retinal
thickness (CRT), measured by means of spectral domain optical coherence tomography (SD-OCT) is
< 400 µm, which may be considered mild DMO. Patients in whom there is drop-out of perifoveal
capillaries contiguous to the area of leakage causing DMO, as determined by fundus fluorescein
angiography, are not good candidates for macular laser. Patients with more severe DMO (CRT on SD-OCT
of ≥ 400 µm) are eligible to receive anti-VEGFs; currently, the anti-VEGFs approved by the NHS are
ranibizumab (Lucentis®; Novartis Pharmaceuticals UK Ltd, London, UK) and aflibercept (Eylea®; Bayer plc,
Reading, UK) (Figure 2).7,8 Bevacizumab (Avastin®; Genentech Inc., South San Francisco, CA, USA) is also
available off label. Intraocular steroids are reserved for patients with DMO who do not respond to
macular laser or anti-VEGFs and are pseudophakic (i.e. have had their cataracts removed).9
Macular laser is delivered in a single session. Re-treatments may be required to clear DMO and are
usually given at no earlier than 3- to 4-month intervals. Anti-VEGF injections are given monthly until
the macula is dry (i.e. DMO clears). Once patients have been treated successfully (i.e. DMO is no
longer present), long-term follow-up is required, as DMO may recur. Typically, once dried, patients
are followed up every 3–4 months following laser treatment for DMO; patients are followed up
monthly initially and every 1–3 months thereafter following treatment with anti-VEGFs.10 Follow-up
continues for the rest of the patient’s life.
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Currently in the NHS, patients with previously treated DMO are evaluated in clinic during follow-up
appointments with ophthalmologists who have expertise in retinal diseases, even if DMO is no longer
present. At each visit, patients receive a visual acuity test, which is most often undertaken by a nurse or
a visual acuity technician, before having a SD-OCT scan, obtained by a photographer or by an imaging
technician, and then being seen by an ophthalmologist. The ophthalmologist checks the back of the eye
using slit-lamp biomicroscopy and, most often, a non-contact fundus lens, and determines, also using
SD-OCT scans, whether DMO is present or absent (Figure 3). SD-OCT is a non-invasive, user-friendly,
fast and safe imaging technology that obtains scans of the back of the eye. SD-OCT allows the CRT to
be measured (which is often increased when DMO is present) and visualises fluid in the retina, which is
the hallmark of DMO (see Figures 1 and 2). SD-OCT has been extensively used in clinical trials and
clinical practice to determine the presence of DMO, select treatment and monitor the patient’s response
to treatment.11–16
Proliferative diabetic retinopathy
In PDR, abnormal, newly formed blood vessels (‘new vessels’) grow on the optic nerve head [the
so-called new vessels in the disc (NVD)] and/or on the surface of the retina [the so-called new vessels
elsewhere (NVE)] and towards the inside of the eye (i.e. the vitreous cavity) (Figure 4). These blood vessels
may bleed, causing what is called a vitreous haemorrhage. They can also lead to the formation of scarring
FIGURE 1 Spectral domain-optical coherence tomography in DMO. Fundus image (left) and spectral-domain optical
coherence tomography scan (right) of the left eye of an individual with diabetes and DMO (top) and, for comparison, of
someone with diabetes but no DMO (bottom). Lipid (the so-called ‘hard exudates’) (arrowheads; hard exudates appear
as white areas on the images) and fluid (arrows; fluid appears as black areas on the image) are present in DMO (top).
The normal structure of the macula (the central area of the retina, marked approximately with the circle on the bottom
image, left) and of the fovea (the central area of the macula, marked approximately with a circle in the bottom image,
right) is observed in the eye with no DMO (bottom).
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FIGURE 3 Spectral domain-optical coherence tomography following resolution of DMO. Fundus image (left) and SD-OCT
scan (right) of the left eye of the patient shown in Figure 2 following anti-VEGF treatment. The DMO has resolved
(no DMO present).
FIGURE 2 Spectral domain-optical coherence tomography in DMO with CRT of > 400 µm. Fundus image (top left) and
SD-OCT scan (top right) of the left eye of a patient with severe DMO, with > 400 µm CRT (454 µm in the central 1 mm
field, bottom left). Thickening of the retina is shown in red in the colour map (bottom right).
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tissue that could then contract and pull on the retina and detach it from the wall of the eye, causing a
tractional retinal detachment (TRD). Both vitreous haemorrhage and TRD can lead to loss of not only
central but also peripheral vision. Once it occurs, vitreous haemorrhage may clear spontaneously or may
require surgery (vitrectomy). If TRD affects or threatens the macula it will require surgery, which is often
very challenging. Furthermore, visual outcomes following TRD repair may be disappointing.
The estimated prevalence of PDR in the individual participant data meta-analysis referred to above
was 6.96%.5 Based on the prevalence of diabetes in the UK,6 it could be assumed that there are
≈ 271,440 people in the UK affected by PDR.
The Early Treatment Diabetic Retinopathy Study (ETDRS)17 demonstrated the value of scatter laser
panretinal photocoagulation (PRP) for the treatment of PDR. Following the results of the ETDRS,
immediate treatment is recommended for all patients with type 1 or type 2 diabetes when high-risk
characteristics are present, including NVD of a certain size (more than one-third to one-quarter of the
disc area) and/or any new vessels if pre-retinal haemorrhage or vitreous haemorrhage are detected.17
Treatment at earlier stages could be considered in selected cases (e.g. poor attendance at clinics) and
FIGURE 4 Fundus images of an eye with HRC PDR and a healthy eye. Fundus image of the right eye (top) of a patient
with PDR and very large new vessels (white arrowheads) and scarring (white bands seen on the image, white arrows),
pre-retinal haemorrhages (black arrows) and vitreous haemorrhage (black arrowheads) obscuring the view of the retina.
For comparison, a fundus image of a healthy eye is shown (bottom). The optic nerve (white arrow) and macular area
(white arrowhead) are healthy.
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especially in people with type 2 diabetes. The cost-effectiveness of applying PRP at earlier stages than
the presence of high-risk characteristics (i.e. when there is PDR but not reaching high-risk characteristics
and when there is severe non-proliferative disease and before new vessels develop) is unclear, and
cannot be recommended for all patients at present.18 PRP is delivered as an outpatient procedure,
under topical anaesthetic or sub-Tenon’s (local) anaesthesia. Most often, treatment is completed in two
sessions. Laser PRP is usually undertaken following ETDRS guidelines. For some time, an argon laser
was the only laser type used to perform PRP, but recently other types of laser, including the so-called
‘pattern’ laser, have been introduced. However, there is no evidence to date of the efficacy and safety
of any lasers other than the argon laser, and of any laser protocols/strategies other than the ETDRS.19
In this regard, it is important to note that a recent, large, well-conducted randomised controlled trial
(RCT) comparing laser PRP with anti-VEGF therapies for the treatment of PDR found that, in the PRP
arm, eyes receiving ‘pattern’ PRP were at a higher risk of worsening PDR [60% vs. 39%; hazard ratio
(HR) 2.04, 99% confidence interval (CI) 1.02 to 4.08; p = 0.008] than those receiving conventional
single-spot PRP laser.20
The National Institute for Health and Care Excellence (NICE) is expected to appraise anti-VEGFs for the
treatment of PDR in the next year or two. Anti-VEGFs are not currently used to treat PDR in the UK.
Once scatter laser PRP is complete, patients require follow-up (Figure 5). Initially, immediately after
treatment, patients are followed up at a shorter time interval (e.g. 4–8 weeks) to ensure that regression
of the disease occurs. However, once the disease is stabilised and regression occurs, patients are often
followed up every 6–8 months or even at longer intervals. Follow-up is required as new vessels in PDR
could return and vitreous haemorrhage and TRD could still ensue. Closer follow-up should be considered
if PRP is performed using a ‘pattern’ laser, given the information provided above.
Currently in the NHS, most patients with treated and stable PDR are followed up in clinic by
ophthalmologists. In fact, it has been shown that a high proportion of all patients with DR reviewed in
hospital eye services have treated and stable PDR.21 At each follow-up visit, patients receive a visual
acuity test, which is most often undertaken by a nurse or a visual acuity technician, followed by a
SD-OCT scan, which is obtained by a photographer/imaging technician, to rule out the presence of
concomitant DMO; they are then seen by an ophthalmologist, an expert on retinal diseases. The
ophthalmologist examines the patient by slit-lamp biomicroscopy using, most often, a non-contact
fundus lens, and determines whether there is active PDR or the disease remains stable. Fundus
photographs (photographs of the retina) are not routinely obtained in clinic to determine whether or
not active PDR is present, although they may be taken in selected cases.
If required, fundus photographs can be obtained with standard cameras that provide 30- to 45-degree
images to allow imaging of the central part of the retina, including the macula (Figure 6). To visualise
other areas of the retina using these standard cameras, the patients are asked to look up, left, down
and right so that images of the superior, nasal, inferior and temporal retina can be obtained, for example,
when imaging a right eye. However, even when this is carried out, the peripheral retina cannot be imaged.
To date, most of the research studies on DR have used seven-field ETDRS imaging to document
the status of the retina. Seven-field ETDRS imaging consists of seven fields that are located in the
mid-peripheral retina as follows (Figure 7):
field 1 – centred at the optic nerve head
field 2 – centred at the fovea
field 3 – temporal to the fovea
field 4 – superotemporal
field 5 – inferotemporal
field 6 – superonasal
field 7 – inferonasal.
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FIGURE 6 Standard fundus image in a patient with DMO. Standard fundus photograph of the left eye of a patient with





FIGURE 7 Scheme demonstrating the seven-field ETDRS fields.
FIGURE 5 Fundus image of an eye treated with laser panretinal photocoagulation and with regressed PDR. Ultra-wide
field fundus image of the right eye of a patient with PDR following laser panretinal photocoagulation. Laser scars (small,
black areas surrounding by clearer ‘halos’) throughout the retina are seen.
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Seven-field imaging takes some time to be obtained and, similarly, to be evaluated; for this reason, it is
impractical and not used in routine clinics.
Furthermore, as shown in Figure 7, much of the retina remains uncovered (i.e. not photographed) when
seven-field ETDRS fundus images are used. More recently, ultra-wide field imaging has become available.
The first ultra-wide field fundus technology developed, which remains the widest field imaging system
in existence, is produced by Optos (Dunfermline, UK). Using a scanning laser ophthalmoscope, a view
of nearly the entire retina (200 degrees) can be obtained in a single image (Figure 8). To visualise the far
peripheral superior and inferior retina as well, patients are asked to look up and down.With the three
images (centre, superior and inferior) the whole retina is covered. Ultra-wide field imaging allows
identification of DR lesions in the peripheral retina that would not be imaged if seven-field ETDRS was
used instead; this could have important prognostic implications.22
The burden of diabetic retinopathy, diabetic macular oedema and proliferative
diabetic retinopathy and NHS pressures to meet service demands
Diabetes is on the rise. The estimated prevalence of diabetes in the UK was 3.9 million in 2019, over
100,000 more than in 2018.6 If nothing changes, 5 million people in the UK will have diabetes by
2025.6 The increasing number of people with diabetes will translate to a larger number of individuals
with DMO and PDR. Given that patients are required to return to clinics at short intervals to receive
treatment (until their disease has been controlled), and that these visits are required for the rest of
FIGURE 8 Ultra-wide field fundus images. Full visualisation of the superior (top), central (centre) and inferior (bottom)
retina. (continued )
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their lives, the already excessive workload in hospital eye services related to DMO/PDR is expected to
worsen. This poses major problems for the ability of ophthalmic clinics to evaluate and treat patients in
time, especially because of the shortage of ophthalmologists. Delaying appointments may subsequently
lead to poorer visual outcomes for patients; such delays are widespread in the UK, as recently highlighted
by the Royal College of Ophthalmologists.23 Hospital eye services are further stretched by the fact that
anti-VEGFs have been introduced not only for DMO but also for other conditions, including age-related
macular degeneration and retinal vein occlusion, and frequent evaluation and treatment is required for
these groups as well. Thus, it is imperative that new ways to increase efficiency and capacity in the NHS
are identified and, if safe and acceptable, implemented.
With the above in mind, EMERALD (Effectiveness of Multimodal imaging for the Evaluation of Retinal
oedema And new vesseLs in Diabetic retinopathy) was conceived with the purpose of determining
whether or not patients who had previously received treatment for DMO and/or PDR and in whom
treatment had been successful [i.e. DMO cleared and PDR became quiescent (inactive)] could be
followed up with multimodal retinal imaging and review of these images by a trained ophthalmic
grader, rather than by ophthalmologists, as is currently standard practice.
FIGURE 8 Ultra-wide field fundus images. Full visualisation of the superior (top), central (centre) and inferior (bottom) retina.
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Chapter 2 Diagnostic accuracy
The purpose of EMERALD was to determine the diagnostic accuracy, acceptability to patientsand health-care professionals, and cost-effectiveness of a new care pathway, the ophthalmic
grader pathway, when compared with the current standard of care (standard care pathway) for the
surveillance of people with previously successfully treated DMO and/or PDR.
Methods
EMERALD was designed as a case-referent, cross-sectional diagnostic study with both sampling
(selection) of patients and data collection carried out prospectively.24 This approach provides both a
cost-efficient study design and a low risk of bias in terms of diagnostic accuracy.25
At the time of study conception, a patient and public involvement (PPI) group was established. EMERALD
was presented to the PPI group and the plans for the study discussed. The PPI group confirmed the
research question was important and that the tests proposed were adequate and feasible to patients.
The PPI group provided essential input to all patient-related materials elaborated for the study (patient
information sheet and consent form). The PPI group will also be actively involved in the dissemination
of the results.
Setting
EMERALD was conducted in 13 specialised hospital eye services in the UK. Participating sites were
in England (n = 11), Scotland (n = 1) and Northern Ireland (n = 1). All participating sites had extensive
experience in the management of people with DR, DMO and PDR.
Population
Patients with DR and DMO and/or PDR were eligible for EMERALD if they met the following
inclusion criteria:
l Adults (aged ≥ 18 years) with type 1 or type 2 diabetes and with previously successfully treated
DMO and/or PDR in one or both eyes, and in whom, at the time of enrolment in the study,
DMO and/or PDR was active or inactive. Patients could be recruited into the study only once.
Active DMO was defined as a CRT of > 300 µm on SD-OCT and/or by the presence of intraretinal/
subretinal fluid on SD-OCT owing to DMO. Inactive DMO was defined as the lack of intraretinal/
subretinal fluid at the macula on SD-OCT. Active PDR was defined as the presence of subhyaloid/
vitreous haemorrhage and/or active new vessels (new vessels with a lack of fibrosis on them), whether
in the disc (NVD) or elsewhere in the retina (NVE). Inactive PDR was defined as the lack of preretinal/
vitreous haemorrhage and the lack of active NVD or NVE.
The exclusion criteria used were as follows:
l patients unable to provide informed consent
l patients unable to read, speak or understand English.
Pathways evaluated
Ophthalmic grader pathway
The new care pathway tested, the ophthalmic grader pathway, consisted of reviewing SD-OCT images
to detect DMO and the review of seven-field ETDRS/ultra-wide field fundus images to detect PDR;
this was carried out by trained, tested and certified ophthalmic graders (see Selection of ophthalmic
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graders and training). Following evaluation of these images, graders determined whether there was
active DMO/PDR, inactive DMO/PDR or whether they were unsure or unable to grade (ungradable),
in which case patients would be referred to an ophthalmologist for assessment. If there was no
DMO and/or inactive PDR only, the grader would arrange a review appointment for the patient in
the ophthalmic grader pathway at a pre-determined interval.
Standard-of-care pathway
The standard-of-care pathway considered in EMERALD was the current standard of care, as follows:
l for people with DMO – ophthalmologist evaluating patients in clinic by slit-lamp biomicroscopy and
with access to SD-OCT scans
l for people with PDR – ophthalmologist evaluating patients in clinic by slit-lamp biomicroscopy.
For the purpose of EMERALD, and owing to ethics considerations, all patients were first evaluated
through the standard care pathway, as explained in Patient flow in EMERALD.
Enhanced reference standard for proliferative diabetic retinopathy
It is possible that ophthalmologists could miss new blood vessels when evaluating patients by slit-lamp
biomicroscopy. To account for this, EMERALD also evaluated an ‘enhanced’ reference standard for PDR
that consisted of the reference standard (i.e. evaluation of the patient by slit-lamp biomicroscopy by
an ophthalmologist) supplemented by the evaluation of seven-field ETDRS and ultra-wide field fundus
images, which were reviewed by an ophthalmologist who was an expert in DR. If active PDR was
detected in one of these three evaluations (slit-lamp biomicroscopy, seven-field ETDRS fundus images
and ultra-wide field fundus images), it was considered that there was active PDR based on the
enhanced reference standard (ERS). To obtain masking to the reference standard, ophthalmologists did
not grade images from their own centre. Seven-field ETDRS and ultra-wide field images of the same
participant were not reviewed by the same ophthalmologist to avoid the reading of one imaging
technology influencing the reading of the other.
Outcome measures
Primary outcome
The primary outcome was the sensitivity of the new pathway (ophthalmic grader pathway) in detecting
active DMO/PDR, using the standard care pathway as the reference standard.
Secondary outcomes
The secondary outcomes were:
l specificity, concordance (agreement) between the new pathway (ophthalmic grader pathway) and
the standard care pathway, and positive and negative likelihood ratios
l cost-effectiveness
l acceptability
l proportion of patients requiring subsequent full clinical assessment
l proportion of patients unable to undergo imaging, with inadequate quality images or
indeterminate findings.
Selection of ophthalmic graders and training
Currently, ophthalmic photographers/imaging technicians obtain images and interpret them routinely,
but make no decisions on the care of patients. In ophthalmic services, there are also ophthalmic
graders that have been trained to interpret findings on fundus images for the purpose of undertaking
DR screening.
DIAGNOSTIC ACCURACY
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For EMERALD, the ophthalmic graders at each participating site were selected as follows. To start,
local principal investigators (PIs) provided names of individuals that they believed had experience of
obtaining and/or grading images of patients with DMO and PDR; these individuals were approached to
confirm their interest and willingness to participate in EMERALD. Some ophthalmic graders who were
selected for EMERALD were already involved in the grading of images for DR screening.
Graders identified by the PIs were asked to fill in questionnaires detailing their experience of imaging/
grading DMO/PDR, their experience of recognising features of DMO/PDR and whether or not they felt
confident identifying DMO on SD-OCT and new vessels on fundus images. Graders who stated that
they did not have experience of imaging/grading DMO/PDR and those stating that they could not
recognise features of DMO/PDR were not invited to take part in EMERALD as graders.
Formal training was then provided to potential EMERALD graders; during training sessions, features of
active/inactive DMO/PDR were reviewed and discussed and extensive clinical examples were presented.
This training was provided to all EMERALD ophthalmic graders prior to the initiation of the study. Thus,
prior to the initiation of the study, a 2-day face-to-face course was provided to potential graders. This
was followed by two additional half-day training sessions.
A web-based teaching module with examples of DMO/PDR was prepared so that graders could
consolidate their knowledge. Clear guidelines on when patients would need to be referred for an
assessment by an ophthalmologist were also given.
To ensure that the graders who were selected had the required level of experience to undertake the
task of grading images, all potential graders were required to take a test involving the reading of
optical coherence tomographies (OCTs) and fundus images. Only graders who reached a minimum
of 80% of correct answers in detecting the presence of DMO (active DMO) and active PDR, when
present, were invited to act as graders. Graders were allowed to undergo further training and take the
test a second time, but if the minimum number of correct answers was not reached at this second test
they were not selected to be graders for EMERALD and did not carry out this role for the study.
Patient flow in EMERALD
Patients with previously successfully treated DMO/PDR were identified from clinical records,
electronic databases or in clinic. Verbal and written information about the study was given to all
potential participants and their questions, if any, were answered. At their review appointment, an
ophthalmologist confirmed patient eligibility, obtained informed consent and determined whether or
not DMO was present and whether there was active or inactive PDR, setting the reference standard.
All participants underwent visual acuity testing, SD-OCT scans and fundus examination, as undertaken
per routine standard practice. In some participating sites, 159 (40%) patients were evaluated in
‘research’ clinics, and in others 238 (60%) patients were evaluated fully within usual NHS clinics.
Once the reference standard was set, non-stereoscopic seven-field ETDRS and ultra-wide angle fundus
images were obtained. These images were then coded (identifiers removed), uploaded to a central
facility [the Central Administrative Research Facility (CARF), Queen’s University, Belfast] and allocated
randomly to the EMERALD ophthalmic graders. Graders did not grade images from their own centre
(to ensure masking to the reference standard) and did not grade seven-field ETDRS/ultra-wide fundus
images from the same patient to prevent the grading of one technology influencing the grading of the
other. For each patient/imaging modality, graders judged whether there was active/inactive DMO
and/or active/inactive PDR, or if they were uncertain about this. Graders also determined, based on
their findings, whether patients needed referral to an ophthalmologist for review/treatment or they
could continue their care in the ophthalmic grader pathway.
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Schedule of assessments for EMERALD
Case report forms (CRFs) were specifically designed to collect all of the information required for the
purpose of the EMERALD study. The following information was obtained during the standard care
pathway and recorded:
l medical and ophthalmic history, including previous treatments for DMO/PDR
l best-corrected visual acuity
l ophthalmologists’ findings on slit-lamp biomicroscopy, including:
¢ presence of anterior segment neovascularisation and possible determinants of poor-quality
images, including media opacity and small pupillary size
¢ presence/absence of DMO and/or active/inactive PDR
¢ presence/absence and location of active/inactive NVD and NVE in the retina and/or
pre-retinal haemorrhage/vitreous haemorrhage
¢ presence of any other co-existent eye disease (e.g. glaucoma)
¢ proposed plan for the patient (observation or treatment).
While in clinic, patients completed the EuroQol-5 Dimensions, five-level version (EQ-5D-5L), National
Eye Institute Visual Function-25 (NEI VFQ-25) and Vision and Quality of Life (VisQoL) questionnaires.
Those willing to participate in the focus group (FG) discussions were asked for their consent and
informed that they might be contacted at a later date for this purpose.
Patients underwent seven-field ETDRS and ultra-wide field imaging. Images were obtained following the
guidelines provided in the standard operational procedures, as set in the EMERALD study manual. Once
obtained, fundus photographs and SD-OCT images were anonymised and transferred to the CARF of
Queens’ University Belfast, where they were uploaded to an electronic website developed for the study
and randomly allocated and made accessible to the EMERALD ophthalmic graders and ophthalmologists
determining the ERS for PDR. Images (SD-OCTs for graders and seven-field ETDRS and ultra-wide
field fundus images for graders and ophthalmologists) were viewed in an ophthalmic viewer platform
(Ophthalsuite, BlueWorks, Coimbra, Portugal) and graded by ophthalmic graders and ophthalmologists.
Ophthalmic graders determined and recorded in the appropriate CRF:
l whether there was active/inactive DMO/PDR or if they were unsure or unable to grade presence
of the disease (ungradable)
l the presence/absence, location and activity of new vessels or whether they were unsure or unable
to grade presence of the new vessels (ungradable)
l the presence/absence and degree of completeness (partial or complete) of previous laser PRP
l the presence/absence of pre-retinal haemorrhage and vitreous haemorrhage
l the presence and type of other abnormalities, if observed
l whether the patient could continue surveillance in the ophthalmic grader pathway or if an
assessment by an ophthalmologist was required and the reasons why.
Similarly, ophthalmologists who were determining the ERS determined and recorded the following
information in the appropriate CRF:
l whether there was active/inactive PDR or if they were unsure or unable to grade presence of the
disease (ungradable)
l presence/absence, location and activity of new vessels or whether they were unsure or unable to
grade presence of the new vessels (ungradable)
l presence/absence and degree of completeness (partial or complete) of previous laser PRP
l presence/absence of pre-retinal haemorrhage and vitreous haemorrhage
l presence and type of other abnormalities, if observed
l whether or not the patient could continue surveillance in the ophthalmic grader pathway or if an
assessment by an ophthalmologist was required and the reasons why.
DIAGNOSTIC ACCURACY
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Masking
Ophthalmic graders and ophthalmologists evaluating images for the ERS were masked to the results
of the reference standard. To ensure this, graders and ophthalmologists did not interpret images from
patients recruited in their own centres; they did not have access to the results of the reference standard.
Ophthalmologists undertaking the standard-of-care evaluation were also masked to the findings/decisions
made by the ophthalmic graders (who reviewed the images at a later date). Patients were also masked to
the findings/decisions made by the ophthalmic graders (these were not available at the time of the clinical
visit for the study).
Data collection and quality checks
As stated above, CRFs were specifically prepared for the purpose of EMERALD and used to collect study
data. Monitoring was undertaken during the study to check the accuracy of entries in CRF’s against
source documents, adherence to protocol and procedures and adherence to the International Conference
of Harmonisation Good Clinical Practice guidelines26 and regulatory requirements. Monitoring visits were
carried out by a monitor from the Northern Ireland Clinical Trials Unit (NICTU). Training on the protocol
and study procedures was provided by the chief investigator and the NICTU to research staff at all
participating sites prior to the initiation of the study.
Study data were transferred from CRFs to a web-based clinical trial database, which was elaborated
for the purpose of EMERALD, by NICTU personnel and processed electronically. Data quality-control
checks were carried out by a data manager to ensure accuracy. Data errors were documented in quality
control reports and corrective actions implemented. Data validation and discrepancy reports were
generated following data entry to identify discrepancies, such as data out of range, inconsistencies or
protocol deviations, based on the data validation checks programmed in the clinical trial database.
Sample size
The sample size was determined by setting a target number of people with reactivated (active) DMO
and PDR required to enable sensitivity to be tested against a prespecified target level of 80%.The required
sample size was calculated using formula T1 fromObuschowski27 in Microsoft Excel® (Microsoft Corporation,
Redmond,WA, USA); this was a Wald test-based calculation. This target level was considered to be the
minimum acceptable for the new pathway (ophthalmic grader pathway) to be clinically viable. A lower
specificity was considered acceptable; a target level of 65% was used to confirm sufficiency of the sample
size to assess specificity. Eighty-nine participants with DMO/PDR that had reactivated (active DMO/PDR)
was sufficient to detect if the sensitivity of the new pathway is 10% and 12% higher than the 80%minimal
target set with 80% and 90% power, respectively, at the two-sided 5% significance level.28 Ninety-three
participants who have not reactivated would enable detection with a specificity 15% higher than the 65%
target with 90% power. A 95% confidence interval for the sensitivity and specificity of the ophthalmic
grader pathway would have a confidence interval (Wilson method) with a width of 10–20% depending
on the observed level.29 Allowing for 10% of missing/indeterminate results, 104 individuals who have
reactivated and 104 who have not reactivated were required (208 individuals for each DMO and PDR),
which led to a need for a maximum of 416 participants in the study. Because some participants had both
DMO and PDR, and they contributed to both DMO and PDR targets, the number of patients required
was smaller than 416.
Statistical analyses
Overview of principal analyses
The statistical analyses were conducted in accordance with the study protocol1 and the statistical analysis
plan, which was signed off and made publicly available on the EMERALDwebsite (www.nictu.hscni.net/
emerald-trial/; accessedMarch 2020) prior to data analyses. Additional analyses conducted beyond those
planned for in the statistical analysis plan are identified as such in this chapter (as well as in Chapter 4). To
address the primary objective, the principal analyses were carried out with DMO and PDR patients assessed
in two separate sets of analyses at the person level, one for each disease (see Table 2). Analyses were focused
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on the participant being considered eligible for the new pathway by virtue of having previously successfully
treated DMO/PDR in one or both eyes (‘Patients eligible for new pathway’). The main analysis was according
to the ophthalmic graders decision to refer to an ophthalmologist (irrespective of the reason, i.e. active
disease or if the grader was unsure or unable to grade; referred to throughout this chapter as ‘referral’=
‘active’+ ‘unsure’+ ‘ungradable’); this would be what would occur if the ophthalmic grader pathway were
to be implemented.The reference standard was standard care: slit-lamp biomicroscopic examination by an
ophthalmologist [referred to throughout this chapter as ophthalmologists face-to-face (O-FTF)] with access
to SD-OCT images (referred to as O-FTF +OCT) for DMO, and slit-lamp biomicroscopic examination by
ophthalmologist (O-FTF) for PDR to detect the presence of active disease (active DMO or active PDR) in
either eye. For PDR only, an ERS was used for some analyses.This consisted of the combined findings of
ophthalmologist slit-lamp biomicroscopic examination (O-FTF), ultra-wide field fundus images (referred to
throughout this chapter as O-OPTOS) and seven-field ETDRS fundus images (referred to throughout this
chapter as O-ETDRS). Positive detection of active PDR constituted a positive ERS result. The diagnostic
performance of the new ophthalmic grader pathway was quantified and compared with that of the standard
care pathway. For PDR, there were two sets of results: one using ultra-wide field fundus imaging-based
assessment (referred to as OPTOS) and one using the seven-field ETDRS-based assessment (referred to as
ETDRS).The impact of using either OPTOS or ETDRS on the diagnostic performance of the new pathway
was formally compared.
Table 1 summarises all of the analyses undertaken in EMERALD. Tables 2 and 3 summarise the
planned principal analyses (main and sensitivity analysis) and the unplanned additional principal
analyses undertaken.
Eligible participants for the EMERALD ophthalmic grader’s pathway
Eligible participants contributed to the principal analyses under the new pathway for DMO (see Table 2)
if they had at least one eye with DMO that was eligible (i.e. previously successfully treated). Similarly,
eligible participants contributed to the principal analyses under the new pathway for PDR (see Tables 2
and 3) if they had at least one eye with PDR that was eligible (i.e. previously successfully treated).
Participants in EMERALD, however, could have one or both eyes with ‘active DMO’ or ‘active PDR’
(‘recurrent’, ‘de novo’ or ‘persistent’; see below for definitions), or ‘inactive DMO’ or ‘inactive PDR’,
or ‘no DMO’ or ‘no PDR’ according to the diagnosis established at the standard care pathway.
Definitions
‘Active, recurrent DMO/PDR’ refers to previously successfully treated DMO/PDR that was present at
the time of the EMERALD examination.
‘Active, de novo DMO/PDR’ refers to DMO/PDR never present before but observed at the time of the
EMERALD examination.
‘Active, persistent DMO/PDR’ refers to DMO/active PDR that was present before, never cleared
(e.g. unsuccessfully treated) and was present at the time of the EMERALD examination.
‘Inactive DMO/PDR’ refers to inactive disease at the time of the EMERALD examination.
Note that some eyes with inactive DMO/PDR would have been previously successfully treated and
would be considered eligible eyes; others, however, may not have had previously successfully treated
disease, but at the time the patient attends the EMERALD visit their disease may be inactive and, thus,
would be considered ineligible eyes (see Eye-level classification).
‘No DMO/PDR’ refers to DMO or PDR never present and not detected at the time of the
EMERALD examination.
DIAGNOSTIC ACCURACY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
Eye-level classification
The eye-level classification was based on the following six scenarios:
‘Scenario 1 – Previous Active, successfully treated, Today Active’ (corresponding to ‘recurrence’) –
also defined as ‘Eligible eye’ for the analysis of new pathway.
‘Scenario 2 – Previous Active, successfully treated, Today Inactive’ (corresponding to ‘inactive’) –
also defined as ‘Eligible eye’ for the analysis of new pathway.
‘Scenario 3 – Previous Active, not successfully treated, Today Active’ (corresponding to ‘persistence’) –
also defined as ‘Ineligible eye’ for the analysis of new pathway.
‘Scenario 4 – Never present, Today Active’ (corresponding to ‘de novo’, i.e. newly diagnosed) –
also defined as ‘Ineligible eye’ for the analysis of new pathway.
‘Scenario 5 – Previous Active, not successfully treated, Today Inactive’ – (corresponding to ‘inactive’)
also defined as ‘Ineligible eye’ for the analysis of new pathway.
‘Scenario 6 – DMO/PDR never present, Today No DMO/PDR’ (i.e. no disease) – also defined as
‘Ineligible eye’ for the analysis of new pathway.
























Person Main analysis Figure 11 Tables 2, 8,
10, 14, 15, 16
and 17SENA1
SENA2 Figure 11 Tables 2, 8,




Additional 1 Figure 11 Tables 3, 8,























Eye SECA1A N/A Table 5 Table 41
SECA1C Table 42
N/A, not applicable; SECA, secondary analysis; SENA, sensitivity analysis; UWF, ultra-wide field fundus images.
a Details of each of these analyses are presented in Table 2.
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Index test positive Reference standard Index test positive Reference standard





DMO in either eye
OPTOS-based
ophthalmic grader
referral for either eye
O-FTF assessment of




referral for either eye
SENA1 Person OCT-based ophthalmic
grader identification








disease in either eye
O-FTF assessment of





disease in either eye









referral for either eye
O-FTF assessment of





referral for either eye









SENA4 Person N/A N/A OPTOS-based
ophthalmic grader
referral for either eye
O-FTF assessment





referral for either eye
SENA5 Person N/A N/A OPTOS-based
ophthalmic grader




referral for either eye



























O-FTF+OCT, reference standard for DMO (i.e. standard care); O-FTF, reference standard for PDR (i.e. standard care);
N/A, not applicable; SENA, sensitivity analysis.
a Principal analyses were focused on ‘eligible patients for the new pathway’ and referred to the analysis carried
out using data from the eligible eye(s) of each patient included in EMERALD. [Note that all patients included in
EMERALD were eligible for the purpose of evaluating one or other disease or both (DMO or PDR); they may have
contributed with data from ‘eligible eyes’ if they have had DMO, PDR or both, in one or both eyes that were
previously successfully treated, becoming stable at one point following treatment – see Methods.]
b Grader referral for DMO or PDR= ‘active’+ ‘unsure’ + ‘ungradable’.
Bold highlights the differences between analyses.
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Participant-level classification
All participants who were included in the EMERALD study were at least eligible for the new DMO or
the new PDR pathway, or eligible for both the DMO and the PDR pathways. Each eye for each EMERALD
participant was assessed with regard to the status of PDR and DMO, irrespective of whether or not they
were ‘eligible’ for both cohorts.What data were included varies according to the analysis (see Tables 2 and 3
for a full list). The statement ‘eligible participants’ for the new pathway refers to analyses from data
obtained from participants contributing with one or both eligible eyes (one or both eyes had to have
previous successfully-treated DMO or PDR, respectively) (Scenario 1 or 2 in one or both eyes).
To be eligible for the new DMO pathway (see Table 2), participants needed to have at least one eye
with previously successfully treated DMO (i.e. ‘eligible’). At the time of the EMERALD examination, if DMO
was present in one or both eyes they were classed as having active DMO (‘recurrent DMO’), and if neither
eye had DMO then participants were classed as having inactive DMO. Inactive DMO includes patients who
have one previously successfully treated eye in which DMO is inactive at the time of examination and who
have no DMO in the other eye. It also includes those for whom one or both eyes had been previously
successfully treated for DMO, but both eyes were inactive at the time of examination. Participants who did
not have an eye that had been previously successfully treated were ineligible for the new DMO pathway.
To be eligible for the new PDR pathway (see Tables 2 and 3), participants needed to have at least one
eye with previously successfully treated PDR (i.e. ‘eligible’). At the time of the EMERALD examination,
if PDR was active in one or both eyes they were classed as having active PDR (‘recurrent PDR’), and
if neither eye had active PDR then participants were classed as having inactive PDR. Inactive PDR
includes patients who had one previously successfully treated eye in which PDR is inactive at the time
of examination and who had no PDR in the other eye. It also includes those in whom one or both








standard Index test positive Reference standard
Additional 1 Person N/A N/A OPTOS-based ophthalmologist
identification of active disease
in either eye
O-FTF assessment of
active PDR in either eye
ETDRS-based ophthalmologist
identification of active disease
in either eye
Additional 2 Person N/A N/A OPTOS-based ophthalmologist
identification of active disease
in either eye
O-FTF assessment




identification of active disease
in either eye
Additional 3 Person N/A N/A OPTOS-based ophthalmic
grader referralb for either eye
O-FTF assessment+
ophthalmologist OPTOS
images of active PDR in
either eye
ETDRS-based ophthalmic
grader referral for either eye
O-FTF assessment+
ophthalmologist ETDRS
images of active PDR in
either eye
N/A, not applicable.
a Three additional analyses on PDR that were not listed in the statistical analysis plan were conducted in the light of
the main PDR results to better understand the content and potential value of the two imagining modalities along
with the reliability of the O-FTF reference standard for PDR.
b Grader referral for PDR = ‘active’ + ‘unsure’ + ‘ungradable’.
Bold highlights the differences between analyses.
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eyes had been previously successfully treated for PDR but both eyes were inactive at the time of
examination. Participants who did not have an eye that had been previously successfully treated were
ineligible for the new PDR pathway.
Definition of grader’s assessments of optical coherence tomography, OPTOS and ETDRS
A grader’s decision on whether or not to refer the patient, an inherently person-level decision, was
used, rather than an assessment of the single eye. The basis of the referral decision was the grader’s
assessment of the corresponding disease (DMO/PDR). Furthermore, to more closely reflect how the
new pathway would function in practice, a patient whom graders classified as having DMO or PDR
within the eye under the category ‘unsure’ or ‘ungradable’ were considered alongside those classified
as ‘active’, as both would be anticipated to require further examination by an ophthalmologist under
the main analysis (referral = ‘active’ + ‘unsure’ + ‘ungradable’). How the ophthalmic graders decision was
tested varied according to the analysis (see Tables 2 and 3 for a full list). Table 4 shows the graders
decision of person-level active status based on the combination of eye-level results. Only those
samples in which there was an overall classification available were included in the sensitivity analyses.
Diagnostic performance of the EMERALD ophthalmic graders
The diagnostic performance of the EMERALD ophthalmic graders was assessed against the standard
care reference standard to determine:
1. sensitivity (the proportion of patients determined by the ophthalmologist to suffer from active
DMO/PDR who had been correctly referred/identified by EMERALD ophthalmic graders)
2. specificity (the proportion of patients determined by the ophthalmologist to suffer from inactive
DMO/PDR who had been correctly referred/identified by EMERALD ophthalmic graders)
3. overall agreement (a measure of how well the ophthalmic graders’ assessment agrees with the
ophthalmologist assessment)
4. positive likelihood ratio (the probability that a patient with active DMO/PDR is correctly assessed
by the ophthalmic graders, divided by the probability that a patient with inactive DMO/PDR is
incorrectly assessed by the ophthalmic graders as being active)
5. negative likelihood ratio (the probability that a patient with active DMO/PDR is incorrectly assessed
by the ophthalmic graders as being active, divided by the probability that a patient with inactive
DMO/PDR is correctly assessed).
Agreement between assessment methods was also quantified, where appropriate.




‘Both’ eyes ‘Active’ or ‘either’ eye ‘Active’, no matter the status of the other eye Referrala Active
‘Both’ eyes ‘Unsure’ or ‘Ungradable’ Referrala Not Active
One eye ‘Unsure’ or ‘Ungradable’, while the other eye ‘No’ disease, ‘Ungradable’ or ‘Unsure’ Referrala Not Active
One eye ‘Unsure’ or ‘Ungradable’, while the other eye ‘Missing’ Referrala Missing
‘Both’ eyes ‘No disease’ or ‘Inactive disease’ Not Active Not Active
One eye ‘No disease’ while the other eye ‘Inactive disease’ and neither eye ‘Missing’ Not Active Not Active
‘Both’ eyes ‘Missing’, and none of the eyes would be referral Missing Missing
One eye ‘No disease’ or ‘Inactive disease’, while the other eye ‘Missing’ Missing Missing
SENA, sensitivity analysis.
For PDR, the enhanced reference was the reference standard for PDR (O-FTF)+ ophthalmologist OPTOS+ ophthalmologist
ETDRS. If a patient was gradable by any of the three tests, he/she was considered as gradable and, hence, the one
available result was used.
a Grader referral for DMO or PDR= ‘active’+ ‘unsure’ + ‘ungradable’.
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Diagnostic performance analysis methods
For all diagnostic accuracy analyses the sensitivity, specificity, and positive and negative likelihood ratios
were calculated (with appropriate 95% CIs). The difference in sensitivity and specificity between OPTOS
and ETDRS fundus images, as assessed by the ophthalmic graders, was compared with corresponding
95% CIs produced using Newcombe’s method for paired data30 and McNemar’s test.31
Sensitivity analyses of diagnostic performance
In addition to the main analysis for DMO and PDR, a number of sensitivity analyses were conducted
(listed in Table 2).
Sensitivity analysis (SENA)1 assessed the impact of the ‘unsure’ and ‘ungradable’ test classifications and
of the ophthalmic grader’s grade on the diagnostic performance by defining the index test positive as
definite assessment of the active disease (in contrast to allowing referral for ‘unsure’ or ‘ungradable’).
The reference standards of the O-FTF +OCT assessment for DMO and the O-FTF for PDR of those
present with active disease were used.
SENA2 assessed the ophthalmic graders’ referral assessments against the reference standard of those
requiring treatment for both DMO and PDR. For DMO only, SENA3 focused on diagnostic performance
for assessment among patients considered to possess a form of DMO that would be more important
to recognise earlier, central-involving DMO (in contrast to non-central-involving DMO against the
reference standard of O-FTF +OCT assessment). For PDR only, SENA4 assessed the diagnostic
performance of the ophthalmic grader against the reference standard of O-FTF assessment to detect
active PDR with pre-retinal or vitreous haemorrhage (i.e. high risk PDR). For PDR only, SENA5 assessed
the diagnostic performance of the ophthalmic grader against the ERS (O-FTF assessment supplemented
by ophthalmologist evaluation using OPTOS and ETDRS images) to detect active PDR. A further
sensitivity analysis (SENA6) assessed diagnostic accuracy for a subset of participants only, who were
assessed in a ‘typical’ NHS clinic setting, in contrast to a research clinic, but otherwise under the same
conditions as the main analysis.
For PDR only, three additional post hoc analyses (see Table 3) that were not listed in the statistical
analysis plan were also conducted in the light of the main PDR results, to further understand the content
and potential value of the two imaging modalities evaluated (ultra-wide field and seven-field fundus
images) along with the reliability of the O-FTF reference standard for PDR. ‘Additional 1’ compared the
ophthalmologists’ identification of active PDR by OPTOS or by ETDRS in either eye with the reference
standard of O-FTF assessment for active PDR. ‘Additional 2’ compared the ophthalmologists’ identification
of active PDR by OPTOS or by ETDRS in either eye with the reference standard of O-FTF assessment
for patients with more severe disease (i.e. PDR with pre-retinal or vitreous haemorrhage). ‘Additional 3’
compared the ophthalmic graders’ referral for either eye by OPTOS or by ETDRS with the reference
standard of O-FTF assessment + ophthalmologist OPTOS assessment of active PDR in either eye or
O-FTF assessment+ ophthalmologist ETDRS assessment of active PDR in either eye.
Secondary analyses of diagnostic accuracy
In addition to the principal analyses that were conducted separately at the person level for DMO and
PDR, two distinct secondary analyses of diagnostic accuracy were planned (Table 5). Both of these
secondary analyses focused on the entire EMERALD participant population (‘All participants’), whether
or not they were eligible for a disease (DMO/PDR) pathway. First, a limited set of eye-level analyses
were carried out using the positive identification of active disease at the eye level [secondary analysis
(SECA) 1A–C]. A random eye was selected when two eyes were eligible, with ophthalmic grader eye-
specific assessment against the reference standard. Second, person-level analyses were carried out
for the overall referral status of a patient, irrespective of whether it was active DMO or PDR that required
referral (SECA2A–C). SECA2A utilised an ophthalmic grader referral assessment for either disease;
for DMO, OCT assessment was used, and for PDR the OPTOS and ETDRS assessment were used in turn
(i.e. two sets of results). The reference standards of O-FTF +OCT assessment for DMO and O-FTF
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selected eye
O-FTF assessment















DMO in either eye






Combined DMO/PDR test positive Combined DMO/PDR reference standard
SECA2A Person Ophthalmic grader referralc based on OCT
for DMO and either OPTOS-based
ophthalmic grader referral for PDR or
ETDRS-based ophthalmic grader referral for
PDR (referral for either disease will be
considered a referral for the combined test)
O-FTF +OCT assessment of active DMO and
O-FTF assessment of active PDR in either eye
Additional 4b Person Ophthalmic grader assessment of active
DMO based on OCT and either OPTOS-
based ophthalmic grader assessment of active
PDR or ETDRS-based ophthalmic grader
assessment of active PDR
O-FTF +OCT assessment of active DMO and
O-FTF assessment of active PDR in either eye
SECA2B Person Ophthalmic grader referral based on OCT for
DMO and either OPTOS-based ophthalmic
grader referral or ETDRS-based ophthalmic
grader referral for PDR, and visual acuity
of < 6/12 (or ETDRS equivalent letter)
(referral for either disease, or owing to visual
acuity, will be considered a referral for the
combined test)
O-FTF +OCT assessment of active DMO and
O-FTF assessment of active PDR in either eye
SECA2C Person Ophthalmic grader referral based on OCT for
DMO and either OPTOS-based ophthalmic
grader referral or ETDRS-based ophthalmic
grader referral for PDR, and visual acuity
of < 6/12 (or ETDRS equivalent letter)
(referral for either disease, or owing to visual
acuity, will be considered a referral for the
combined test)
O-FTF +OCT assessment of active DMO and
O-FTF assessment of active PDR in either eye
requiring treatment
N/A, not applicable.
a The ‘All patients’ population will include in the analysis those with ‘persistent’ disease, ‘de novo’ disease, or ‘no disease’
in one eye, irrespective of the disease status of the other eye, as well as those who were eligible for the new
ophthalmic grader pathway (i.e. those who had previously successfully treated DMO/PDR).
b One additional analysis on PDR that was not listed in the statistical analysis plan was conducted to further
understand the content and potential implementation method of the new pathway.
c Grader referral for DMO or PDR= ‘active’+ ‘unsure’ + ‘ungradable’.
Notes
O-FTF +OCT is the reference standard for DMO (i.e. standard care); O-FTF is the reference standard for PDR
(i.e. standard care). Bold highlights the differences between analyses.
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assessment for PDR for those present with active disease were used (either disease constituting active
disease at the person level). SECA2B was the same as SECA2A, except that a visual acuity of less than
6 out of 12 would also be considered a valid reason for referral. SECA2C was the same as SECA2A,
except the reference standard was an ophthalmologist’s assessment of the presence or absence of active
disease that required treatment. Diagnostic performance for both secondary analyses was assessed
using the same outcomes and methods as for the principal analyses.
One additional post hoc analysis (‘Additional 4’) that was not listed in the statistical analysis plan was
also conducted to further understand the content and the potential implementation method of the new
pathway. The test results for Additional 4 were graders’ assessment of active disease(s) in either eye
rather than graders’ referral [which would include active disease(s), unsure or ungradable] in either
eye (SECA2A). Both SECA2A and Additional 4 would be of interest to how the new pathway would
function in clinical practice.
Results
Participant characteristics
A flow diagram is provided (Figure 9) that shows the flow of participants and the O-FTF assessment
reference standard for each disease. In total, 490 patients were screened, of whom 401 (82%) consented
and were recruited. A total of 397 patients were eligible to participate in the study and four patients
were ineligible. Five eyes could not be assessed and were excluded at eye-level assessment, but were
included at patient-level assessment (assessed the other eye only): one right eye could not be assessed
owing to blindness; four left eyes could not be assessed owing to blindness (n = 2), total retinal
detachment (n = 1) and artificial eye (n = 1).
Sample description
Baseline characteristics of participants
The median age of the 397 patients included in EMERALD was 60 (range 18–103) years. Nearly
two-thirds (65%) of the patients were male and the majority (86%) were of white ethnicity. In total,
317 (80%) patients had a diagnosis of DMO and of these 182 (57%) were from the older (≥ 60 years)
age group. A total of 287 (72%) patients had a diagnosis of PDR and of these 136 (47%) were from
the older age group (Table 6). The participants’ characteristics by active diseases status are summarised
in Appendix 1, Table 36.
Reference standard diagnosis characteristics
Tables 7 and 8 display the EMERALD population at eye level and at person level based on the six
patient classification scenarios for DMO and for PDR, respectively. The reference standard was
determined at both the eye and person level. Of the 397 patients included in the analyses, 272 (80%)
were eligible for DMO in the new pathway and these patients were used in the principal person-level
diagnostic accuracy analyses for DMO. Of these, 152 (56%) had DMO at least in one eye that was
previously successfully treated and was active (i.e. had recurrence of DMO) when evaluated in the
EMERALD study visit (i.e. when entering the study). A total of 120 (44%) had DMO in at least one
eye that had been previously successfully treated and remained inactive (i.e. had no DMO present)
when evaluated in the EMERALD study visit (i.e. when entering the study) (see Figure 9 and Table 7).
In total, 281 (71%) of the 397 patients were eligible for PDR in the new pathway and these patients
were used in the principal person-level diagnostic accuracy analyses for PDR. Of these, 111 (40%) had
PDR in at least one eye that was previously successfully treated and was active (i.e. had recurrence
of active PDR) when evaluated in the EMERALD study visit (i.e. when entering the study). A total
of 170 (60%) patients had PDR in at least one eye that had been previously successfully treated
and remained inactive when evaluated in the EMERALD study visit (i.e. when entering the study)
DOI: 10.3310/hta25320 Health Technology Assessment 2021 Vol. 25 No. 32
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Lois et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
21
(see Figure 9 and Table 8). In total, 272 (69%) out of the 397 participants had active DMO or active
PDR, and 49 (12%) had active DMO and active PDR according to the ophthalmologists assessments
(see Appendix 1, Table 36).
Eye characteristics and eye comorbidities of participants
Appendix 1, Tables 37 and 38, describes other findings (abnormalities) that were identified by
ophthalmologists when undertaking slit-lamp biomicroscopy and were recorded as potential factors
that could lead to inadequate image quality, as well as comorbidities noted. Comorbidities were
uncommon in EMERALD participants. The most common comorbidities were epiretinal membrane
and glaucoma (reported in approximately 3% of eyes) (see Appendix 1, Table 38).
Grading results diagnosis characteristics
Table 9 displays the OCT-based ophthalmic graders’ grading results at eye level against the reference
standard for assessing DMO. OCT images were available for 385 (97%) right eyes and 380 (97%) left
eyes. Of these, only a very small number, six (2%) right eyes and five (1%) left eyes, were considered
ungradable. In a similarly small number of eyes, the grader was unsure if DMO was present [13 (3%)
right eyes and 12 (3%) left eyes]. A total of 198 (51%) right eyes and 188 (49%) left eyes were identified





• Patient aged < 18 years, n = 1
• Unable to provide informed consent, n = 1
• Patient did not want to take part in study, n = 54
• Other reasons, n = 30
• No given reason, n = 3
Patients recruited
(n = 401)
Ineligible patients for study
(n = 4)
Eligible patients for study
(n = 397)
Eligible patients for

































FIGURE 9 Study flow diagram.
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Eligible for DMO in
the new pathway




Eligible for PDR in
the new pathway




Male 205 (65) 175 (64) 187 (65) 185 (66) 257 (65)
Female 112 (35) 97 (36) 100 (35) 96 (34) 140 (35)
Age (years)
18–59 135 (43) 113 (42) 151 (53) 148 (53) 188 (47)
≥ 60 182 (57) 159 (58) 136 (47) 133 (47) 209 (53)
Ethnic origin
White 274 (86) 240 (88) 240 (84) 234 (83) 340 (86)
Black 20 (6) 17 (6) 19 (7) 19 (7) 26 (7)
Asian 16 (5) 11 (4) 20 (7) 20 (7) 22 (6)
Middle
Eastern
3 (1) 1 (< 1) 5 (2) 5 (2) 5 (1)
Other 4 (1) 3 (1) 3 (1) 3 (1) 4 (1)
TABLE 7 The DMO classification based on slit-lamp biomicroscopic examination by an ophthalmologist with access to
SD-OCT images (reference standard)
DMO status
Eye level Person level
Right eye
(N= 396),a n (%)
Left eye
(N= 393),a n (%)
Person (either eye)
(N= 397), n (%)
Active Previously successfully treated
(scenario 1)
97 (24) 92 (23) 152 (38)
Previously unsuccessfully treated
(scenario 3)
30 (8) 17 (4) –
Newly diagnosed (scenario 4) 15 (4) 11 (3) –
Inactive Previously successfully treated
(scenario 2)
113 (29) 119 (30) 120 (30)
Previously unsuccessfully treated
(scenario 5)
19 (5) 23 (6) –
No disease Scenario 6 121 (31) 127 (32) –
Unclassifiableb 1 (< 1) 4 (1) –
Owing to no view of fundus: cataract 1 (< 1) –
Owing to no view of fundus:
haemorrhage
– 3 (1) –
Owing to no view of fundus – 1 (< 1) –
Ineligible for new DMO pathwayc – – 125 (31)
a Five eyes in total could not be assessed. One right eye could not be assessed owing to blindness; four left eyes could
not be assessed owing to blindness (n = 2), total retinal detachment (n = 1) and artificial eye (n= 1).
b One participant had unclassifiable DMO in their left eye owing to no view of fundus (vitreous haemorrhage present
and right eye ineligible for new DMO pathway based on O-FTF +OCT assessment): this patient was classified as
ineligible for the new DMO pathway at the person level. This participant was eligible for the new PDR pathway.
The other four participants who had an unclassifiable eye were eligible for the new DMO pathway.
c Ineligible participants for the new DMO pathway referred to those with both eyes ineligible for the new DMO
pathway, which included both eyes not having been previously successfully treated (Scenarios 3 and 5), de novo
disease (Scenario 4) or no disease (Scenario 6), with the exception of one participant (listed above) who had one eye
DMO unclassifiable and the other eye ineligible for the new DMO pathway.
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TABLE 8 The PDR classification based on slit-lamp biomicroscopic examination by an ophthalmologist (reference standard)
PDR status
Eye level Person level
Right eye
(N= 396),a n (%)
Left eye
(N= 393),a n (%)
Person (either eye)
(N= 397),a n (%)
Active Previously successfully treated
(scenario 1)
72 (18) 71 (18) 111 (28)
Previously unsuccessfully treated
(scenario 3)
4 (1) 4 (1) –
Newly diagnosed (scenario 4) 4 (1) 4 (1) –
Inactive Previously successfully treated
(scenario 2)
180 (45) 171 (44) 170 (43)
Previously unsuccessfully treated
(scenario 5)
0 (0) 1 (< 1) –
No disease (Scenario 6) 134 (34) 140 (36) –
Unclassifiableb 2 (1) 2 (1) –
Owing to no view of fundus:
cataract
1 (< 1) – –
Owing to no view of fundus:
corneal graft
– 1 (< 1) –
Owing to no view of fundus:
reason not specified
1 (< 1) 1 (< 1) –
Ineligible for new PDR pathwayc – – 116 (29)
a Five eyes in total could not be assessed. One right eye could not be assessed owing to blindness; four left eyes could
not be assessed owing to blindness (n= 2), total retinal detachment (n = 1) and artificial eye (n= 1).
b All four participants who had an unclassifiable eye were eligible for the new PDR pathway.
c Ineligible participants for the new PDR pathway referred to those with both eyes ineligible for the new PDR
pathway, which including both eyes not been previously successfully treated (Scenarios 3 and 5), de novo disease
(Scenario 4) or no disease (Scenario 6).
TABLE 9 The DMO grading data: graders assessment based on OCT images compared with reference standard
DMO grading
Graders OCT (G-OCT) Reference standard (O-FTF+OCT)
Right eyea (n= 396) Left eyea (n= 393) Right eyea (n= 396) Left eyea (n= 393)
Total DMO present (active) 198 188 142 120
No DMO 168 175 253 269
Unsure if DMO present 13 12 – –
Ungradeable 6 5 1 4
No images 11 13 – –
G-OCT, grader assessment based on SD-OCT images; O-FTF +OCT, reference standard for DMO.
a Five eyes in total could not be assessed: one right eye could not be assessed owing to blindness; four left eyes could
not be assessed owing to blindness (n= 2), total retinal detachment (n = 1) and artificial eye (n= 1).
Shaded cells refer to the reference standard.
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Table 10 displays the UWF OPTOS and seven-field ETDRS-based ophthalmic graders’ and ophthalmologists’
grading results for PDR patients at eye level against the reference standard. Seven-field ETDRS images
were available for 376 (95%) right eyes and 362 (92%) left eyes. Of these, a small number [19 (5%) right
eyes and 27 (7%) left eyes] were considered ungradable. In a similarly small number of eyes, the grader
was unsure if PDR was present [20 (5%) right eyes and 17 (5%) left eyes]. A total of 88 (23%) right eyes
and 83 (23%) left eyes were identified as having active PDR based on seven-field ETDRS images. There
was a small number of eyes in which PDR was identified, but the grader stated that they were unsure if
there was active disease or not [12 (3%) right eyes and 14 (4%) left eyes]. A total of 71 (42%) right eyes
and 65 (40%) left eyes were classified by the graders as having inactive PDR, and 166 (44%) right eyes
and 156 (43%) left eyes were classified by the graders as having no PDR. UWF OPTOS images were
available for 379 (96%) right eyes and 374 (95%) left eyes. Of these, a small number [16 (4%) right eyes
and 21 (6%) left eyes] were considered ungradable. In a similarly small number of eyes, the grader was
unsure if PDR was present [20 (5%) right eyes and 21 (6%) left eyes]. A total of 85 (22%) right eyes and
73 (20%) left eyes were identified as having active PDR based on UWF OPTOS images. There was a
small number of eyes in which PDR was identified but the grader was unsure if there was active disease
or not [11 (3%) right eyes and 16 (4%) left eyes]. A total of 95 (25%) right eyes and 81 (22%) left eyes
were identified as having inactive PDR, and 152 (40%) right eyes and 162 (43%) left eyes were
identified as having no PDR, based on UWF OPTOS images.
Missing test images
Table 11 displays the reasons for missing test images in EMERALD at the person level. Of the 397 patients
included in the analyses, 345 (87%) had SD-OCT, seven-field ETDRS and ultra-wide field fundus images
for each eye available for assessment. A total of 52 patients had at least one imaging assessment missing.
Of these, 17 (33%) would be considered as not assessable by images and, therefore, the patient would
need to be referred to clinical practice (e.g. media opacity). In total, 35 (67%) patients would be considered
as missing for the EMERALD study and would also be considered as missing in practice (e.g. patient
does not attend for the taking of the image). The details of eye-level missing images by assessment
are summarised in Appendix 1, Table 39.
Diagnostic performance of the imaging tests
The results of the diagnostic performance of the EMERALD ophthalmic graders are presented in the
following three sections:
1. Diagnostic performance for DMO patients eligible for the new ophthalmic grader pathway.
2. Diagnostic performance for PDR patients eligible for the new ophthalmic grader pathway.
3. Secondary sensitivity analyses on combined diseases (DMO and PDR) for all patients.
Diagnostic performance for diabetic macular oedema patients eligible for the new
ophthalmic grader pathway
Summary of ophthalmic graders’ grading results for diabetic macular oedema
Table 12 displays the OCT-based ophthalmic graders’ grading results at the person level against the
reference standard. The graders’ decision on whether or not to refer the patient, an inherently person-
level decision, was used rather than an assessment of the single eye. Furthermore, to address how the
new pathway would function in practice, graders’ assessment results of DMO of ‘unsure’ and ‘ungradable’
were considered alongside those classified as ‘active’ to be referred to an ophthalmic clinic for ophthalmological
assessment. Of the 272 DMO patients who were eligible for the new pathway, 152 (56%) were identified
by the ophthalmologists’ slit-lamp biomicroscopic examination with access to SD-OCT images (O-FTF+OCT
is the reference standard) as having DMO that was active at the time of recruitment, whereas 120 (44%) were
identified by the O-FTF+OCTreference standard as having DMO that was inactive at the time of recruitment.
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seven-field (O-ETDRS) Graders UWF (G-OPTOS)
Ophthalmologist UWF





















Total PDR present 171 162 185 185 191 170 206 213
Active 88 83 58 60 85 73 70 75 80 79
Inactive 71 65 98 106 95 81 117 121 180 172
Unsure if active 12 14 29 19 11 16 19 17 – –
No PDR 166 156 150 137 152 162 143 125 134 140
Unsure if PDR
present
20 17 30 31 20 21 25 23 – –
Ungradable 19 27 9 10 16 21 4 12 2 2
No images 20 31 22 30 17 19 18 20 – –
G-ETDRS, grader assessment based on seven-field ETDRS fundus images; G-OPTOS, grader assessment based on ultra-wide field fundus images using OPTOS; O-ETDRS, ophthalmologist
assessment based on seven-field ETDRS fundus images; O-FTF, reference standard for PDR; O-OPTOS, ophthalmologist assessment based on ultra-wide field fundus images using OPTOS.
a Five eyes in total could not be assessed. One right eye could not be assessed owing to blindness; four left eyes could not be assessed owing to blindness (n = 2), total retinal
detachment (n = 1) and artificial eye (n= 1).






































TABLE 11 Missing images at person level
Number of participants (n= 397)
All images are available (all threea imaging modalities for both eyesb) 345
Missing at least one imaging assessment 52
Image missing: patient would need referral 17
No view of fundus: vitreous haemorrhage 2
No view of fundus: corneal graft 1
Poor pupillary dilatation 4
Patient unable to co-operate with imaging 1
Patient unable to sit at the camera 2
Media opacity 5
Patient could not stand the light 1
Unable to see fundus owing to pathology 1
Image missing: missing 35
Patient does not attend for the taking of the image 9
Only one eye image capturedc 5
Images not recorded correctly 11
Other unknown reason 10
a OCT, ETDRS and OPTOS.
b Five eyes in total could not be imaged. For these five patients, only three imaging assessment per patients
were taken.
c At the initiation of the study and for a short period until an amendment was implemented, images were being
obtained in ‘eligible’ eyes only.
TABLE 12 Diabetic macular oedema classifications: eligible patients for new pathway (n= 272)
Classification














Positive 152 85 132 220 209 177
Negative 120 187 139 40 50 80
Missing/cannot
classify
0 0 1 12 13 15
G-OCT, grader assessment based on SD-OCT images; O-FTF +OCT, reference standard for DMO.
a Ophthalmologist slit-lamp biomicroscopic examination with access to OCT images identifying active DMO in
either eye.
b Ophthalmologist slit-lamp biomicroscopic examination with access to OCT images identifying active DMO in either
eye requiring treatment.
c Ophthalmologist slit-lamp biomicroscopic examination with access to OCT images identifying central-involving active
DMO in either eye.
d Grader referral for DMO: ‘active’ + ‘unsure’+ ‘ungradable’.
e Graders’ referral of DMO based on OCT images, which includes ‘DMO present’, ‘Unsure if DMO present’ and
‘Ungradable’. In practice, patients under these three categories would be referred to an ophthalmic clinic.
f Grader identification of active DMO (active DMO only, ‘unsure’ and ‘ungradable’ excluded) in either eye based on
OCT images.
g Grader identification of central-involving active DMO in either eye based on OCT images.
Shaded cells refer to the reference standard.
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Compared with this reference standard, 220 (81%) out of the 272 patients under graders’ assessment
(G-OCT) were referred for further ophthalmological examination; of these, 209 (209/220; 95%) were
referred because graders (G-OCT) identified active DMO (i.e. active DMO present in their opinion) and
11 (11/220; 5%) because graders were unsure or considered OCT images ungradable.
The flow of study participants who followed the new pathway of graders’ assessment for DMO based
on OCT is shown in Figure 10. Of the 397 EMERALD participants, four (1%) had missing OCT images
for both eyes and were excluded from the analyses. Eleven (3%) participants were excluded from the
main analysis and 12 (3%) were excluded from SENA1 because of missing OCT images for one eye,
which led to no overall graders assessment result at the patient level. Of the 382 participants who had
valid grading results from the graders to be included in the main analysis, 281 (74%) were identified by
the graders as referring for DMO (i.e. having active DMO or unsure or ungradable), of whom 220 (78%)
were eligible for the new DMO pathway. In total, 101 (26%) of the 382 participants were identified by
the graders as not having active DMO (including no DMO and inactive DMO), of whom 40 (40%) were
eligible for the new DMO pathway. Of the 381 participants who had valid grading results from the
graders to be included in SENA1, 262 (69%) were identified by the graders as having active DMO
(i.e. excluding unsure and ungradable), of whom 209 (80%) were eligible for the new DMO pathway.
In total, 119 (31%) out of the 381 participants were identified by the graders as not having active DMO,
of whom 50 (42%) were eligible for the new DMO pathway. The diagnostic performance for the main
analysis and sensitivity analyses for DMO patients are given in Table 13. Results from the main analysis
and SENA1 are also presented in the flow diagram (see Figure 10). Owing to missing OCT images that
led to no overall graders assessment result, the grader’s diagnostic performance under main analysis
was tested with a slightly smaller number of referral for DMO [disease present, n = 147; true positive
(TP), n = 142; false negative (FN), n = 5] than the O-FTF-OCT (ophthalmologist face-to-face examination
with access to optical coherence tomography scans) examination of active DMO (n = 152), and a slightly
smaller number of not active DMO [disease absent, n = 113; false positive (FP), n = 78; true negative
(TN), n = 35] than the O-FTF-OCT examination of not active DMO (n = 120). The grader’s diagnostic
performance under SENA1 was also tested with a slightly smaller number of active DMO (disease
present, n = 146; TP, n = 139; FN, n = 7) than the O-FTF-OCT examination of active DMO (n = 152),
and a slightly smaller number of not active DMO (disease absent, n = 113; FP, n = 70; TN, n = 43)
than the O-FTF-OCT examination of not active DMO (n = 120).
Results: main analysis for diabetic macular oedema
The main analysis tested the ophthalmic graders’ decision of referring patients to ophthalmologists
because of the presence of active DMO, or if they were unsure or unable to grade the images
(ungradable) in either eye based on the OCT images. The reference standard was the ophthalmologist
slit-lamp biomicroscopic examination with access to OCT images identifying active DMO in either eye.
Under this main analysis of DMO, graders were found to have a sensitivity of 97% (95% CI 92% to
99%) with a specificity of 31% (95% CI 23% to 40%) when compared with the reference standard.
Results: sensitivity analysis for diabetic macular oedema
Sensitivity analysis 1
Sensitivity analysis 1 assessed the impact of the ‘unsure’ and ‘ungradable’ ophthalmic graders’ grading
results on the diagnostic performance, by defining the index test positive as definite assessment of active
DMO (in contrast to allowing referral for unsure or ungradable DMO). Under this analysis, graders were
found to have a sensitivity of 95% (95% CI 90% to 98%) and a specificity of 38% (95% CI 30% to 47%).
Sensitivity analysis 2, 3 and 6
Similar results were obtained for the analysis evaluating people with DMO requiring further treatment,
as determined by the ophthalmologist in the standard of care pathway (sensitivity 95%, 95% CI
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FIGURE 10 Flow diagram: diagnosis as determined by the ophthalmic graders for DMO patients – main and SENA1.
Note that this flow diagram presents only the grading results from the graders’ assessment based on SD-OCT images.
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
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89% to 98%; specificity 21%, 95% CI 15% to 27%), and those with central-involving DMO (sensitivity
94%, 95% CI 88% to 97%; specificity 56%, 95% CI 48% to 65%) when compared with the reference
standard. Sensitivity and specificity values for the grader’s pathway were found to be similar to those
presented for the main analysis when referral for active DMO was considered only (excluding ‘unsure’
and ‘ungradable’) and when patients were assessed specifically in NHS clinics (vs. in ‘research’ clinics).
Diagnostic performance for proliferative diabetic retinopathy patients eligible for the
new ophthalmic grader pathway
Summary of the ophthalmic graders’ grading results
Table 14 shows the UWF OPTOS and seven-field ETDRS-based ophthalmic graders’ and
ophthalmologists’ grading results for PDR patients at the eye level against the reference standard.
To mimic the way that the new pathway would function in clinical practice, graders’ results of PDR
of ‘active’, ‘unsure’ and ‘ungradable’ were considered to require a referral to the clinic to be assessed
by an ophthalmologist. Of the 281 PDR patients who were eligible for the new ophthalmic grader
pathway, 111 (40%) were identified by the ophthalmologist slit-lamp biomicroscopic examination
(O-FTF is the reference standard for PDR) as having active PDR at the time of recruitment in the
EMERALD study. A total of 170 (60%) patients were identified by the O-FTF reference standard as
having inactive PDR at the time of recruitment. In total, 161 (57%) out of the 281 patients under
TABLE 13 Diagnostic performance for DMO patients





DMO in either eye
Sensitivity (%) 142/147 97% (92% to 99%)
Specificity (%) 35/113 31% (23% to 40%)
Positive likelihood ratio – 1.40 (1.23 to 1.59)





DMO in either eye
Sensitivity (%) 139/146 95% (90% to 98%)
Specificity (%) 43/113 38% (30% to 47%)
Positive likelihood ratio – 1.54 (1.32 to 1.78)





DMO in either eye
requiring treatment
Sensitivity (%) 81/85 95% (89% to 98%)
Specificity (%) 36/175 21% (15% to 27%)
Positive likelihood ratio – 1.20 (1.10 to 1.31)








Sensitivity (%) 121/129 94% (88% to 97%)
Specificity (%) 72/128 56% (48% to 65%)
Positive likelihood ratio – 2.14 (1.75 to 2.62)







eye of eligible patients
in routine clinic
Sensitivity (%) 81/85 95% (89% to 98%)
Specificity (%) 26/65 40% (29% to 52%)
Positive likelihood ratio – 1.59 (1.30 to 1.95)
Negative likelihood ratio – 0.12 (0.04 to 0.32)
G-OCT, grader assessment based on SD-OCT images; O-FTF +OCT, reference standard for DMO.
a Grader referral for DMO= ‘active’ + ‘unsure’ + ‘ungradable’.
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TABLE 14 Proliferative diabetic retinopathy classifications: eligible patients for the new pathway (n = 281)
Classification






















Positive 111 96 85 146 95 75 161 109 170 118
Negative 170 166 167 135 186 206 104 155 92 139
Missing/cannot
classify
0 19 29 0 0 0 16 17 19 24
G-ETDRS, grader assessment based on seven-field ETDRS fundus images; G-OPTOS, grader assessment based on ultra-wide field fundus images using OPTOS; O-ETDRS, ophthalmologist
assessment based on seven-field ETDRS fundus images; O-FTF, reference standard; O-OPTOS, ophthalmologist assessment based on ultra-wide field fundus images using OPTOS.
a Ophthalmologist slit-lamp biomicroscopic examination of active PDR.
b Ophthalmologist’s identification of active PDR based on UWF OPTOS fundus images.
c Ophthalmologist’s identification of active PDR based on seven-field ETDRS fundus images.
d ERS combined the ophthalmologist slit-lamp biomicroscopic examination, ophthalmologist grading of UWF OPTOS and ophthalmologist grading of seven-field ETDRS imaging.
Active PDR was defined as ‘Active’ detected by any of these three ophthalmologist assessments.
e Ophthalmologist slit-lamp biomicroscopic examination of active PDR in either eye requiring treatment.
f Ophthalmologist slit-lamp biomicroscopic examination disclosed pre-retinal or vitreous haemorrhages in either eye indicative of high-risk PDR.
g Grader referral for PDR= ‘active’+ ‘unsure’ + ‘ungradable’.
h Grader referral for PDR based on UWF OPTOS fundus images, which includes ‘active PDR’, ‘unsure if PDR active’, ‘unsure if PDR present’ and ‘ungradable’. In practice, patients
under these four categories would be referred to an ophthalmic clinic for ophthalmological assessment.
i Grader identification of ‘active’ PDR in either eye by UWF OPTOS fundus images.
j Grader referral for PDR based on seven-field ETDRS fundus images, which includes ‘active PDR’, ‘unsure if PDR active’, ‘unsure if PDR present’ and ‘ungradable’. In practice,
patients under these four categories would be referred to an ophthalmic clinic.
















































































































































































































































































































































graders’ assessment based on OPTOS (G-OPTOS) were referred for further examination. Of these
patients, 109 (68%; 109/161) were assessed by the graders based on OPTOS (G-OPTOS) as having
PDR that was ‘active’, whereas 52 (32%; 52/161) were assessed by the graders (G-OPTOS) as ‘unsure’
or ‘ungradable’. In total, 170 (60%) of the 281 patients under graders’ assessment based on ETDRS
(G-ETDRS) were referred for further examination. Of these, 118 (69%; 118/170) patients were assessed
by the graders based on ETDRS (G-ETDRS) as having ‘active’ PDR, whereas 52 (31%; 52/170) were
assessed by the graders (G-OPTOS) as ‘unsure’ or ‘ungradable’. Compared with the reference standard,
146 (52%) of the 281 patients were identified by the enhanced standard as having ‘active’ PDR.
The flow of study participants who followed the new pathway of graders’ assessment of PDR based
on OPTOS and ETDRS images is shown in Figure 11. Of the 397 EMERALD participants, nine (2%)
participants who had missing OPTOS images for both eyes were excluded from the analyses that used
OPTOS images. Twelve (3%) participants who had missing ETDRS images for both eyes were excluded
from the analyses that used ETDRS images. Of the 388 participants assessed using OPTOS images,
13 (3%) were excluded from the main analysis and 14 (4%) were excluded from SENA1 owing to
missing OPTOS images for one eye that led to no overall graders’ assessment result at the patient
level. In comparison, 15 (4%) and 20 (5%) of the 385 participants assessed using ETDRS images were
excluded from the main analysis and SENA1, respectively; this was because of missing ETDRS images
for one eye that led to no overall graders’ assessment result at the patient level.
In total, 375 participants who had valid OPTOS grading results were available to be included in the
main analysis, of whom 207 (55%) were identified by the graders as referring for PDR (i.e. having
active PDR or unsure or ungradable). A total of 161 (78%) out of the 207 referrals for PDR were
eligible for the new PDR pathway. In total, 168 (45%) out of the 375 participants were identified by
the graders as having not active PDR (including no PDR and inactive PDR), of whom 104 (62%) were
eligible for the new PDR pathway. A total of 374 participants had valid OPTOS grading results and
were available to be included in SENA1. In total, 131 (35%) participants were identified by the graders
as having active PDR (i.e. excluding unsure and ungradable), of whom 109 (83%) were eligible for the
new PDR pathway. A total of 243 (65%) out of the 374 participants were identified as having not active
PDR, of whom 155 (64%) were eligible for the new PDR pathway. Results from the main analysis and
SENA1 for OPTOS are also presented in the flow diagram (see Figure 11). Owing to missing OPTOS
images that led to no overall graders’ assessment result, grader’s diagnostic performance under main
analysis was tested with a slightly smaller number of referrals for PDR (disease present, n = 105; TP
n = 87; FN, n = 18) than that for the O-FTF examination of active PDR (n = 111), and a slightly smaller
number of not active PDR referrals (disease absent, n = 160; FP, n = 74; TN, n = 86) than that for the
O-FTF examination of not active PDR (n = 170). Graders’ diagnostic performance under SENA1 was
also tested with a slightly smaller number of active PDR referrals (disease present, n = 105; TP, n = 66;
FN, n = 39) than that for the O-FTF examination of active PDR (n = 111), and a slightly smaller number
of not active PDR referrals (disease absent, n = 159; FP, n = 43; TN, n = 116) than that for the O-FTF
examination of not active PDR (n = 170).
In total, 370 participants who had valid ETDRS grading results were available to be included in the
main analysis, of whom 214 (58%) were identified by the graders as referring for PDR (i.e. having
active PDR or unsure or ungradable). A total of 170 (79%) out of the 214 referrals for PDR were
eligible for the new PDR pathway. A total of 156 (42%) out of the 370 participants were identified by
the graders as having not active PDR (including no PDR and inactive PDR), of whom 92 (59%) were
eligible for the new PDR pathway. In total, 365 participants had valid ETDRS grading results and were
available to be included in SENA1. A total of 138 (38%) participants were identified by the graders as
having active PDR (i.e. excluding unsure and ungradable), of whom 118 (86%) were eligible for the new
PDR pathway. A total of 227 (62%) out of the 365 participants were identified as having not active
PDR, of whom 139 (61%) were eligible for the new PDR pathway. Results from the main analysis and
SENA1 for ETDRS are also presented in the flow diagram (see Figure 11). Owing to missing ETDRS
images that led to no overall graders assessment result, grader’s diagnostic performance under the
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FIGURE 11 Flow diagram: diagnosis as determined by the ophthalmic graders for PDR patients comparing OPTOS
and ETDRS – main and SENA1. This flow diagram only presents the grading results from the graders’ assessment
based on UWF OPTOS images and seven-field ETDRS images.
DOI: 10.3310/hta25320 Health Technology Assessment 2021 Vol. 25 No. 32
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Lois et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
33
main analysis was tested with a slightly smaller number of referrals for PDR (disease present, n = 102;
TP, n = 87; FN, n = 15) than that for the O-FTF examination of active PDR (n = 111), and a slightly
smaller number of not active PDR referrals (disease absent, n = 160; FP, n = 83; TN, n = 77) than that
for the O-FTF examination of not active PDR (n = 170). Graders’ diagnostic performance under SENA1
was also tested with a slightly smaller number of active PDR referrals (disease present, n = 99; TP,
n = 70; FN, n = 29) than that for the O-FTF examination of active PDR (n = 111), and a slightly smaller
number of not active PDR (disease absent, n = 158; FP, n = 48; TN, n = 110) than that for the O-FTF
examination of not active PDR (n = 170).
The diagnostic performance for the main analysis, sensitivity analyses and additional analyses for PDR
patients are given in Table 15.
TABLE 15 Diagnostic performance for PDR patients
Analysis Results Reference standard
Diagnostic




active PDR in either eye
Sensitivity (%) 87/105 83% (75% to 89%)
Specificity (%) 86/160 54% (46% to 61%)
Positive
likelihood ratio
– 1.79 (1.48 to 2.16)
Negative
likelihood ratio




active PDR in either eye
Sensitivity (%) 87/102 85% (77% to 91%)
Specificity (%) 77/160 48% (41% to 56%)
Positive
likelihood ratio
– 1.64 (1.39 to 1.95)
Negative
likelihood ratio




active PDR in either eye
Sensitivity (%) 66/105 63% (53% to 71%)
Specificity (%) 116/159 73% (66% to 79%)
Positive
likelihood ratio
– 2.32 (1.73 to 3.12)
Negative
likelihood ratio




active PDR in either eye
Sensitivity (%) 70/99 71% (61% to 79%)
Specificity (%) 110/158 70% (62% to 76%)
Positive
likelihood ratio
– 2.33 (1.78 to 3.04)
Negative
likelihood ratio
– 0.42 (0.30 to 0.58)
Additional 1 O-OPTOS identified
active PDR
O-FTF examination of
active PDR in either eye
Sensitivity (%) 74/103 72% (62% to 80%)
Specificity (%) 137/159 86% (80% to 91%)
Positive
likelihood ratio
– 5.19 (3.46 to 7.80)
Negative
likelihood ratio
– 0.33 (0.24 to 0.45)
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TABLE 15 Diagnostic performance for PDR patients (continued )
Analysis Results Reference standard
Diagnostic




active PDR in either eye
Sensitivity (%) 65/98 66% (57% to 75%)
Specificity (%) 134/154 87% (81% to 91%)
Positive
likelihood ratio
– 5.11 (3.31 to 7.87)
Negative
likelihood ratio




active PDR in either eye
requiring treatment
Sensitivity (%) 77/90 86% (77% to 91%)
Specificity (%) 91/175 52% (45% to 59%)
Positive
likelihood ratio
– 1.78 (1.49 to 2.13)
Negative
likelihood ratio




active PDR in either eye
requiring treatment
Sensitivity (%) 74/84 88% (79% to 93%)
Specificity (%) 82/178 46% (39% to 53%)
Positive
likelihood ratio
– 1.63 (1.40 to 1.91)
Negative
likelihood ratio







Sensitivity (%) 62/71 87% (78% to 93%)
Specificity (%) 95/193 49% (42% to 56%)
Positive
likelihood ratio
– 1.71 (1.45 to 2.02)
Negative
likelihood ratio







Sensitivity (%) 53/66 80% (69% to 88%)
Specificity (%) 79/196 40% (34% to 47%)
Positive
likelihood ratio
– 1.35 (1.14 to 1.59)
Negative
likelihood ratio
– 0.49 (0.29 to 0.82)






Sensitivity (%) 57/70 81% (71% to 89%)
Specificity (%) 153/192 80% (73% to 85%)
Positive
likelihood ratio
– 4.01 (2.96 to 5.42)
Negative
likelihood ratio







Sensitivity (%) 42/64 66% (53% to 76%)
Specificity (%) 145/188 77% (71% to 83%)
Positive
likelihood ratio
– 2.87 (2.09 to 3.94)
Negative
likelihood ratio
– 0.45 (0.31 to 0.63)
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TABLE 15 Diagnostic performance for PDR patients (continued )
Analysis Results Reference standard
Diagnostic
parameter n/N Estimate (95% CI)
SENA5 G-OPTOS referral
for PDR
ERS Sensitivity (%) 110/138 80% (72% to 86%)
Specificity (%) 76/127 60% (51% to 68%)
Positive
likelihood ratio
– 1.98 (1.58 to 2.49)
Negative
likelihood ratio
– 0.34 (0.24 to 0.49)
G-ETDRS referral
for PDR
ERS Sensitivity (%) 111/135 82% (75% to 88%)
Specificity (%) 68/127 54% (45% to 62%)
Positive
likelihood ratio
– 1.77 (1.45 to 2.17)
Negative
likelihood ratio
– 0.33 (0.22 to 0.49)
Additional 3 G-OPTOS referral
for PDR
O-FTF+O-OPTOS
identified active PDR in
either eye
Sensitivity (%) 101/125 81% (73% to 87%)
Specificity (%) 80/140 57% (49% to 65%)
Positive
likelihood ratio
– 1.89 (1.53 to 2.32)
Negative
likelihood ratio




identified active PDR in
either eye
Sensitivity (%) 103/122 84% (77% to 90%)
Specificity (%) 73/140 52% (44% to 60%)
Positive
likelihood ratio
– 1.76 (1.46 to 2.13)
Negative
likelihood ratio
– 0.30 (0.19 to 0.46)
SENA6 G-OPTOS referral
for PDR in routine
clinic
O-FTF examination of
active PDR in either eye
of eligible patients in
routine clinic
Sensitivity (%) 63/77 82% (72% to 89%)
Specificity (%) 47/92 51% (41% to 61%)
Positive
likelihood ratio
– 1.67 (1.32 to 2.11)
Negative
likelihood ratio
– 0.36 (0.21 to 0.60)
G-ETDRS referral for
PDR in routine clinic
O-FTF examination of
active PDR in either eye
of eligible patients in
routine clinic
Sensitivity (%) 60/74 81% (71% to 88%)
Specificity (%) 41/91 45% (35% to 55%)
Positive
likelihood ratio
– 1.48 (1.19 to 1.83)
Negative
likelihood ratio
– 0.42 (0.25 to 0.71)
G-ETDRS, grader assessment based on seven-field ETDRS fundus images; G-OPTOS, grader assessment based on
ultra-wide field fundus images using OPTOS; O-ETDRS, ophthalmologist assessment based on seven-field ETDRS
fundus images; O-FTF, reference standard for PDR; O-OPTOS, ophthalmologist assessment based on ultra-wide field
fundus images using OPTOS.
a Grader referral for PDR = ‘active’ + ‘unsure’+ ‘ungradable’.
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Results: main analysis for proliferative diabetic retinopathy
The main analysis tested the ophthalmic graders decision of referring patients to ophthalmologists
because of the presence of active PDR, they were unsure if PDR was active, or they were unsure if PDR
was present or ungradable in either eye based on OPTOS or ETDRS images. The reference standard
was the ophthalmologist slit-lamp biomicroscopic examination (O-FTF) identifying active PDR in either
eye. Under the main analysis of PDR, graders were found to have similar sensitivity and specificity
whether they used UWF fundus images (G-OPTOS: sensitivity 83%, 95% CI 75% to 89%; specificity 54%,
95% CI 46% to 61%) or seven-field ETDRS fundus images (G-ETDRS: sensitivity 85%, 95% CI 77% to 91%;
specificity 48%, 95% CI 41% to 56%).
Results: sensitivity analysis for proliferative diabetic retinopathy
Sensitivity analysis 1
Sensitivity analysis 1 (SENA1) assessed the impact of the ‘unsure’ and ‘ungradable’ ophthalmic
graders’ grading results on the diagnostic performance by defining the index test positive as definite
assessment of active PDR. Under this analysis, graders were found to have a sensitivity of 63% based
on OPTOS (G-OPTOS: sensitivity 63%, 95% CI 53% to 71%; specificity 73%, 95% CI 66% to 79%) and
a sensitivity of 71% based on ETDRS (G-ETDRS: sensitivity 71%, 95% CI 61% to 79%; specificity 70%,
95% CI 62% to 76%).
Sensitivity analyses 2, 4, 5 and 6
Values for sensitivity and specificity were very similar to those from the main analysis when graders
evaluated patients who required further treatment, as determined by the ophthalmologist in the
standard care pathway (G-OPTOS: sensitivity 86%, 95% CI 77% to 91%; specificity 52%, 95% CI
45% to 59%) (G-ETDRS: sensitivity 88%, 95% CI 79% to 93%; specificity 46%, 95% CI 39% to 53%).
When determining the sensitivity of the ophthalmic graders’ pathway to detect more severe disease
(PDR with pre-retinal or vitreous haemorrhage), the sensitivity and specificity of the graders pathway
when using ultra-wide-field fundus imaging was slightly higher (G-OPTOS: sensitivity 87%, 95% CI
78% to 93%; specificity 49%, 95% CI 42% to 56%) than that when using seven-field ETDRS images
(G-ETDRS: sensitivity 80%, 95% CI 69% to 88%; specificity 40%, 95% CI 34% to 47%) when compared
with the reference standard. When determining the sensitivity and specificity of the graders pathway
against the ERS, results were similar to the comparison with the reference standard (G-OPTOS
sensitivity: 80%, 95% CI 72% to 86%; specificity 60%, 95% CI 51% to 68%) (G-ETDRS: sensitivity 82%,
95% CI 75% to 88%; specificity 54%, 95% CI 45% to 62%). The sensitivity and specificity of graders
were found to be similar to those presented in the main analysis when patients were assessed
specifically in NHS clinics (vs. in ‘research’ clinics).
Results: additional analysis for proliferative diabetic retinopathy
Additional analyses 1–3
Three sets of additional ad hoc analyses for PDR patients who were not listed in the statistical analysis
plan were also conducted in the light of the results of the pre-planned analysis for PDR to understand
the content and potential value of the two imaging modalities better along with the reliability of the
O-FTF reference standard for PDR. Additional 1 compared the ophthalmologist identifying active
PDR by OPTOS or by ETDRS in either eye with the reference standard of O-FTF assessment of active
PDR. The sensitivities of ophthalmologist performance (O-OPTOS: sensitivity 72%, 95% CI 62% to
80%; O-ETDRS: sensitivity 66%, 95% CI 57% to 75%) did not differ greatly from those of graders’
performance (SENA1). Ophthalmologist performance was only better than that of the graders when
using UWF OPTOS fundus images (difference in sensitivity when comparing the diagnostic performance
of ophthalmologists with that of graders based on OPTOS: 9%); whereas graders’ performance was
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better than that of the ophthalmologists when using seven-field ETDRS fundus images (difference in
sensitivity when comparing the diagnostic performance of ophthalmologists with that of graders’ based
on ETDRS: –5%). However, compared with graders, the ophthalmologists were much better at ruling
out not active PDR. The specificity of the ophthalmologists (O-OPTOS specificity 86%, 95% CI 80% to
91%; O-ETDRS specificity 87%, 95% CI 81% to 91%) was higher than that of the graders (G-OPTOS
specificity 73%, 95% CI 66% to 79%; G-ETDRS specificity 70%, 95% CI 62% to 76%). Additional 2
compared the ophthalmologist identification of active PDR by OPTOS or by ETDRS in either eye against
the reference standard in patients where the O-FTF assessment identified pre-retinal or vitreous
haemorrhage (i.e. people with high-risk PDR). Although the specificity of the ophthalmologists (O-OPTOS
specificity 80%, 95% CI 73 % to 85%; O-ETDRS specificity 77%, 95% CI 71% to 83%) was much higher
than that of the graders (G-OPTOS specificity 49%, 95% CI 42% to 56%; G-ETDRS specificity 40%, 95% CI
34% to 47%), the sensitivity of the ophthalmologists was much lower than that of the graders’ pathway
when using seven-field ETDRS images (O-ETDRS sensitivity 66%, 95% CI 53% to 76%; G-ETDRS sensitivity
80%, 95% CI 69% to 88%). The sensitivity of the ophthalmologists when using UWF OPTOS fundus
imaging was similar to that of the graders (O-OPTOS sensitivity 81%, 95% CI 71% to 89%; G-OPTOS
sensitivity 87%, 95% CI 78% to 93%) when compared with the reference standard. Additional 3
compared the ophthalmic graders’ referral for either eye by OPTOS or by ETDRS against the O-FTF
assessment combined with O-OPTOS or O-FTF assessment combined with O-ETDRS of active PDR in
either eye. This additional analysis was aimed at comparing the diagnostic performance of graders using
OPTOS or using ETDRS as, in practice, images could be obtained with only one imaging modality. The
sensitivity and specificity of the graders were similar to the set reference standard. Some other useful
results on the percentage agreement among test positive and reference standard or enhanced standard
can be found in Appendix 1, Table 40.
Paired comparisons of OPTOS and ETDRS assessment of proliferative diabetic retinopathy
The difference in sensitivity and specificity between OPTOS and ETDRS fundus images assessed by the
ophthalmic graders in the main analysis and SENA1 were also compared with corresponding 95% CIs
produced using Newcombe’s method for paired data30 and McNemar’s test.31 The results show no
evidence of statistically significant difference in sensitivity and specificity between OPTOS and ETDRS
fundus images in both analyses (Tables 16 and 17). However, a difference of a meaningful amount
cannot be ruled out, with 95% CI for difference in sensitivity under SENA1 in particular ranging from
–21% to 5%.
TABLE 16 Paired comparisons in sensitivity and specificity between G-OPTOS and G-ETDRS (main analysis)
Main analysis G-ETDRS G-ETDRS
G-OPTOS Positive Negative Positive Negative
Positive 72 11 45 27
Negative 14 4 35 49
Sensitivity (n= 101) Specificity (n= 156)
OPTOS (95% CI Wilson) 82% (74% to 88%) 54% (46% to 61%)
ETDRS (95% CI Wilson) 85% (76% to 90%) 49% (41% to 56%)
Difference (95% CI) –3% (–14% to 8%) 5% (–5% to 16%)
McNemar’s test p-value p = 0.55 p = 0.31
G-ETDRS, grader assessment based on seven-field ETDRS fundus images; G-OPTOS, grader assessment based on
ultra-wide field fundus images using OPTOS.
DIAGNOSTIC ACCURACY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
38
Secondary sensitivity analyses on combined diseases (diabetic macular oedema and
proliferative diabetic retinopathy) for all patients
In addition to the principal analyses that were conducted at the person level separately for DMO
and PDR, three planned secondary analyses and one additional analysis at person level that focused on
the overall referral status of a patient, irrespective of whether it was active (or unsure or ungradable)
DMO or PDR that required referral due to disease, were conducted first. These four secondary analyses
focused on the entire EMERALD patient population (‘All patients’) rather than only those patients who
were eligible for the new pathway. Table 18 displays the reference standard for the secondary analyses
and the ophthalmic graders’ grading results for both diseases and for all patients at eye level against the
reference standard. The reference standards of O-FTF +OCT assessment for DMO and O-FTF for PDR
of those present with active disease were used (either disease constituting active disease at the person
level) or active disease which required treatment. Diagnostic performance for the secondary analyses
was assessed using the same outcomes and methods as for the principal analyses and the results are
given in Table 19.
The results showed an overall high sensitivity for the new ophthalmic grader pathway in detecting DMO
and PDR (either or both diseases). The sensitivity of graders referral for combined diseases (SENA2A) was
similar among the two combinations of images (G-OCT +G-OPTOS vs. G-OCT +G-ETDRS); however, the
specificity was much higher when they used G-OCT+G-OPTOS (sensitivity 96%, 95% CI 92% to 97%;
specificity 33%, 95% CI 25% to 42%) than when they used G-OCT + G-ETDRS (sensitivity 95%, 95% CI
92% to 97%; specificity 22%, 95% CI 15% to 30%). Additional 4 was also conducted in the light of the
results of the pre-planned analysis, to test graders’ assessment of active disease(s) rather than graders’
referral of active disease(s) (i.e. including ‘unsure’ and ‘ungradable’). Compared to graders’ referral of
active disease(s) (including ‘unsure’ and ‘ungradable’) (SECA2A), graders’ assessment of strictly active
disease(s) (Additional 4) presented similar sensitivity (93% compared with 95%), but higher specificity
(G-OCT + G-OPTOS, Additional 4: 48% vs SECA2A: 33%; G-OCT + G-ETDRS, Additional 4: 38% vs.
SECA2 A: 22%). Both SECA2A and Additional 4 demonstrate how the new pathway would function
in practice.
Three eye-level secondary analyses were also conducted, and the results are displayed in Appendix 1,
Tables 41 and 42.
TABLE 17 Paired comparisons in sensitivity and specificity between grader OPTOS and ETDRS (SENA1)
SENA1 G-ETDRS G-ETDRS
G-OPTOS Positive Negative Positive Negative
Positive 47 14 22 23
Negative 22 15 27 84
Sensitivity (n= 98) Specificity (n= 156)
OPTOS (95% CI Wilson) 62% (52% to 71%) 71% (64% to 78%)
ETDRS (95% CI Wilson) 70% (61% to 79%) 69% (61% to 75%)
Difference (95% CI) –8% (–21% to 5%) 3% (–7% to 12%)
McNemar’s test p-value p = 0.18 p = 0.57
G-ETDRS, grader assessment based on seven-field ETDRS fundus images; G-OPTOS, grader assessment based on
ultra-wide field fundus images using OPTOS.
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TABLE 18 Patient-level classifications: all patients (n = 397)
Classification
O-FTF+OCT and O-FTF Combined test – grader
Active DMOa Active PDRb
Either eye combined –
active DMO or PDRc
Either eye combined –












or PDR based on
G-OCT+G-OPTOSi
Referral of DMO




Positive 198 123 272 178 281 207 214 341 350 217
Negative 198 272 125 219 101 168 156 53 40 180
Missing/cannot
classify
1 2 0 0 15 22 27 3 7 0
G-ETDRS, grader assessment based on seven-field ETDRS fundus images; G-OPTOS, grader assessment based on ultra-wide field fundus images using OPTOS; G-OCT, grader
assessment based on SD-OCT images; O-FTF, reference standard for PDR; O-FTF+OCT, reference standard for DMO.
a ‘Active DMO’ defined as active DMO (active refers here to ‘recurrence’ ‘de novo’ and ‘persistence’) under ophthalmologist slit-lamp biomicroscopic examination with access to
OCT images.
b ‘Active PDR’ defined as active PDR (active refers here to ‘recurrence’ ‘de novo’ and ‘persistence’) under ophthalmologist slit-lamp biomicroscopic examination.
c Active DMO or PDR (active refers here to ‘recurrence’ ‘de novo’ and ‘persistence’) identified by reference standard in either eye.
d Active DMO or PDR (active refers here to ‘recurrence’ ‘de novo’ and ‘persistence’) identified by reference standard in either eye that requiring treatment.
e Graders’ referral for DMO/PDR = ‘active’ + ‘unsure’ + ‘ungradable’.
f Graders’ referral for DMO based on OCT images, which includes ‘DMO present’, ‘Unsure if DMO present’ and ‘Ungradable’.
g Graders’ referral for PDR based on UWF OPTOS fundus images, which includes ‘Active PDR’, ‘Unsure if PDR active’, ‘Unsure if PDR present’ and ‘Ungradable’.
h Graders’ referral for PDR based on seven-field ETDRS fundus images which includes ‘Active PDR’, ‘Unsure if PDR active’, ‘Unsure if PDR present’ and ‘Ungradable’.
i Graders’ referral for DMO or PDR based on OCT and UWF OPTOS fundus images, which includes ‘active’, ‘unsure’ and ‘ungradable’.
j Graders’ referral for DMO or PDR based on OCT and seven-field ETDRS fundus images which includes ‘active’, ‘unsure’ and ‘ungradable’.






































TABLE 19 Secondary analyses at patient level: all patients
Results Reference standard
Diagnostic
parameter n/N Estimate (95% CI)
SECA2A G-OPTOS referrala for
PDR+G-OCT referral
for DMO
O-FTF active PDR and
O-FTF +OCT active
DMO in either eye
Sensitivity (%) 258/270 96% (92% to 97%)
Specificity (%) 41/124 33% (25% to 42%)
Positive
likelihood ratio
– 1.43 (1.26 to 1.62)
Negative
likelihood ratio




O-FTF active PDR and
O-FTF +OCT active
DMO in either eye
Sensitivity (%) 253/266 95% (92% to 97%)
Specificity (%) 27/124 22% (15% to 30%)
Positive
likelihood ratio
– 1.22 (1.10 to 1.34)
Negative
likelihood ratio
– 0.22 (0.12 to 0.42)
Additional 4 G-OPTOS identified
active PDR +G-OCT
identified active DMO
O-FTF active PDR and
O-FTF +OCT active
DMO in either eye
Sensitivity (%) 245/263 93% (89% to 96%)
Specificity (%) 56/117 48% (39% to 57%)
Positive
likelihood ratio
– 1.79 (1.50 to 2.13)
Negative
likelihood ratio




O-FTF active PDR and
O-FTF +OCT active
DMO in either eye
Sensitivity (%) 242/260 93% (89% to 96%)
Specificity (%) 45/117 38% (30% to 48%)
Positive
likelihood ratio
– 1.51 (1.31 to 1.75)
Negative
likelihood ratio
– 0.18 (0.11 to 0.30)
SECA2B G-OPTOS referral for
PDR+G-OCT referral
for DMO +VA
O-FTF active PDR and
O-FTF +OCT active
DMO in either eye
Sensitivity (%) 263/271 97% (94% to 99%)
Specificity (%) 26/124 21% (15% to 29%)
Positive
likelihood ratio
– 1.23 (1.12 to 1.35)
Negative
likelihood ratio




O-FTF active PDR and
O-FTF +OCT active
DMO in either eye
Sensitivity (%) 262/270 97% (94% to 98%)
Specificity (%) 20/124 16% (11% to 24%)
Positive
likelihood ratio
– 1.16 (1.07 to 1.25)
Negative
likelihood ratio
– 0.18 (0.08 to 0.41)
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Discussion
The diagnostic performance of the EMERALD ophthalmic graders’ pathway (proposed new pathway)
for the detection of active, recurrent DMO and/or PDR (i.e. in previously successfully treated eyes,
reactivation of the disease with fluid present indicative of DMO and active PDR present) was compared
for the EMERALD population against the current standard of care, which was considered the reference
standard (O-FTF+OCT for DMO and O-FTF for PDR). Participants included in the study had at least one
of the two diseases in at least one of their two eyes (except one participant who had an artificial left eye)
and had been previously successfully treated (disease became ‘inactive’ for DMO = no fluid present, for
PDR = no signs of active PDR). The EMERALD population included a greater number of participants
with active DMO and a smaller number of participants with active PDR. It is important to note that the
overall EMERALD cohort should not be taken as a representative reflection of the clinical population.
This is due to the balance of groups being intentionally manipulated as part of the study design to
increase statistical efficiency in terms of data and to reduce the overall sample size needed. The order
in which recruitment to the four target groups ceased does seem to indicate that active PDR is less
common among patients being monitored for recurrence of DMO or PDR in hospital eye services
(which makes sense clinically as recurrences are infrequent in people with PDR following laser PRP).
The sensitivity of the new pathway to detect active DMO was around 95% (range 94% to 97%) in the
main analysis and in all four sensitivity analyses undertaken in EMERALD, suggesting that, for DMO,
the new pathway would be safe and could be implemented. The main analysis that was based on
graders’ decision to refer patients to ophthalmologists had the highest sensitivity across analyses, and
a relatively lower specificity. Comparatively, SENA1, which was based on graders’ definite detection of
active DMO only (excluding the ‘unsure’ and ‘ungradable’), had a small trade-off of higher specificity for
a lower sensitivity. The new pathway also performed very well in ruling in and ruling out the presence
of central-involving DMO (in contrast to non-central-involving DMO). This is important as central-
involving DMO is expected to affect sight and would require identification and treatment earlier than
non-central-involving DMO which often does not affect vision and would require time to progress to
central-involving DMO. Thus, missing the latter until next evaluation would be expected to have less of
a repercussion on the patient than missing central-involving DMO.
TABLE 19 Secondary analyses at patient level: all patients (continued )
Results Reference standard
Diagnostic
parameter n/N Estimate (95% CI)
SECA2C G-OPTOS referral for
PDR+G-OCT referral
for DMO +VA
O-FTF active PDR and
O-FTF +OCT active
DMO in either eye
requiring treatment
Sensitivity (%) 174/178 98% (94% to 99%)
Specificity (%) 30/217 14% (10% to 19%)
Positive
likelihood ratio
– 1.13 (1.07 to 1.20)
Negative
likelihood ratio




O-FTF active PDR and
O-FTF +OCT active
DMO in either eye
requiring treatment
Sensitivity (%) 174/177 98% (95% to 99%)
Specificity (%) 25/217 12% (8% to 16%)
Positive
likelihood ratio
– 1.11 (1.06 to 1.17)
Negative
likelihood ratio
– 0.15 (0.05 to 0.48)
G-ETDRS, grader assessment based on seven-field ETDRS fundus images; G-OCT, grader assessment based on
SD-OCT images; G-OPTOS, grader assessment based on ultra-wide field fundus images using OPTOS; O-FTF, reference
standard for PDR; O-FTF +OCT, reference standard for DMO; VA, Visual acuity < 6/12 considered as a referral to
ophthalmic clinic.
a Grader referral for DMO/PDR = ‘active’ + ‘unsure’+ ‘ungradable’.
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One methodological issue to note is that the grader DMO diagnostic accuracy results may be somewhat
optimistic in terms of the true performance of a grader’s OCT for DMO assessment as the OCTwas also
part of the reference standard. Nevertheless, this reflects current clinical practice in the NHS and in
terms of answering the research question of this study this is not, in our view, a substantive concern.
SD-OCT assessments were undertaken by different individuals for the index test (grader) versus its use
in the reference standard (determined by the ophthalmologist); this will somewhat reduce the optimism
bias associated with the same imaging modality informing the reference standard as well as being the
index test. No imputation of any missing data was undertaken in the EMERALD analysis. Given the
small number of missing images, this would not have been expected to affect the results presented.
The impact of the ‘unsure’ and ‘ungradable’ assessment by the graders was explored.
The sensitivity of the new pathway to detect active PDR was generally over 80% (range 63% to 88%)
in the main analysis and in five sensitivity analyses undertaken in EMERALD; the exception was SENA1,
which evaluated by graders’ performance specifically related to the identification of active PDR. The
trade-off of lower sensitivity for higher specificity was substantial if graders would only allow referral
to the ophthalmologist for those patients who present with active PDR (excluding those in whom they
are unsure and/or those that cannot be graded, i.e. ungradable) to ophthalmologist. Comparing the
diagnostic performance of the two different types of images that the graders assessed and on which
they based their referring decisions, there was no evidence of statistically significant differences in
sensitivity and specificity. This suggests that both the ultra-wide field fundus images and the seven-
field fundus images could be used, although there may be some minor but still important differences
between the two modalities in terms of sensitivity and specificity (circa 10%). However, it should be
noted that ultra-wide field fundus imaging had slightly higher sensitivity to detect people with high-risk
active PDR (PDR with pre-retinal and/or vitreous haemorrhage), suggesting that if a new pathway
involving graders were to be introduced for the surveillance of people with treated PDR, this technology
might be preferred to reduce the number of people who could potentially be missed with this more
severe disease.
The diagnostic accuracy results for PDR raise a number of issues and potential areas for further
research. Graders would seem to find assessment of PDR more difficult than that of DMO, both in
terms of differentiating between active and inactive PDR, and also identifying the presence of PDR. The
identification of DMO is certainly simpler; on a SD-OCT, fluid is clearly visualised. The lower specificity
in DMO for the grader pathway could be explained by the fact that graders may have ‘referred’ patients
even with minimal amount of fluid; these cases may not have been classed by ophthalmologists as
‘DMO’ (active DMO). Identifying PDR, however, requires the meticulous evaluation of the entire retina;
in the case of the graders and ophthalmologists assessing seven-field and ultra-wide fundus images, and
the very detailed check of every field of the seven fields in ETDRS and every field of the three fields
of the ultra-wide field images for the presence of new vessels. For both diseases there was a small
number of eyes ‘unclassifiable’ due to no view of fundus that led to no assessment under the respective
reference standard and these were excluded from the analyses. In practice these may or may not be
assessed with imaging prior to referral to an ophthalmologist, if the new pathway were in use.
An assessment of the graders’ diagnostic performance was also evaluated against the enhanced
reference, in a planned analysis. The findings of the various assessments, and the relative levels of
agreement suggest that each modality (including the ophthalmic slit-lamp assessment) may be missing
a substantial proportion of people with active PDR. Further work to explore this would be valuable.
A number of additional analyses were carried out for PDR to explore the findings of the planned
analyses further. These suggest that there is not generally an issue with the grader’s assessment for
PDR versus an ophthalmologist’s assessment for PDR based on both OPTOS and ETDRS imaging (with
the exception that the ophthalmologists have a lower number of uncertain assessment and, therefore,
rule out active disease more often). This suggests a more inherent issue that the different modalities
are not assessing exactly the same thing or at the very least each has its own share (and a roughly
similar amount) of disagreeable assessments.
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EMERALD used a cross-sectional case-referent design.24 This played a key role in reducing the cost
of the study substantially in that it was not longitudinal. It was also efficient in terms of reducing
the overall sample size (which also reduced costs). Furthermore, it benefited from being able to use
some participants in the main analysis of both DMO and PDR. As the data were readily available and
as patients in clinical practice will be assessed for both diseases in both eyes irrespective of history,
the full data were collected for all participants. This is reflected in the substantially larger number of
people with inactive PDR and active DMO than that set as the target (n = 104). It also provided disease-
naive assessments and indication of de novo disease even though this was not the primary reason for
an individual to be in the monitoring pathway. The case-referent design, however, has limitations over
a cohort design. It does not provide an overall assessment of prevalence of the respective diseases and
disease states (active/inactive). An implication of this was the change in the relative proportion of the
four groups of interest (DMO inactive and active, and PDR active and inactive) at the time when groups
were still being recruited versus the final numbers once recruitment had ceased to all four groups (see
Appendix 1, Table 43). Furthermore, the number of referrals from this analysis will not translate directly
to application in clinical practice due to the use of the case-referral design. The use of a case-referent
design might be viewed as potentially increasing the likelihood of a bias sample. However, as consecutive
individuals were assessed for eligibility and approached, it is very unlikely that it would have biased the
sample in EMERALD. In EMERALD, all patients considered potentially eligible (even those with media
opacities, poor co-operation, etc.) were approached to ensure that a consecutive un-biased sample was
obtained. Patients not approached and recruited would mainly reflect the incapacity of the EMERALD
team to recruit in very busy NHS clinics and, thus, would not be expected to have caused any systematic
bias. Assessment of imaging was done independently and separately from the reference standard for
both DMO and PDR, avoiding the potential for bias. Similarly, the grading of one imaging technology
was done independently of the grading of another, preventing the reading of one imaging modality from
affecting the other.
As patients with either disease are routinely assessed in the monitoring for DMO and PDR in both eyes,
a secondary analysis explored the performance of a combined overall strategy of grader assessments for
DMO and PDR. The overall sensitivity of combining tests was over 96% in all three diagnosis sensitivity
analyses, which further supports the claim that the new ophthalmic grader pathway would be safe and
could be implemented in clinical practice for the surveillance of people with previously successfully
treated DMO and PDR. The various results show the difficulties in using multiple tests and the increasing
chance of a false positive result, which would lead to referral to the ophthalmologist. EMERALD was
a cross-sectional study; monitoring over time would lead to a substantial number of individuals being
unnecessarily referred. However, the poor performance in regard to specificity was more driven by the
PDR assessment than by the DMO.When referral related to presence of ‘active PDR’ only, sensitivity
and specificity improved. Given current pressures in the NHS to meet demands, reducing the number
of visits by one-third would be a sizeable release of valuable ophthalmologist time (in this regard,
see also Chapter 4).
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Chapter 3 Focus group research
The aim of the focus group work
The aim of the FG work was to explore the acceptability of a new pathway, the ophthalmic grader
pathway, for the surveillance and care of current NHS patients with previously treated and stable
DMO and PDR.
Focus groups can function in various ways. In this case, they were used to signal key issues that
concern patients in their routine encounters with ophthalmology clinics. FGs cannot tell us how those
issues are distributed in a wider population, or enlighten us about every issue that might concern
patients (other types of research, such as randomised survey research, would be needed to provide
data on how opinions are distributed by age, class, ethnicity or gender). However, and as is indicated
in Appendix 2, there are sound reasons to believe that techniques of the kind used in FGs can capture
a considerable amount of information about attitudes, opinions, behaviours, hopes and fears in any
given population. Most importantly, they help to sharpen our vision about what is important from
‘the patient’s point of view’, because despite the fact that a FG discussion is guided, it is not
determined by a questioner (as is the case in research driven by a structured interview schedule).
Methods
Sampling and recruitment strategy
The original plan was to recruit FG participants via ophthalmology clinics and according to the strategy
outlined in Table 20. All patients had to have previously successfully treated DMO and/or PDR to be
eligible; at the time of enrolment in the EMERALD study their disease could be active or inactive.
Some patients had one or the other disease (i.e. only DMO or only PDR), whereas others were under
review for both conditions.
Unfortunately, as the recruitment of patients for the main study progressed it became increasingly
clear that the targets for FG recruitment were unlikely to be met. Many clinics were seemingly unable
to gain consent from more than a handful of patients for a FG meeting. Naturally, some clinics were
more successful than others, and towards the end of 2018 it was decided to concentrate on just five
localities: Belfast, Fife, Frimley, Gloucester and London. Even then, the prospect of holding FG meetings
for different age groups had to be abandoned in four of the five centres. Holding gender-specific
meetings was, however, possible in three of the centres.
TABLE 20 Proposed maximum variation sampling strategy for FGs in the UK: number of groups in each category by
country and age group
Country
Age group (years)
Total18–25 26–60 > 60
Scotland 1 2 2 5
England 1 2 2 5
Northern Ireland 1 2 2 5
Total number of groups 3 6 6 15
Estimated number of individuals 15–24 30–48 30–48 75–120
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Consent is one thing and attending a group is another, and so it proved. Only approximately one-third
of those who had consented and agreed to attend a meeting did so. As a result, our final sample was
as described in Table 21. The average age of all patient attendees was 59.75 years. The lowest average
age was 48 years (for a Belfast group) and the highest average age was 70 years (for the group from
Fife). In the text that follows, the FG identification numbers do not reflect the order of the groups
in Table 21.
What happened in the focus groups?
The activities were carried out in five stages:
1. Introduction – following a welcome and first name introductions, the sessions began with a brief
outline of the EMERALD project. It was explained to participants that although proceedings would
be recorded and subsequently transcribed, whatever was said within the meeting would remain
confidential. It was also stated that the doctors who organised their care and treatment were
‘very keen to get their views about the service that patients were offered, and about some changes
in the service that were being considered’. (Patient consent had been obtained and information
was given to patients by doctors and research nurses at each clinic before the FG meeting.)
2. Phase 1: images – the investigative component of the sessions began with the moderator showing
the members of the group a series of photographs. The first photograph was of a doctor and a
patient engaged in a slit-lamp examination. Participants were asked what, in particular, they
appreciated (or disliked) about ‘this stage’ of routine clinic visits. The second photograph was of a
nurse (in uniform) and a patient undertaking an acuity test. Again, respondents were asked what
they appreciated about ‘this stage of your visit’. The third photograph was of a room with a chair/
bench, in which antivascular endothelial growth factor (anti-VEGF) injections (a standard treatment
for people with DMO) were given; participants were asked to comment on their experiences. The
fourth photograph was of fundus imaging equipment [specifically an ultra-wide field fundus camera
(OPTOS) in use and an spectral domain optical coherence tomography (SD-OCT) machine in the
background]. The photograph was designed to stimulate discussion about what patients appreciated
(or disliked) about their engagement with the photographer. The fifth and sixth photographs were of a
waiting room and an empty corridor lined with chairs: typical of almost any corridor queue in a medical
clinic. Again, participants were asked to comment on their ‘experiences’ with waiting.
3. Phase 2: vignettes – three vignettes were presented to participants. All of the vignettes concerned
the provision of a virtual clinic. The first presented the story of 58-year-old man (Mr Smith) with DR
who attended the ophthalmology clinic, had an eye scan and was told that he would get a result by
letter. The second was a story of an ophthalmologist (Dr Xi) who wished to reduce waiting times for
new patients and, therefore, decided to triage his existing patients so as to concentrate on those
whose condition was ‘active’. The third was of a 65-year-old woman (Mrs McWilliams) with DMO
who was told that she will need to see the consultant only if the ophthalmic grader detects some
changes in her eye condition. All three vignettes served as useful stimuli for discussions on
virtual clinics.
4. Phase 3: a ranking exercise – participants were asked, as a group, to rank each of six statements in
order of importance to them, and to arrive at an agreed order. The statements are listed in Table 22.
5. End of meeting – the meetings ended with an opportunity for participants to raise any issues that
they ‘felt had not been dealt with’. They were thanked for their attendance and given £20 in cash
per person for travel expenses.
Focus groups for professionals
The FG for consultants and the two FGs for ophthalmic photographers and graders took a different
form. Some of the above materials were used, but only in the context of feeding back patient views to
the professional group. Participants were encouraged to comment on the views of patients and to
suggest ways in which patient concerns might be addressed.
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Analysing the data
The audio files were listened to repeatedly. A number of key issues were subsequently identified by the
researcher, and a list of codes or node labels was composed. Node labels were subsequently attached
by hand to relevant parts of the data transcripts. Examples of such node labels are present in Figure 12.
For example, the ‘Lampex’ node refers to talk surrounding a slit-lamp biomicroscopy phase of a clinical
examination. ‘Inject’ refers to talk concerning anti-VEGF injections and ‘Wait’ refers to talk about the
experience of waiting in clinic for different procedures to be conducted. Most of the nodal issues were
introduced to the participants by the researcher. These included issues about waiting times, technology
and tools in use, and experiences of interaction with, for example, consultants, photographers and nurses.
However, a number of other issues were brought into the discussion by participants independently.
One such issue was ‘Diabetes’. Thus, participants often identified themselves as ‘diabetic’, sometimes as
type 1 or type 2, or as insulin dependent for X number of years and so forth, and often implied that their
diabetes (rather than retinopathy) was their number one health issue. Nevertheless, the most important
issue to be brought forward in discussion was related to ‘feedback’, from the professionals to the patient.
We will return to the issue of feedback later. Following the identification of nodal issues or themes, the
Microsoft Word® (Microsoft Corporation, Redmond,WA, USA) version of the transcripts was searched
TABLE 21 Number of patients who were invited, gave consent and attended FG meetings at five UK study sites
Study site Location for FG Date
Number of
patients invited




Belfast Europa Hotel 16 February 2019 3 Males aged > 60 years 2
Belfast Europa Hotel 16 February 2019 6 All female participants 2
Belfast Europa Hotel 16 February 2019 24 Males aged 26–60 years 7
Belfast Europa Hotel 23 March 2019 11 All who have consented 2
QM Fife Holiday Inn, Dunfermline 9 March 2019 10 All male participants 5
QM Fife Holiday Inn, Dunfermline 9 March 2019 6 All female participants 1
Frimley Farnborough Village Club 16 March 2019 21 All who have consented 11
Gloucester Holiday Inn 6 April 2019 10 All female participants 2
Gloucester Holiday Inn 6 April 2019 6 All male participants 2
KCL King’s College London,
Denmark Hill
11 May 2019 11 All who have consented 2
Total 108 36
KCL, King's College London; QM, Queen Margaret Hospital (Dunfermline, Fife).
TABLE 22 Ranking of preferences
Statement Rank group 1 Rank group 2
1. Being told that my eyes are stable or not at the end of clinic visit 3 4
2. Being able to discuss my eye condition with someone at the clinic 4 3
3. More time with the doctor if my eyes get worse 1 2
4. Shorter waiting times for new patients 5 1
5. Spending less time waiting at the clinic 6 5
6. Seeing the eye doctor during every visit 2 6
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for key terms (e.g. photographer/grader/scan/image/technician) so as to identify all potential talk about a
nodal issue in any one FG meeting.
Figure 12 provides a diagrammatic representation of issues discussed in one FG. The diagram is presented
in the form of an ‘issue web’, outlining the range of issues discussed by participants in FG5.We can see
how one issue links to another, which are the most frequently discussed issues and who contributes to the
discussion and have a glimpse into whether something is evaluated positively or negatively (broken lines




















FIGURE 12 Issues discussed by male participants in focus group 5. ANX, anxiety; AI, artificial intelligence for detecting
change in retina; DIABETES, my diabetes; DRIVE, car driving; THE DOC, consultant; FEEDBAK, information and results
for ‘me’; FOTOG, photographer; GP, general practitioner; INJECT, injections; LAMPEX, slit-lamp examination with doctor;
OPTOS, Optos ultra-wide field imager; VIRT CLINIC, virtual consultation; WAIT, waiting during routine visits. Participants
are labelled ‘Pn’.
BOX 1 How Figure 12 was constructed
The issue web was constructed using textual codes and numerical counts. Initially, each ‘turn’ (or phase of
talk) in the transcript was linked to an identifiable speaker. Following that, the content of the turn was
allocated to a node label or code (sometimes a number of codes). Node labels used included ‘my diabetes’,
‘injections’, ‘eye test’, ‘virtual clinic’, ‘the doctor’, ‘nurse’, ‘photographer’ and so forth. A simple count of the
number of times that a specific speaker could be linked to a code, and the number of times that one code
was associated with another in the same turn, was subsequently used as the basis for the construction
of a matrix (a 20 × 20 square matrix in the case of Figure 12). The matrix was then integrated into social
network software (using Pajek32) to generate a graphical representation of the discussion. Within the graph,
node size reflects the number of turns that an individual speaker took during the meeting, or the number
of times that an issue was referred to. The thickness of the links between nodes (the arcs) reflects the
number of times that any one code was associated with another in the responses of participants. Because
the diagram was generated using a Fruchterman–Reingold projection, distances between nodes are
suggestive of the closeness (or otherwise) of the links between them (unfortunately, overlapping P2, P3 and
P4 nodes, had to be separated manually to enhance clarity). Given large variations in the node and arc size,
the counts were scaled using a square root transformation.
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Issue webs, such as the above, offer a view on the conversational proceedings, albeit one that
generates a somewhat truncated image of the entire field. Figure 12 shows, for example, that some
speakers took more turns than others (P5, smaller red box, spoke least; P1, larger yellow box, spoke
the most). It also shows that the major concern of these participants was with what they called
‘feedback’ (large pink box towards the centre of the diagram) or getting information on their eye
condition, usually at the time of a clinic visit. Also note that participants introduced topics that were
not included in the moderator’s script. Examples include references to ‘my diabetes’, driving and the
GP service. More importantly, we can detect differences in attitude to, say, the acceptance of a virtual
consultation (dotted lines between nodes signal negative associations) or the use of fundus imaging
equipment (specifically the OPTOS ultra-wide field imager). Thus, participants 2, 3 and 4 openly
disliked the idea of a virtual clinic: ‘For the peace of mind of the patient, they should be seen regularly
by the consultant’. Equally, participant 1 ‘hated [OPTOS] with a passion’. Finally, we can see that
participants frequently cross-reference issues (line thickness indicates a strength of association between
one topic and another); indeed, they rarely talked in terms of single issues or themes. For the sake of
clarity, however, the presentation of findings that follows is presented in terms of single, sequential
concerns, rather than one that emphasises cross-referencing and cross-talk.
Findings
Naturally, each FG contained divergent views and raised specific matters of interest. However, given
that all groups were led through the same sequence of topics, it is not hard to identify common themes
or familiar response patterns emerging from the transcripts. However, the researcher has attempted
to be sensitive to diversity of views where such diversity was apparent. In most cases, the origin of a
quote is attributed to a specific FG using a number (FGn). In some cases, however, the identification
of the FG has been omitted so as to obscure information that could lead to the identification of a
participant, hospital or health professional.
Focus group phase 1: the journey through the clinic
As stated above, phase 1 of the FG was built around a set of photographs that were intended to
stimulate discussion around a version of current clinic practice in which patients move through various
stages of the ophthalmology service (e.g. from the waiting room to the room in which the visual acuity
is evaluated, back to the waiting room, to the photographer, SD-OCT, ‘Optos’ ultra-wide field imager,
accepting an anti-VEGF injection and ending with a slit-lamp examination with the consultant).
The trajectory and the objects in the pictures were seemingly familiar to all participants.
Waiting
‘Waiting’ was not generally regarded as a problem by any of the patients in the FGs. Participants
accepted that long waits were often to be expected and, therefore, ought to be planned for. Where
delays in clinic processes did occur, patients wanted some kind of signal as to the extent of the delay.
A number of patients attending for routine appointments aimed to get to their clinics early in the day
so as to avoid long waits. Others suggested taking some form of distraction (such as a book or an audio
device) to cope with the waiting. In FG1, however, one participant suggested that waiting was not a
problem because he was retired, but had he been working then the amount of time spent at a clinic
would have been critical. So it may well be that attitudes to waiting were, at least partly, a reflection
of the employment status of the FG members. There is some support for that conclusion from the FGs
with consultants, ophthalmic photographers and graders, in which some of the participants complained
about ‘DNAs’ (did not attend) and claimed that non-attendance was a significant problem.
‘Waiting’ also arose in a few other contexts. First, there were issues around waiting for the results of
a clinical investigation. Second, there were issues connected to waiting lists (for an appointment).
Both sets of issues will be referred to in the sections that follow.
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Engagement with the nursing staff
The photograph of a patient undertaking an acuity test was the trigger for discussions of nurse–patient
relationships. Patients appreciated interaction with nursing staff and thought that good interpersonal
skills of nurses were essential to a good clinic visit. However, it seemed that most interaction was
strictly functional: nurses administered, for example, eye drops, injections and acuity tests, and for
most people verbal interaction was based on ‘small talk’ or ‘chit chat’. Thus, when asked if they ‘spoke
to the nurse’ at all, one participant in FG8 replied ‘Yeah: about the weather’. However, patients did
appreciate when nurses provided feedback, such as telling a patient that their acuity test results
implied that there was no change in their eye sight or perhaps that it had improved a touch. The male
participants in FG5, for example, were very appreciative of their interaction with nurses. For example,
the moderator asks about ‘talking to the nurse’ during the acuity phase of the clinic visit (in quotations,
Mn refers to Male Participant n):
M1: It’s good to get feedback. It’s sort of 3/4 months between appointments and it’s a case of I’m reading
this [line of print], is that the one I read the last time? And they actually tell you, they’ve got notes there
in front of them, you read one smaller than the last time and just give you the feedback, there’s a slight
deterioration, or not, as the case may be.
M2: When you’re actually doing the eye test with the chart, I like the way they . . . certainly, my
experience is I like the way they try and encourage you to go another one down . . .
M3: Yeah.
Similarly, male participants in FG9 stated that they always asked questions of the nurse (with respect to
intraocular pressure, acuity test results and so forth) and appreciated ‘knowing what’s what’. However,
although nurses might convey bits of information to a patient, they were not regarded as a key source of
knowledge about a patient’s underlying eye condition. For that, a consultant was required. ‘I want to ask
questions’, said a female participant in FG6, ‘but I don’t until I see the consultant’; ‘I like seeing the main one’.
Engagement with the photographers
Most of the FG participants seemed confused about the status of the photographers. The female
participants in FG8 and the male participants in FG3 thought that they were specialist nurses (which was
not the case). The male participants in FG9 had no name for the people who took images. A participant
in FG4 referred to ‘the guy on the machine’ and a participant in FG1 spoke of ‘the two men and the girl
who do the scans’. A participant in FG5 thought that they were dealing with an optometrist. The male
participants in FG10 thought that the photographers were doctors (although they also made a reference
to a nurse practitioner at a later stage). In FG7, the following exchange took place [in quotations, Fn refers
to Female Participant n, and LP refers to Lindsay Prior (who undertook the focus group discussion)]:
LP: When you meet photographers in the clinic, do you discuss anything with them?
F1: What photographers do we meet?
M1: The people who take scans of the back of your eye.
F1: Oh those . . .
M2: Oh, yeah, oh yeah.
M3: The lady who runs the scan machine.
LP: The lady who runs the scan machine, OK.
F1: She’s quite sweet, and she says ‘oh, just go and see the doctor’. Wait for [some] hours.
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Some participants referred to photographers as ‘technicians’ (FGs 6 and 7), and only one participant
(an active member of a diabetes support group in FG5) mentioned the word ‘grader’. However,
whatever word was used to describe the role of the person who took images of the retina, it was
clear that the level of information exchange between photographer and patient was minimal:
LP: When you have your photographs taken, who takes the photographs?
F: The technician.
LP: The technician, yeah. Do you speak to the technician at all?
F: Yes. Usually just social conversation.
There was also confusion about the level of understanding and expertise that photographers/
technicians/scanners had in determining whether an eye condition was active or stable.
It is worth noting that the technical details of the imaging technology used in clinics appeared to be
of little significance to FG participants: patients assessed technology in terms of how it meshed into
interactional contexts. Thus, the slit-lamp examination was spoken of favourably because it brought
the patient into contact with the consultant, whereas the OPTOS ultra-wide field imager was disliked
partly because it introduced a barrier between the patient and the clinic personnel. Generally speaking,
‘technology’ was viewed as a friend and its use was welcomed for the detection of eye problems
(see section 3.3.2). Nevertheless, imaging equipment was always evaluated in the context of the social
relations that were fostered or hindered by it.
Meeting with the ophthalmologist
It appeared that nearly all of the participants in the FG discussions currently met with an
ophthalmologist during their routine clinic visits. Many participants spoke of their relationship with
their consultant as a personal one, established perhaps over some time and based on mutual respect.
(This was in stark contrast to the ways in which some FG members spoke of their GP, about whom
they could be openly negative.)
Meeting the consultant during a clinic visit was above all ‘reassuring’. Thus, one of the male FG
participants stated that ‘I think it gives you a lot of reassurance to speak one to one to [consultant X],
because there’s questions that you ask that only probably [he] could answer. That’s what I like, to be
quite honest’. In addition, a female participant stated that meeting with the consultant offered ‘a great
reassurance that you know you’re going to be looked at, and at the end of day, the treatment that
I have had, I can’t thank them enough for it, you know’. Some FG participants even mentioned feeling
‘relaxed’ once they had spoken with a consultant.
Asking questions about one’s condition and how problems might develop were regarded as essential
by most participants. Thus, one of the male participants in FG3 stated that he appreciated ‘the fact it’s
an ophthalmologist there, because it’s not just, you know, the checking of your eyes that’s important
at these visits, it’s being able to ask questions’, and a male participant in FG5 claimed that seeing the
doctor ‘. . . is necessary, isn’t it? It’s for the doctor to look into your eye and see and make an opinion.
I mean, I don’t see my GP, I haven’t seen my GP for years. I see a nurse specialising in diabetes. I’ve
seen [the ophthalmologist] more than I’ve seen my GP’. In FG9, one of the participants spoke of being
able to discuss his eye problems ‘in-depth’ whenever he met with his consultant.
As the above extracts suggest, asking questions and getting answers (‘there and then’) constituted
both the high point and a suitable end point for routine clinic visits. Indeed, the capacity for getting
‘feedback’ and obtaining ‘information’ was regarded as a key feature of the patient–doctor interaction,
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which is something that shows up very clearly in Figure 12. It was the potential loss of this capacity
(in a virtual clinic) that worried patients most of all. (One male participant in FG3 stated that he would
‘go private’ rather than miss out on seeing a consultant.)
Administration of the clinic
Although most FG participants were positive about the medical care that they received, there were a
number of occasions when they were critical of the ‘non-clinical admin side’. Nearly all of the negative
responses concerned the process of getting an appointment. In some cases, it seemed, there was a
disjunction between the time until next appointment as specified to the patient by a consultant (e.g.
‘see you again in 3 months’) and the ability of the patient to get an appointment in the specified time
frame. Some patients spoke of how they had to ‘fight’ for an appointment; a member of one FG said:
It’s no good being told, when you phone up after 6 months, ‘where’s my appointment?’. ‘Oh, we’re not
seeing anybody now until May,’ or 4 or 5 months down the line, that’s really not good enough.
On the other hand, there were some FGs in which both the medical and the administrative arrangements
were regarded as praiseworthy, as illustrated by this quotation from a male participant in FG9:
The other thing about X Hospital Eye Department, they keep a very good diary; once they’ve got you,
they don’t let you go.
Diabetes and anxiety
Diabetes was not only a condition that had to be managed, but also very clearly a source of identity
for many patients. This was particularly evident in the discussions between FG members that occurred
before the formal start of proceedings. Individuals would often introduce themselves as a ‘type 1’ or
‘type 2’, compare the number of years that they had ‘been on insulin’ or compare the age at which they
were first diagnosed as a person with diabetes. In some cases it was evident that diabetes drove the
daily schedule of an individual, in which one course of action had to be ‘juggled’ with another, and the
disorder was uppermost in the thoughts of many FG participants. Some FG members were puzzled as
to why the review of their eye condition and the review of their diabetes were undertaken at different
times and at different clinics; thus, a male participant in FG10 stated:
Holistic is the only way to deal with diabetes.
Another male participant from FG3 spoke of his new clinic in the following terms:
It was bright, it had a TV screen there that told you a bit about the different eye conditions, there was
lots of literature and promotional material for different support groups and things like that, and I found
the staff . . . I have never written a compliment letter in all my time as a diabetic, but I did after my first
appointment there, because I thought it was really impressive compared to [the previous clinic].
Anxiety emerged as another cross-cutting theme. Anxiety might be ever present, but it could also
be accentuated by clinical or administrative procedures. Not being told about the result of a scan,
receiving a clinic re-call letter or the use of an ill-judged phrase could send ‘blood pressure through the
roof’ because ‘of all the senses, the sight is probably people’s most important one not to lose. I would
say that we all worry about our sight being lost’ (FG3).
Some further references to anxiety appear in the next section.
Focus group phase 2: the virtual clinic
The acceptability of a ‘virtual consultation’ or ‘virtual clinic’ was explored via the use of three vignettes.
(However, the word ‘virtual’ was not used by either the moderator or the participants.) The discussion that
ensued from the presentation of the vignettes moved in various directions, as is evident from Figure 12.
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For most participants, however, the provision of a clinic in which people were assessed for ‘stability’ and
given routine assessments and treatments, but not informed of the result ‘on the day’, was unacceptable:
Yeah, I mean, anxiety, everybody’s the same, but if you are anxious about something like this, it can put
your blood sugar up and that screws up your general diabetic health. So I just think it’s important to go
in, if you find out there’s bad news and something needs treated, I mean, they have the stuff there, get it
all done [on the day].
M, FG3
Thus, patients spoke of the virtual clinic as ‘half a service’, a ‘backward step’ and ‘retrograde’.
Fears were also expressed about being ‘isolated’ and ‘cast adrift’ without an opportunity to
‘have a talk [with the consultant] and get any problems in’. One participant in FG8 spoke about
the following:
Waiting for the postman to bring a letter and you’re worrying, you’re anxious. And the thing is, with
diabetes, being anxious and stressed doesn’t do it any good.
The male participants in FG5 also traced a direct link between waiting and anxiety. Another female
participant in FG6 talked of being ‘left in limbo’ in the absence of any information about her eyesight
and the need for ‘reassurance’ before leaving the clinic:
Walking away not knowing; that’s not nice.
In a similar manner, a male participant in FG1 stated that he would not want ‘to go away [from the
clinic] wondering’, and a participant in FG9 stated that he would not want to ‘go away thinking, is
there something wrong?’. The following exchange occurred in FG2 with respect to the vignette
on ‘Mr Smith’:
F2: So he doesn’t know the results, does he?
LP: He doesn’t.
F2: So he’s sat there worried sick.
Those who regarded the provision of a virtual clinic as acceptable did so on a number of grounds.
Some were accepting of the pathway as long as their eyes were stable (although there is something of
a ‘catch-22’ there). A few accepted the proposal on the grounds of ‘trust’. Thus, when the moderator
asked one of the male participants in FG4 how he would feel in his own case, if an ophthalmic
photographer/grader said that he would get a letter about his results, he stated:
That’s fine. I trust him, he knows his stuff.
Likewise, a member of FG10 said the following of the nurse practitioner who dealt with the
eye scans:
I trust her implicitly. Frankly, I trust her more than I trust some of the younger doctors.
Some participants (e.g. in FG4 and FG10) saw the proposed arrangement as equivalent to and as
acceptable as the screening service that they had experienced in other medical settings.
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In FG7, divergence emerged in the following exchange, which opens with a participant talking about
leaving the clinic without a ‘result’, and consequently waiting for the letter that will confirm stability
or suggest further investigation:
M7: I think that’s the problem, is waiting for that letter. I’d rather, on the day, be told rather than have to
wait. Like the sword of Damocles hanging over me.
Yes [several answer].
F3: Plus, letters get lost as well.
M2: I must admit, I’ve been on the reception of that, and it’s worked without any problems at all. I got
the letter, it told me what I needed to know, and they said ‘we’ll see you in 3 months,’ and I knew exactly
there was a plan and that was fine. But I could imagine, as the lady said over there . . .
LP: And you didn’t see the consultant at all?
M2: No. And I didn’t need to, because again, if it’s an objective test and objective results then why do
I need to see a doctor?
Exchanges of that kind sometimes led to discussion as to how ‘results’ might be communicated to
patients. As is evident above, patients were not always favourably disposed to traditional mail as a form
of communication, and suggested that other media could be effectively used for the transmission of test
results, including e-mails, text messages and cell telephone messages; these routes were considered to
be quicker than communication by letter. A few participants thought that it would be advantageous to
have their scanned images mailed to them in addition to any evaluations.
Linked to fears and anxieties about not seeing the consultant were concerns about the professional
skills and expertise of the ophthalmic photographers and graders. As already indicated, the individuals
who do the scanning are of uncertain status to the participants; they are seen only through a ‘glass
darkly’, as it were. Consequently, few participants were happy about leaving the decision of whether or
not DR was active to a non-medical professional of any kind (the male participant referred to in FG10,
above, was unusual in this respect). This is despite the moderator indicating that the individuals who
reviewed the images were highly trained. Thus, a female participant in FG2 said of the person who
scanned her eyes that he was ‘just a photographer’. A participant FG3 suggested that ‘someone more
trained’ should be looking at the images. A participant in FG1 was adamant that decisions of whether
or not the retinopathy was ‘active’ ‘should not be left to the photographer/grader’. In FG6, some of
the participants stressed the fact that consultants had expert or tacit knowledge that was simply
unavailable to others.
In a number of FGs, discussion turned to the issue of whether a ‘robot’ or an advanced artificial
intelligence (AI) system might be able to detect change in the retina better than a human actor
(AI appears in Figure 1, for example). However, none of those who said that they would feel content
with a robotic assessment imagined that the (expert) consultant could be removed from the care
pathway; clinical judgements were for clinicians alone.
In nearly all FGs, participants drew a distinction between themselves and future patients. Current
patients were used to and comfortable with the existing service and would not want it changed.
Future patients, who might experience the virtual service, might not know any better. Changing the
care pathway now, and for ‘us’, would only lead to dissatisfaction. In addition, if change were to occur
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then the rationale for such change ought to be fully explained to those affected. It was a position
nicely summed up by a member of FG9:
People like [John] and myself, we’ve been there for some period of time now and we know the procedures
and we know what we need to do and we know what they need to do as well, because it becomes a
matter of fact, and we look for that all the time. If something changes you’re aware of it straightaway.
If they want to change the system then they’ve got to advertise the fact to all people who are under
their care so that they’re aware, otherwise it falls flat and people get concerned.
Focus group phase 3: the ranking exercise
The ranking exercise was originally intended as a means of stimulating discussion among participants
about the key issues, and perhaps reaching a consensus on what was most important to them. In
truth, discussion in most groups was minimal, but the final rank order of key statements did serve as
something of a confirmatory signal on the ‘feeling of the meeting’. For example, in FG7 it seemed to
the moderator that two distinct camps emerged on the acceptability of the virtual clinic; therefore,
instead of asking everyone present to rank the six statements, the group was divided into two. As can
be seen from Table 22, there was indeed a considerable divergence between the two factions on the
importance of ‘seeing the eye doctor during every visit’ (highest rank = 1; lowest rank = 6).
As with most other groups, the issue of waiting was regarded as of low importance. Reducing waiting
times for new patients was also of low importance for most groups. The high rank of this item in group
2 was explained to the moderator by saying that ‘it was number 1 for others’ but not for ‘us’. For most
of the other FGs, the highest-ranked statement was statement 1.
Responses of consultants
The moderator began the meeting with the six consultants by asking them to outline the potential
advantages of the EMERALD care plan for patients, the NHS and themselves. Various responses
emerged, but foremost was the idea that the EMERALD study would reduce in-clinic waiting times for
patients (as well as referral times for new patients). Given that the patient groups persistently claimed
that in-clinic ‘waiting’ was not a problem, the issue deserves some consideration.
From a consultant stand point, it seems clear that failure to attend clinic appointments (did not
attends) are a problem for professionals and patients. Thus, one consultant spoke of patients with very
serious conditions who failed to attend the retina clinic because of long in-clinic waiting times, and
who had to be chased up in other settings (e.g. the glaucoma clinic). In the light of this, a reduction
of routine waiting times could well be an advantage for patients. It may be (as was suggested above)
that the FG sample was biased towards people who were retired or not economically active, and for
whom in-clinic ‘waiting’ was a minor inconvenience (however, FG1, FG3, FG5, FG6 and FG10 clearly
contained some economically active and self-employed individuals). Either way, there appears to be a
strong difference of opinion here on the virtues of reduced in-clinic waiting times. Other advantages
of the EMERALD study that were mentioned by the consultants included the potential for reduced
(labour) costs for the NHS, and an increased ability to provide personalised treatment to patients
with active conditions. This latter advantage is in precise accord with the wishes of the patients
(as expressed via the ranking exercise); however, it is equally clear that patients welcome a medical
consultation even when their condition is ‘stable’.
On patient reactions to the photograph of the slit-lamp examination, consultants adopted a straightforward
technical stance.The slit-lamp examination was useful for ‘active’ eyes only. There was no need to use such
methods for patients who were stable, and no real need to meet with such patients. It was further argued
that the use of SD-OCT images plus ultra-wide field photography was ‘as good as a personal exam’ for
detecting changes to eye tissue. However, as we have noted above, patients view the clinic as a site for
the exchange of information and a source of reassurance, as well as a site for diagnosis and treatment.
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Therefore, for patients, the slit-lamp photograph reflected an occasion in which questions could be put
and answers obtained from a medical expert. Consequently, one issue that arises out of the provision of
virtual clinics is where patients can get advice and reassurance about their condition.Various suggestions
were made by consultants. For example, one consultant reported that she currently told the clinic
photographers to tell patients that they could ask for her to contact them by telephone if they wished to
discuss anything. Others suggested that more ‘patient education’ was required: informing patients of the
merits of SD-OCT and ultra-wide field images over a personal examination.
On the provision of virtual clinics more generally, it seemed as if they were already in operation in
some regions. Two consultants reported that although there had been some complaints when virtual
clinics were originally organised, there were no complaints any more. Both new and long-term patients
(who had experienced the previous care pathway) seemed to accept the reorganised service, and a
view was expressed that the new care pathway as proposed by the EMERALD study will work
‘eventually’ (none of the FG patients was drawn from these clinics).
When asked to discuss how patients might get ‘results’ of clinic reviews quickly, a number of responses
were offered. At the simplest level were proposals to e-mail, telephone or text message results to
patients (which is exactly in accord with what patients suggest). More advanced was a proposal that
patients could be offered a system whereby they could log-in to a personal account and ‘view results
for themselves’, which would also be in accord with some of the more technically minded patients.
Another suggestion was that patients be offered a guarantee that images would be reviewed and
assessments returned within 48 hours.
In addition to communication strategies of the above kind, some consultants proposed organisational
change. For example, it was suggested that if photographers were expertly trained to grader status, it
would be possible for the graders to give ‘results’ to most patients immediately. One consultant suggested
that a grader might sit with the photographer and offer on-the-spot assessments.Whatever technical,
administrative and legal difficulties there might be with such proposals, it quickly became clear that they
would meet with resource problems of various kinds. For example, one consultant claimed that there
were no graders available to her retina clinic as they were all deployed in the screening service. Implicit
agreement among the consultants did, however, emerge on some points. First, that it might be possible to
get ‘results’ back to patients in a ‘1-day virtual clinic’ if there were sufficient numbers of trained graders to
assess images. Second, that even if results were to be forwarded to patients on a day other than the day of
a clinic visit, but in a timely manner, more photographers would need to be trained to grader status.
Finally, issues relating to diabetes emerged during the discussion. The problem of dealing with
retinopathy in the context of diabetes was fully recognised, and a number of references were made
to a Royal College of Ophthalmologists working-group on the potential provision of a ‘one-stop shop’
for patients.
Responses of photographers and graders
Two FGs containing five photographers and two graders were held. As with the consultants, the
moderator began the meeting by asking participants to outline the potential advantages of the proposed
EMERALD care plan for patients, the NHS and themselves. Interestingly, the photographers and graders
paid quite a bit of attention to the infrastructure costs of the new pathway, for example purchase of
imaging equipment, buying software licenses and training of graders. As with the consultants, however,
the primary advantage of the proposed EMERALD pathway for patients was said to be a reduction of
in-clinic waiting time; participants voiced surprise at the low ranking of the ‘waiting time’ item in the
patient-group ranking exercise.
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Photographers and graders were well aware of patient anxiety regarding getting ‘results’. Some said
that, currently, they were nearly always asked for indications as to the patients ‘stability’. As a
consequence, all had developed conversational strategies (or stock replies) for dealing with the
problem. For example, a photographer/grader might say to a patient:
Well; we have some very good images now and they just need to be examined by the doctor.
Another response was:
As you know, you’re in this clinic because you are low-risk and this is just a routine check-up.
As with consultants, photographers and graders thought that it would be a good idea to explore the
use of electronic media (as well as traditional mail) for getting results to patients. An existing time
frame for getting results to patients was mentioned as ‘4 to 6 weeks’ in one of the FGs. As to the idea
of graders giving results to patients, there was considerable reluctance on a number of grounds. One
participant mentioned lack of indemnity insurance as a barrier. Another stated that, even if they were
trained to grader status, they would feel too ‘vulnerable’ to be responsible for making final decisions on
images. More fundamentally, both photographers and graders suggested that although it might be OK
for suitably trained individuals to give a result to a patient who was evidently ‘stable’, in cases of active
conditions a number of problems arose. Primarily, offering a judgement about new bleeds or changes
in the retina would lead the patient to ask further questions about consequences and treatments:
questions that the graders felt that they would not be able to answer. It was suggested that intimating
to a patient that something had changed, without offering a treatment or advice response there and
then, would only intensify anxiety. It was considered far better to notify patients at a later stage,
telling them how they could be accommodated in a consultant-led clinic. In addition, nearly all of
the photographers and graders pointed out that there were always cases in which they simply did
not know whether or not there was something awry; some images required interpretation by a
medical expert.
All but one of the photographers and graders seemed to have some experience of virtual clinics,
such as maculopathy or glaucoma clinics, and considered them to be both highly efficient and acceptable
to most of the patients who they encountered. It was suggested that a virtual retinopathy clinic was
comparable to a screening clinic and fulfilled the same public health role, with an emphasis on preventative
rather than curative medicine. As with the consultant group, considerable emphasis was placed on the
need for ‘patient education’ if virtual clinics were to be fully acceptable.
Discussion
Patients tend to see the ophthalmology clinic as offering a space in which diagnosis, treatment and the
exchange of information concerning DR and other eye conditions takes place. For the participants in
this study, all three functions were equally important and a clinic that failed to offer all three was
generally regarded as less than good, possibly ‘half a service’. Indeed, most members of most of the
FGs feared that with a virtual clinic the third function would be missing or delayed. They also voiced
fears that a lack of ‘engagement’ and ‘reassurance’ would characterise such a clinic. Only the male
participants in FG4 and FG10, who spoke of ‘trust’ and ‘confidence’ in the clinical service, were
unperturbed about the possibility of a virtual clinic.
Although participants did not speak of a gold-standard service, it is not unreasonable to summarise
patient opinion in terms of what ‘gold’-, ‘silver’- and ‘bronze’-standard services would offer to patients.
A gold-standard clinic would offer a ‘one-stop shop’ (FG3). Here, eyes would be investigated (via scans,
photographs, etc.), relevant treatment (such as anti-VEGF injections) would be offered on the day,
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and information and discussion about eye conditions and diabetes would be available from a medically
trained professional: an expert. A patient whose condition was stable would exit the clinic with
‘results’. In cases in which new activity was detected, the nature and consequences of such activity
would be explained, and treatment options would be offered ‘within a reasonable time, say a week’
(FG6). It is a system that is summed up by the following male participant in FG6:
I want it over with on the day, not mess around, if and but, maybe there’s something, maybe there’s not,
maybe I’ve got a problem, on tenterhooks the whole time. Get it sorted on the day. If you are stable, there’s no
problem, you nip in and see the doctor, 5 minutes, straight out, no problem; it doesn’t really take any effort.
A silver- to bronze-standard clinic would be one in which screening and essential treatments were
offered and the exchange of information within the clinic was minimal, but in which results of routine
check-ups were available within days of a clinic visit, communicated via e-mail, text or telephone.
In cases in which new activity was detected, access to an ophthalmologist would be timely: patients
would not have to ‘struggle to get an appointment’. (According to some consultants, it seems that this
kind of service is already in operation in a few centres, although it was not clear how much
of a time gap occurred between the patient visit to the clinic and the receipt of a ‘result’.)
A zinc-standard clinic would be one in which screening and routine treatments were offered, but in
which the exchange of information between the patient and the medical professionals was minimal.
‘Results’ of routine screening were delayed for more than a few days, and medically trained
professionals were rarely met with. In cases of active DR, the zinc-standard clinic would inform
the patient by letter that there was a problem, without offering what patients considered a timely
appointment for consultation with an ophthalmologist (the longer the delay the greater the anxiety).
One of the key issues that emerged from the FGs was the emphasis that patients placed on getting
results from a clinic visit ‘on the day’. For a virtual clinic, it would be a critical problem. For example,
although rapid results may be well suited to patients whose eye condition is stable, they may not be
beneficial for those whose condition is active, especially in the absence of opportunities for further
discussion or explanation of the consequences. Indeed, as both the photographers and the graders
suggested, any hint or suggestion that things were ‘not quite right’ would only accentuate anxiety
without offering ‘solutions’. Thus, it would probably be more acceptable that in the presence of active
disease patients were contacted at a later date with a plan for a timely consultation in which ‘results’
could be fully discussed.
Summary
Patients in the 10 FGs were overwhelmingly positive about the care they currently received and were
supportive of the NHS in general. They recognised that the existing ophthalmology service was ‘under
pressure’, but still viewed the service as meeting their needs. They had no wish to see it altered in any
fundamental way.
Patients spoke of the ophthalmology clinic as a place in which eye problems are diagnosed and treated,
and in which information and advice (‘feedback’) about their eye condition can be obtained. The provision
of information, especially ‘results’, and advice is regarded as central to a good service.
A good service was also one that communicated the result of investigations on the day of a clinic visit,
and provided an opportunity to discuss eye problems with a health professional, preferably a doctor.
Although patients were supportive of the work of all those who worked in the clinics that they attended,
they regarded the consultant as the true expert and as the primary source of reliable information about
their condition.
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The role of photographers and graders in the ophthalmology service was unclear and uncertain as far
as patients were concerned. Nearly all of the patients were confused about who was ‘behind the
scanner’ as well as the ability of graders to detect emerging eye problems.
Views on the provision of a ‘virtual clinic’ or ‘virtual consultation’ (in which a patient is reviewed via
images rather than a face-to-face examination) were mixed. Most participants disliked the idea of such
an arrangement and saw it as offering ‘half a service’. Fears were expressed about being ‘isolated’,
‘forgotten’ and ‘cast adrift’.
Those who were unperturbed about the provision of a virtual clinic regarded it as acceptable only as
long as ‘results’, and any necessary treatment, were provided quickly.
The data suggest that in planning ‘virtual clinics’ for people with previously treated and stable DMO
and/or PDR, the following issues ought to be considered:
l Using a range of media (including but not limited to postal communications) to deliver test results
and clinical assessments to the patients quickly and efficiently.
l In cases in which ‘activity’ is identified in the retina by a grader, timely appointments to meet with
an ophthalmologist should be offered.
l An organisational capacity to provide ‘reassurance’ and assuage anxiety, even for patients who are
stable or low risk, ought to be recognised as key features of the ophthalmology service.
It appears that the image, role and function of ophthalmic photographers and graders need and
deserve sharper definition, no matter what the outcome of the EMERALD trial.
Conclusion and implications
For patients, the ophthalmology clinic is nestled in a set of human relationships. Consequently, the
clinical service is not simply one in which pathology can be identified and treated, but also a service in
which knowledge and information about eye conditions can be exchanged, reassurances can be given
and anxieties assuaged. Consultant-staffed clinics offer all of the above.
Patients fear that a virtual clinic will fall short on offering reassurance, information and advice, and
that they are likely to lose from this change if such clinics are rolled out. (However, FG participants
recognised that future cohorts of patients who would be unaware of the current system may well
accept a virtual pathway without further ado.) The suggestion of the consultants and photographers/
graders who have worked with virtual clinics is that patients will come to accept them and to
appreciate the shorter waiting times involved.
In the absence of meeting a consultant at a clinic visit, patients want feedback on routine investigations
fairly promptly. In fact, probably the best way of ‘selling’ the virtual clinic to patients would be to
guarantee quick ‘results’; doing so for patients who are stable is probably feasible. Communicating
results to patients for whom some degree of activity is evident in their images, however, is more
problematic. The suggestion that something is ‘wrong’ would undoubtedly generate anxiety in patients,
and both photographers and graders suggest that little purpose would be served by patients receiving
bad news without having recourse to on-site medical advice.
However, no matter the conclusions of the EMERALD study, it is evident that the identity, role and
function of photographers and graders needs to be clarified, both for the benefit of patients and for
the good of the imaging specialists. Above all, patients deserve to know the level of expertise of the
person who is reviewing their images and who it is that is making decisions about their treatment
and care.
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Chapter 4 Cost–consequences analysis
Introduction
In this chapter, we examine the costs and consequences of the new ophthalmic grader pathway for
the surveillance of people in whom treatment for DMO or PDR has resulted in the condition in their
eyes being considered inactive and stable. The purpose of follow-up in these patients is to detect
reactivation (i.e. ‘recurrence’) of DMO or PDR so that further timely treatment can be given, if required.
The current standard of care for the surveillance of patients with DMO is slit-lamp biomicroscopy
undertaken by an ophthalmologist who has access to SD-OCT images. In EMERALD, the new pathway
for DMO entails the reading of SD-OCT images by trained ophthalmic graders.
The current standard of care for the surveillance of patients with PDR is slit-lamp examination
undertaken by an ophthalmologist. The new pathway tested in EMERALD for PDR is the reading of
either seven-field ETDRS fundus photographs or ultra-wide field fundus photographs by trained
ophthalmic graders.
In addition to the comparison between findings in the grader’s pathway and findings in the standard
of care pathway for PDR, we examined the costs and consequences of using the ophthalmic grader
pathway as compared with the results of the ERS. Under the ERS, a patient was considered to have
active PDR if detected on any one of the slit-lamp biomicroscopic examination undertaken by an
ophthalmologist, the grading of seven-field fundus photographs by an ophthalmologist or the grading
of ultra-wide field fundus images by an ophthalmologist. Data on the comparisons between ophthalmic
grader’s pathway, reference standard and ERS is contained in Chapter 2 (see Table 15).
Methods
Resource use was captured on trial CRFs at each participant’s EMERALD clinic visit to compare the
costs of delivering the standard care pathway, the ophthalmic grader pathways and the ERS. The cost
analysis took the perspective of the NHS and Personal Social Services and costs are in Great British
pounds in 2019/20 prices.
The costs included staff costs, based on the time taken for various procedures, including:
l undertaking best corrected visual acuity
l the time for the photographers/imaging technicians (and their grade) to obtain SD-OCT, seven-field
and ultra-wide field fundus images, costed at band-6 salary scale
l for DMO and PDR, the time and grade of the ophthalmologist undertaking slit-lamp biomicroscopy
and review of the SD-OCT images (for DMO) as well as the time invested counselling the patient
l the time taken by graders to grade SD-OCT, seven-field and ultra-wide field fundus photographs,
costed at band-7 salary scale.
l the time taken for ophthalmologists to grade seven-field and ultra-wide field fundus photographs
for the purpose of the ERS.
The time and grade for the above procedures were used to estimate costs of the standard and new
care pathway (ophthalmic grader pathway), and the ERS.
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The staff costs reflect NHS salary, superannuation, national insurance and overhead costs attributable
to different grades of staff (Table 23).
Other costs included the equipment required, overheads and consumables.
Costs were applied to each resource item to value total resource use in each pathway using national
sources such as the Unit Costs of Health and Social Care,33 published by the Personal Social Services
Research Unit (PSSRU) annually, and NHS Reference Costs 2017/2018.35
Both the standard care pathway as currently undertaken and the new ophthalmic grader pathway
would require a nurse, an optometrist or a visual acuity technician to check visual acuity. Therefore,
this cost would not differ between pathways, nor would the cost of taking the OCT images.
The costs of obtaining and grading seven-field ETDRS fundus images were estimated and compared
with those for ultra-wide field fundus photography. If there was no difference in diagnostic accuracy
between these two imaging modalities, the lower cost one would be favoured.
The costs of the various investigations are not simply the ‘direct cost’ of time multiplied by salary cost,
because many other ‘indirect’ costs need to be taken into account, including support staff (e.g. clinic
reception), medical records, if needed (some clinics have electronic records) or IT support, as well as
‘hotel’ costs (e.g. buildings, heating and lighting). These are included in the standard reference cost for
ophthalmology follow-up visits, which we use as the base-case cost.34
By deriving the direct cost of the ophthalmologist’s time for the face-to-face examination and
comparing that with the NHS Reference Costs 2017/2018,35 we obtained an adjustment factor to apply
to the direct costs (salary multiplied by time) of grader or ophthalmologist reading of photographs. This
is not a perfect solution because the indirect costs might vary between ophthalmologists and graders,
but is a pragmatic approach.
TABLE 23 Staff costs (2019 prices)
Resource item
AfC pay
scale band Unit cost (£) Measurement unit Source
Ophthalmic photographer/
imaging technician
6 49.00 Per working hour aPSSRU 2019, page 14333
Ophthalmic grader 7 59.00 Per working hour PSSRU 2019, page 14333
Ophthalmologist (consultant
medical)
N/A 109.00 Per working hour PSSRU 2019, page 15033
Associate specialist N/A 108.00 Per working hour PSSRU 2019, page 15033
Specialty registrarb N/A 47.00 Per working hour PSSRU 2019, page 15033
Ophthalmologist (average cost)c N/A 108.50 Per working hour Average based on unit





N/A 58.00 Per patient contact NHS 2019/20 National
Tariff Payment System34
AfC, agenda for change; N/A, not applicable.
a We chose the cost per hourly rate of radiographers as the more relevant unit cost for ophthalmic imaging technicians.
b Although patients may be seen by specialty registrars, we assumed that unless advanced in training, most will be
closely supervised by associate specialists or consultants, hence the average unit cost for an ophthalmologist (used
in current analysis) is based on associate specialist and consultant salaries.
c Average unit cost for an ophthalmologist based on associate specialist and consultant salaries.
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In Table 24 we have included the costs of equipment, such as camera and OCT machines, based on
the acquisition and maintenance costs, divided by the lifetime of the equipment and throughputs of
9000 patients per year.36 These estimates are approximate, but, given that they make up a very small
proportion of total costs, the approximations are acceptable. Costs are discounted at 3.5% per annum.40
The ERS consisted of the evaluation of the patient by the ophthalmologist using slit-lamp biomicroscopy
in clinic and, in addition, the ophthalmologist evaluation of the seven-field ETDRS fundus photographs
and ultra-wide field fundus images. Obtaining and reading such images is not currently part of standard
care. To maintain masking, the ophthalmologist evaluating the patient by slit-lamp biomicroscopy was
not the same as the ophthalmologist who graded the fundus images. Furthermore, to avoid the reading
of one technology influencing the reading of the other, different ophthalmologists graded the seven-
field ETDRS images and the ultra-wide field fundus images. In the ERS, any patient graded as having
‘active PDR’ based on any one of slit-lamp biomicroscopy, seven-field ETDRS fundus photographs or
ultra-wide field fundus images would be considered to have active PDR.
We also provide some exploratory post hoc comparisons not included in the original protocol.1
We provide these in view of the findings in Table 15 of the diagnostic accuracy results, which suggest
that the ophthalmologist face-to-face examination (O-FTF) (reference standard) may be less sensitive
than the ERS.
Outcome measures
Health-related quality of life was assessed using the EQ-5D-5L instrument. The EQ-5D-5L is a
generic measure of health status that consists of a descriptive system and the visual analogue scale.
The descriptive system includes five questions addressing mobility, self-care, usual activities, pain or
discomfort, and anxiety or depression. Each dimension is assessed at five levels ranging from ‘no
problems’ to ‘extreme problems’. The EQ-5D-5L utility scores were derived using an EQ-5D-5L index
value calculator (version 2.0)41 that maps the EQ-5D-5L descriptive system data onto the EuroQol-5
TABLE 24 Unit costs of equipment (2019 prices)












14,500: purchase price 8 9000 2431.18 0.27
500: annual maintenance





88,255: purchase pricec 10 9000 11,243.17 1.25
5250: maintenance




11,300: purchase priced 10 9000 1569.15 0.17
1750: maintenance
cost sold as extended
warranty (once-off fee)
a Annual throughput estimate: University Hospital Southampton NHS Foundation Trust36 and personal communication
(Professor Noemi Lois, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and
Biomedical Sciences, Queen’s University Belfast, 2020).
b Equipment price: Topcon Ireland Medical, Dublin, Ireland.37
c Equipment price: Optos Plc, Dunfermline, UK.38
d Equipment price: Veatch Ophthalmic Instruments.39
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Dimensions, three-level version (EQ-5D-3L) valuation set.42 Detailed description of the mapping
methodology is described elsewhere.42 We also estimated quality of life using two vision-specific
measures: NEI VFQ-2543 and VisQoL questionnaires.44 The NEI VFQ-25 is widely validated, and
contains 11 subscales (general vision, near activities, distance activities, peripheral vision, colour
vision, driving, ocular pain, role difficulties, dependency, social functioning and mental health) and
a general health rating item. A composite score was obtained by averaging the scores across the
11 subscales. The VisQoL questionnaire is a six-item-level instrument that focuses on the effects of
visual impairment on the risk of injury, coping, friendships, organising assistance, fulfilling roles and
everyday activities. A standardised score for the VisQoL was computed using the published algorithm
by the Centre for Health Economics, Monash, Australia.45 Higher scores represent better function for
all three measures.
Our aim was to compare the results obtained from using the much simpler and quicker to administer
VisQoL method with NEI VFQ-25 and EQ-5D-5L. Given that this was a cross-sectional study, we
simply explore the results of the various outcome measures, including for different levels of visual
acuity that are known to be linked with utility levels.46,47 We also compare the findings in active DMO
and PDR with inactive DMO and PDR using the ophthalmologist’s face-to-face (reference standard)
classification, with a null hypothesis that there should be no difference.
Results
Costs
The average time taken in minutes to complete specified activities by either the graders or the
ophthalmologists is shown in Table 25.
Some of the times in the minimum column are very small, but are as recorded in the CRF. They may indicate
that problems, such as recurrent PDR, were detected very quickly and a decision was made to refer.
The costs in Table 23 were obtained from the standard source, PSSRU.33 It may seem odd that the
costs per hour for consultants and associate specialists are almost identical. In addition, no cost is
given for staff doctors (sometimes referred to as ‘trust doctors’).
TABLE 25 Time (in minutes) taken to complete specified activities per patient by ophthalmologists and ophthalmic graders
Time-related activity
Time (minutes)
Mean (SD) Median Minimum Maximuma
Reference standard: O-FTF 15.3 (7.60) 14 4 50
Ophthalmic photographer/imaging technician taking ETDRS
photographs
15.3 (8.37) 13 2 57
Ophthalmic photographer/imaging technician taking ultra-wide
field fundus images
10.4 (7.17) 9 1.98 60
Ophthalmic grader reading seven-field ETDRS fundus images 10.6 (6.5) 9 1.98 58
Ophthalmic graders reading ultra-wide field fundus images 9.3 (5.87) 8 1 41
Ophthalmologist reading seven-field ETDRS images 11.9 (4.99) 11 2 31
Ophthalmologists reading ultra-wide field fundus images 10.1 (4.03) 9.5 2 28
Grader reading OCT images 4.2 (3.31) 3.98 0.98 31
a We excluded entries for which the time to perform task was equal to zero or above 60 minutes, as these values
were considered outliers and likely mistakes. Thus, n varies slightly across time-related activities.
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Patients may be seen by one of four grades of staff:
l consultants – starting salary £80,000 up to £108,000 (after about 20 years; there are yearly
increments at years 2–5, then larger increments at 5-yearly intervals)
l associate specialists – starting salary £56,000, potentially up to £96,000 after 20 years
l staff doctors – starting salary £40,000, up to about £76,000 after 20 years
l specialist registrars – under supervision with checking by more senior staff, so costs were not used.
Table 26 presents alternative costing that would give a slightly lower cost for ophthalmologist time.
However, in the analysis, we have abided by the standard PSSRU costs. These are based on observed
costs, and the absence of a difference in cost between consultants and associate specialists may
relate to seniority: if the average seniority of associate specialists is much greater than that of the
consultants, they will have accumulated more salary increments.
The NHS reference cost is our default cost. Where no reference cost was available, we used the
difference between the NHS reference costs and the time-multiplied salary cost (£26.51) for
ophthalmologist time, to derive an indirect cost weight factor of 2.2 to assess the full cost of grader
pathways. However, the PSSRU costs include overheads, so the indirect adjustment factor was not
necessary. Table 27 shows the costs of the different procedures.
TABLE 26 Alternative costs for staff time
Resource item
AfC pay





6 49 Per hour aPSSRU 2019, page 14333
Ophthalmic grader 7 59 Per hour PSSRU 2019, page 14333
Ophthalmologist (consultant)b N/A 93,764 Per year Pay and Conditions Circular
(M&D) 2/2019 R2, page 1348,49
Associate specialistc N/A 74,267 Per year Pay and Conditions Circular
(M&D) 2/2019 R2, page 1848,49
Staff graded N/A 53,287 Per year Pay and Conditions Circular
(M&D) 2/2019 R2, page 2348,49
Ophthalmologist (average cost)e N/A 95 Per hour A calculated average based on




N/A 58 Per patient
contact
NHS 2019/20 national tariff
payment system34
AfC, agenda for change; M&D, Medical and Dental; N/A, not applicable.
a We chose the cost per hourly rate of radiographers as the most relevant unit cost for ophthalmic
imaging technicians.
b We took the mid-point of the consultants’ salary scale, i.e. starting salary £80,000 up to £108,000.
c We took the mid-point of the associate specialists’ salary scale, i.e. starting salary approximately £56,000 up
to £92,000.
d We took the mid-point of the staff doctors’ salary scale, i.e. starting salary approximately £37,000 up to £69,500.
e Average cost per hour for an ophthalmologist is based on average salaries of an associate specialist, staff grade
doctor and consultant, assuming a 40-hour working week equivalent to 1701 hours. We used an adjustment factor
of 2.2 to account for indirect costs.
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Diabetic macular oedema: comparison of the ophthalmic grader pathway with current
standard of care
The sensitivity of graders as determined in the main analysis of EMERALD was very good, 96.6% in the
main analysis (see Chapter 2, Table 14), when compared with the standard of care (slit-lamp biomicroscopy
undertaken by the ophthalmologist who also had access to SD-OCT images). The specificity of graders,
also determined in the main analysis, was not as good, at 31%, although this could still lead to an
ophthalmologist seeing approximately one-third fewer patients with inactive DMO in clinics. The main
analysis included referrals from graders to ophthalmologists when they detected the presence of DMO
(recurrent DMO) but also when graders were not sure if DMO was present (i.e. grading stated ‘unsure’) or
when images could not be graded by the graders (i.e. grader stated ‘ungradable’). This would also be the
procedure followed if this new pathway were to be used in clinical practice.
However, the savings in ophthalmologist time would apply only if neither eye had active DMO or
active PDR, as under these circumstances the patient would still require an ophthalmologist evaluation
and treatment. Table 28 shows the relative costs of follow-up of DMO by ophthalmic graders and
ophthalmologists.
We used the results of several sensitivity analyses as reported in Chapter 2, Table 13. There were no
significant differences in sensitivity, but specificity varied from as low as 21% (i.e. 79% of patients
having to be referred to ophthalmologists, reducing the savings) to 56% if graders were asked to
identify central-involving active DMO only.
It appears from these analyses that even with low specificity, follow-up by graders could provide useful
savings in ophthalmologist time, which could be then redirected to the timely evaluation and treatment
of people with sight-threatening disease.
TABLE 27 The costs of procedures
Item Cost (SD) per patient (£) Notes
O-FTF clinic visit for slit-lamp examination
(base case)
58.00 NHS 2019/20 national tariff for an
ophthalmology outpatient follow-up
appointment with a consultant
O-FTF clinic visit for slit-lamp examination
(sensitivity analysis)
27.88 (13.75) Calculated as time cost of conducting
assessment × hourly salary rate +
equipment cost (per patient)
Ophthalmic photographer/imaging
technician obtaining seven-field ETDRS
photographs (band 6)
12.78 (6.83) Time cost × photographer
salary + equipment cost
Ophthalmic photographer/imaging
technician obtaining ultra-wide field
fundus images (band 6)
9.75 (5.85) Time cost × photographer
salary + equipment cost
Reading ETDRS photos by ophthalmic
grader (band 7)
10.45 (6.40) Time cost × grader salary
Reading ultra-wide field fundus images by
ophthalmic grader (band 7)
9.10 (5.77) Time cost × grader salary
Reading ETDRS photos by ophthalmologist 21.58 (9.02) Time cost × salary
Reading ultra-wide field fundus images by
ophthalmologist
18.23 (7.28) Time cost × salary
Taking OCT Occurs in both pathways Cost not included
Reading OCT: grader (band 7) 4.08 (3.25) Time cost × salary
Equipment cost is a small percentage of total cost. Salary costs include employers costs at 20%. Reading SD-OCT by
ophthalmologist is included in the NHS reference cost for ophthalmologist OP visits.
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Proliferative diabetic retinopathy: comparison of grader pathway with
current standard of care
The main analysis undertaken in the EMERALD study compares the current standard of care pathway
for PDR (i.e. O-FTF with slit-lamp biomicroscopy) with the ophthalmic grader pathway (review of
either seven-field ETDRS fundus images or ultra-wide field fundus images by the grader). As in the
DMO analysis, in the PDR analysis ‘referral’ by the grader included those patients identified as having
active PDR by the grader and those identified as ‘unsure’ and ‘ungradable’ (see the main analysis in
Chapter 2, Table 15).
Chapter 2, Table 16, shows a sensitivity of 82% with a specificity of 54% for graders when grading
ultra-wide field fundus imaging, and a sensitivity of 85% with a specificity of 48% when grading was
based on seven-field ETDRS fundus photographs. The small differences are insignificant (see 95%
confidence intervals in Table 16). Ultra-wide field fundus images appear to be more cost-effective given
that they provide as good sensitivity and specificity as the ETDRS ones, or in the case of PDR with
high-risk characteristics, better sensitivity and specificity, but require less time to take and read, and
are therefore less costly.
In SENA1, the diagnostic performance of the graders was assessed based on their specific identification
of active PDR (‘unsure’ and ‘ungradable’ were not included). Their specificity improved but their
sensitivity was much poorer. Therefore, this option would be less costly because the improved specificity
means that fewer patients would be referred to ophthalmologists. However, many patients with active
disease would be missed. However, this would not be how the grader pathway would be implemented
because graders in routine care would be referring patients whether they identified active disease or if
they were to be unsure or unable to grade the images.
In SENA2, the ophthalmic grader pathway was assessed by how well it identified eyes requiring
treatment [some recurrences of PDR may not need immediate treatment or immediate treatment may
not be possible (e.g. in cases of vitreous haemorrhage the view of the back of the eye would be poor
and further laser could not be undertaken until the blood clears, which may take weeks to happen);
under the latter circumstances, patients will be followed and re-assessed at the next visit]. The graders’
sensitivity for detecting these more seriously affected eyes was much better: 86% with ultra-wide field
imaging and 88% with seven-field ETDRS photographs. Specificity was 52% and 46%, respectively,
which was similar to the main analysis.
TABLE 28 Relative costs of follow-up of DMO
Pathway Sensitivity Specificity
Cost per










97% 31% (4.08 × 100) +
(69 × 58) = 4410.00b
Time cost × salary. Cost compared with standard
ophthalmologist outpatient visit
Cost difference 1390.00 Ophthalmologist reference cost for outpatient
follow-up visit × 100 minus (ophthalmologist
cost for 69 outpatient visits+ grader costs for
reading 100 OCTs)
a The costs for grader options take into account the specificity, so that in each 100 patients a proportion will still need
to be referred to an ophthalmologist, with the reference standard cost for ophthalmologist follow-up applied. So if
specificity of the grader pathway is 31%, then 69% of patients will be seen by ophthalmologists.
b Costs of grader reading images for 100 patients + ophthalmologists’ time of reviewing 69 patients classified as
possibly active DMO when DMO is inactive, based on specificity.
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Analysis SENA4 shows the sensitivity of ophthalmic graders’ assessment of images when the reference
standard involves the detection of pre-retinal or vitreous haemorrhages (i.e. people with high-risk PDR).
The sensitivity was 87% for ultra-wide field images (95% CI 78% to 93%) and 80% (95% CI 69% to 88%)
for seven-field ETDRS images. Specificities were 49% and 40%, respectively.
Table 29 shows costs of care related to PDR as drawn based on the main analysis of EMERALD
(comparing the new ophthalmic grader’s pathway with the current standard of care: ophthalmologists
face-to-face evaluation using slit-lamp biomicroscopy and taking into account referrals by the grader
related to ‘active PDR’, ‘unsure’ and ‘ungradable’). Overall, there could be savings from the graders
reading the fundus images compared with the ophthalmologists’ face-to-face examinations. Table 30
shows the same comparison but for eyes needing treatment, and Table 31 for eyes with pre-retinal or
vitreous haemorrhages.
In both of the above scenarios, the savings are modest with seven-field ETDRS photographs, but higher
with ultra-wide field images. However, these scenarios refer only to PDR requiring treatment and PDR
with pre-retinal or vitreous haemorrhage; these would be the groups that would be more important
not to be missed by the ophthalmic graders.











Grader evaluating seven-field ETDRS fundus
images, inclusive referral
85% 48% 5339.00 461.00b
Grader evaluating ultra-wide field fundus
images
83% 54% 4611.00 1189.00
a The analysis from which the sensitivity and specificity values are derived in this table are based on either eye being
active. If either eye has active PDR, it is referred to the ophthalmologist. The cost will not be increased if both eyes
show active PDR.
b Calculated as (time of taking ETDRS photos + costs of grader reading ETDRS photos) × 100 + (52 × O-FTF OP
appointment costs). Owing to the specificity, 52% of patients will be referred to the ophthalmologist.











Grader evaluating seven-field ETDRS fundus
images for eyes requiring immediate
treatment
88% 46% 5455.00 345.00a
Grader evaluating ultra-wide field fundus
images for eyes requiring immediate
treatment
86% 52% 4669.00 1131.00
a Calculated as (time of taking ETDRS photos + costs of grader reading ETDRS photos) × 100 + (54 × O-FTF OP
appointment costs). Owing to the specificity, 54% of patients will be referred to the ophthalmologist.
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Proliferative diabetic retinopathy: comparison with enhanced reference standard
The cost of the ERS reflects the three elements: O-FTF with slit-lamp biomicroscopy, plus the
ophthalmologist reading of both seven-field ETDRS and ultra-wide field fundus images. The ERS in
EMERALD was carried out because it was accepted as possible that new vessels could be missed on
the ophthalmologist slit-lamp examination but be seen on fundus images. Both sets of photographs,
however, could not be carried out routinely in clinic in the NHS. For the cost–consequences analysis,
the value of the ERS is that it allows us to compare the costs, sensitivity and specificity of having
photographs read by an ophthalmologist or ophthalmic graders. However, for completeness, we give
the costs of the ophthalmic grader pathway compared with those of the ERS in Table 32. As before,
‘inclusive referral’ means that the ophthalmic graders refer to ophthalmologists all eyes in which they
diagnose ‘active PDR’, plus those about which they are ‘uncertain’ and those with ‘ungradable’ images.
One interpretation of the above figures is that, assuming that the ERS has 100% sensitivity, the
marginal cost of each 1% sensitivity is (£7771.00/21.3) £364.84 for ultra-wide field images. Therefore,
using the ERS might seem to be good value if it costs only £364.84 to detect each extra case of PDR.
However, the cases of PDR will include a mixture of active PDR requiring immediate treatment and
active PDR that is less urgent and might only be brought back at the next regular visit (or earlier).





with standard care (£)
O-FTF Assumed 100% Assumed 100% 5800.00 –
Grader evaluating seven-field
ETDRS fundus images for eyes
with haemorrhages
80% 40% 5803.00 No savinga
Grader evaluating ultra-wide
field fundus images for eyes with
haemorrhages
87% 49% 4843.00 957
a Calculated as (time of taking ETDRS photos + costs of grader reading ETDRS photos) × 100 + (60 × O-FTF outpatient
appointment costs). Owing to the specificity, 60% of patients will be referred to the ophthalmologist.






Ophthalmologist ERS Assumed 100% Assumed 100% 12,034.00a
Note 1
–
Grader ETDRS, inclusive referral 82.2% 53.5% 4991.00 7043
Grader OPTOS, inclusive referral 79.7% 58.8% 4263.00 7771
a The cost of the ERS includes, for each patient, the £58 cost of the O-FTF in the outpatient clinic, plus £12.78 for
taking ETDRS images, £9.75 for wide-angle images, £18.23 for reading wide-angle images and £21.58 for reading
ETDRS images. The cost would be £2798 lower if only wide-angle images were obtained.
Notes
The ERS comprised the combined findings of the O-FTF, and findings of ophthalmologists reviewing 7-field ETDRS
and ultra-wide field images. We have assumed 100% sensitivity and specificity. If the ophthalmologist had only the
ultra-wide field images or the seven-field ETDRS images in addition to their O-FTF (as would happen in clinical
practice if images were to be added to the current standard of care), the sensitivity might be lower.
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The comparison of O-FTF with ERS shows that the ERS identifies more reactivated (recurrent) PDR
than was identified using images only. This may not be surprising given that some patients have
problems sitting still and focusing on the right point during slit-lamp biomicroscopic examination.
However, as shown in Table 14, direct O-FTF identifies some eyes with PDR that were not identified
from reading the ultra-wide field or seven-field ETDRS fundus images. This suggests that the clinically
most effective method of follow-up might be to use a combination of O-FTF and photographs, of which
ultra-wide field images appear to be the better choice based on the lower cost of both taking and
reading the photographs, and the higher sensitivity and specificity at detecting the more severe form
of PDR (i.e. with pre-retinal haemorrhage and/or vitreous haemorrhage).
If the optimal method of follow-up was a combination of O-FTF and reading of ultra-wide field images,
one question would be who reads the photographs.
Table 33 shows a simple cost comparison of the reading of photographs by the grader and the
ophthalmologist for 100 patients. The data compare ophthalmologist and grader sensitivity for
detecting active PDR from ultra-wide field images, using O-FTF as the reference standard. Specificity
is higher when ophthalmologists read the photographs, with no overlap of 95% CIs (see Table 15).
Sensitivity is better by approximately 9% for ophthalmologists reading ultra-wide field images, but CIs
overlap. There is little difference in sensitivity between ophthalmologists and graders with ETDRS
photographs, with overlapping CIs.
However, in the ERS scenario, the ophthalmologists see all of the patients and would want the images
to be available at that time to come to a definite diagnosis and to counsel the patient accordingly. It is
likely that the ophthalmologist would want to check areas on the images that had looked suspicious on
slit-lamp biomicroscopy. Therefore, even if all of the images came with reports from the ophthalmic
graders to the ophthalmologist by the time of the slit-lamp examination, it is likely that the ophthalmologist
would still spend time looking at the images and the savings in Table 33 become an overestimate.The EMERALD
study cannot provide data to address this. In any case, logistically, it would be difficult to have a grader grading
the images in clinic prior to patients being seen by the ophthalmologists.
Results for EQ-5D-5L, NEI VFQ-25 and VisQoL measures
Tables 34 and 35 show the mean scores for the generic health-related quality-of-life measure EQ-5D-5L
and the two vision-specific questionnaires (NEI VFQ-25 and VisQoL) for patients with DMO or PDR.The
patients who had active DMO status had slightly higher scores, but these were not statistically significant
(see Table 34). However, patients who had inactive PDR had slightly higher EQ-5D-5L scores; NEI VFQ-25 and
VisQoL scores followed a similar pattern to that observed for DMO. However, the differences were not
statistically significant for any of the outcome measures.
TABLE 33 Costs comparison of the reading of images by graders and
ophthalmologists for 100 patients





Note that in the ‘enhanced monitoring’ option of O-FTF plus reading of one
set of photographs the increased specificity of the ophthalmologist would
provide no advantage because all patients would have O-FTF.
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Figure 13 shows that there were no significant differences between patients who had active DMO and
patients who had inactive DMO in the different NEI VFQ-25 subscales or in the composite score.
Figures 14 and 15 show graphically the scoring of the severity levels for the EQ-5D-5L dimensions. Overall,
there was no difference between the active or the inactive eye status for patients with either DMO or PDR.






n Mean SD n Mean SD
EQ-5D-5L utility score 151 0.75 0.28 116 0.74 0.27 0.007 –0.06 to 0.07
EQ-5D-5L visual analogue scale 152 72.05 23.92 120 66.23 25.29 5.83 –0.11 to 11.77
NEI VFQ-25 composite score 152 81.45 19.75 117 78.21 22.58 3.23 –1.95 to 8.42
VisQoL standardised score 146 74.69 21.87 112 70.49 26.75 4.20 –1.93 to 10.33






n Mean SD n Mean SD
EQ-5D-5L utility score 107 0.72 0.27 165 0.75 0.28 –0.20 –0.09 to 0.04
EQ-5D-5L visual analogue scale score 107 64.03 25.39 165 68.08 25.06 –4.05 –10.12 to 2.03
NEI VFQ-25 composite score 107 80.52 19.91 167 77.32 24.14 3.20 –2.08 to 8.48













































































































FIGURE 13 Mean NEI VFQ-25 scores among patients eligible for the new ophthalmic grader pathway categorised by
DMO status (active vs. inactive). a, Composite score is an average of the vision-targeted sub-scale scores, excluding the
general health rating question.
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Surveillance of people with DMO by trained ophthalmic graders using SD-OCT was found to have very
good sensitivity (97%) but with much poorer specificity, ranging from 31% to 56% depending on the
scenario. However, even that level of specificity would still allow useful savings in ophthalmologist
time, which could be used for other patients. However, there might be some disutility owing to anxiety
and the lack of reassurance gained by seeing an ophthalmologist (see Chapter 3). This could be resolved
if patients wishing to talk to ophthalmologists could do so by telephone, but there would be a time
cost to that.
As noted in Chapter 2, the sensitivity and specificity vary according to the comparison. For example,
the term ‘inclusive referral’ meant that graders referred DMO when they consider it to be definitely
active, when they were unsure about the activity of the disease and when there were ‘ungradable’
images. However, in all scenarios in DMO, sensitivity remained over 90%.
Active DMO does not progress rapidly and visual acuity is not expected to drop rapidly either; therefore,
significant harm would be unlikely if active DMO were to be missed in 3% of cases at one visit, especially
considering that not all eyes with DMO need immediate treatment. The proportion of eyes with DMO
requiring treatment is approximately only 58% (85/147) of all active DMO (see Table 13).
Proliferative diabetic retinopathy
In PDR, comparison of the grader pathway with the standard care of O-FTF in the main analysis showed
a sensitivity that may or may not be considered acceptable in clinical practice. It should be noted, however,
that the sensitivity varies according to the grade of PDR, being higher in PDR requiring immediate treatment
and reaching nearly 90% if ultra-wider field imaging is used in people with more severe PDR with pre-retinal
and/or vitreous haemorrhage.
In PDR, an important finding, albeit from a post hoc analysis, was that the standard care of O-FTF had
poorer sensitivity than the ERS. The ERS used both seven-field ETDRS and ultra-wide field images in
addition to O-FTF. Obtaining both sets of images would not be feasible in routine care. Further analysis
of a post hoc nature would be required to assess the accuracy of O-FTF plus ultra-wide fundus images
only, as this is what could be implemented in clinical practice (ultra-wide field fundus images would be
the choice when compared with seven-field fundus images considering that the former take less time
to take and grade and have higher sensitivity to detect the more severe form of PDR with pre-retinal
and vitreous haemorrhage).
One issue is whether or not the grading of images by ophthalmic graders would be seen as taking
extra responsibility, meriting an increase in salary band. We have assumed that it would, so estimates
presented herein use costs based on graders being on band 7. We have also assumed that the
photographers/imaging technicians obtaining the images are on band 6.
Cost would be reduced further if the grader specificity could be improved by feedback and perhaps
additional training and by other measures (e.g. patient selection prior to entering the pathway and
improved monitors to visualise images).
Our mean time estimates for obtaining ultra-wide field images and seven-field ETDRS photographs
were higher than those reported in an earlier study by Silva et al.49 that, for this purpose, included
only 22 patients. That study reported that the mean (± SD) time required to acquire non-mydriatic
ultra-wide field images was 2.8 (± 1.3) minutes versus 6.2 (± 2.2) minutes for ETDRS photography.49
In comparison, our study found that it took 10.4 (± 7.2) minutes to take ultra-wide field images and
15.3 (± 8.2) minutes to capture seven-field ETDRS photographs. However, the timing by Silva et al.
appears to start from when the patient was positioned at the camera, whereas in EMERALD the time
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was recorded from when the patient entered the room to be imaged; therefore, the times are not
comparable. In addition, the study by Silva et al. was undertaken in a single centre (rather than being
a multicentre study as in EMERALD). Patients included in the Silva et al. study had a mean age of
54 years, which is a little lower than EMERALD patients (over half of whom were > 60 years of age).
However, both the Silva et al. and the EMERALD studies found that taking ultra-wide field images was
quicker than obtaining seven-field ETDRS.
Our estimate for the direct cost of the O-FTF is similar to that by Prescott et al.,50 who estimated a
direct cost per slit examination of £27.29 using a similar approach.
The data from the FGs (see Chapter 3) showed that patients value being seen by the ophthalmologist.
They gain reassurance, have reduction in anxiety and can ask questions. Furthermore, not seeing the
ophthalmologist could lead to some disutility, which would persist until the patient was next seen. We
do not have data to quantify this. As noted earlier, patients do not understand the professional standing of
the photographers/imaging technicians, and have probably never heard of ophthalmic graders. This could
perhaps be remedied by the provision of information. In this regard, the EMERALD results demonstrating
good sensitivity of graders evaluating DMO images when compared with ophthalmologists (see Chapter 2,
Sensitivity analyses 2, 4, 5 and 6 and Additional analyses 1–3) should provide reassurance to patients.
Modelling of cost-effectiveness
We had planned that, if there were to be differences among the assessment methods, a Markov
model-based cost–utility analysis would be undertaken to examine the cost-effectiveness of the
potential surveillance pathways.
The sensitivity of the grader pathway for DMO was very good, and no trade-off between cost savings
and vision would be expected if implemented. Specificity was not high, but it is likely that this could be
improved (e.g. in the EMERALD study, graders did not have access to any previous clinical information,
such as visual acuity, and they did not have access to previous images: both could potentially lead to
higher specificity). Poor specificity means that cost savings would be less than hoped for. However, no
modelling was required for this part and, thus, it was not conducted.
The overall sensitivity of 80% for the detection of reactivated PDR in the main EMERALD analysis was
within the originally accepted level. Indeed, there was the historical precedent of the 80% sensitivity,
which was deemed acceptable for DR screening programmes (although it is unclear where this figure
came from). Sensitivity was higher for the higher-risk group (high-risk PDR), as it was close to 90%
when using ultra-wide field imaging.
Modelling was not possible, however, given that modelling would require knowledge of the following:
l The proportion of the missed reactivated PDR that would progress, and how many patients would
have needed treatment if detected.
l How much vision a patient would lose before the next visit, if any.
l What proportion of people would have reactivation detected at the next visit – would some
changes be missed again?
l How successful treatment was for those detected at each time point. This could be vision
maintained or, for some, improved.
l What would happen if reactivated PDR was missed again at the next visit – what proportion of
people would suffer irreversible visual loss and to what extent.
l The quality-of-life consequences for all of the above.
l The costs of treatment of reactivated PDR.
l Differences in costs and quality-adjusted life-years between grader and standard care pathways.
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All of the above information would be required for the ophthalmic grader pathway and for the
standard face-to-face ophthalmologist pathway (current standard of care). We know from the ERS
that the sensitivity of the standard care pathway is not 100%, and that ophthalmologists, for example,
may also miss active new vessels (i.e. active PDR) in some patients.
Unfortunately, information regarding most of the above points is not available and this precluded our
ability to undertake modelling as initially planned. Furthermore, not everyone with a recurrence of
PDR after PRP needs or can have treatment when the recurrence is first noted (e.g. if a vitreous
haemorrhage occurs, patients are often managed by observation until the haemorrhage clears). Data
on the proportion of patients needing immediate treatment, treatment at a later date or no treatment
at all are not available either.
Research is needed into the natural history of treated PDR, including the timelines for recurrence,
the forms that recurrence takes, the need for treatment and the effectiveness of treatment.
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Chapter 5 General discussion
Statement of principal findings
The EMERALD study evaluated diagnostic accuracy, acceptability to users and cost-effectiveness of a
new care pathway, the ophthalmic grader pathway, using multimodal imaging for the surveillance of
people with previously treated and stable DMO and/or PDR, when compared with the current standard
of care (ophthalmologists evaluating patients in clinic by slit-lamp biomicroscopy, supplemented by
SD-OCT in the case of DMO). The study found that for DMO the grader’s pathway had excellent and
consistent sensitivity of 94% and above based on all pre-planned analyses undertaken, demonstrating
that the pathway would be accurate and safe for patients. The specificity for DMO detection was low,
ranging from 20% to 56%, depending on the analysis (in the main analysis, 31%). However, even those
levels of specificity would still provide a useful release of ophthalmologists’ time for other patients.
Thus, the pathway could be implemented in the NHS. The EMERALD study found the sensitivity of the
ophthalmic grader pathway for PDR, as determined in the main analysis (i.e. grader referring patients to
ophthalmologists because of presence of active PDR, if they were unsure or if images were ungradable,
which fits with how the pathway would be implemented in practice), to be lower than that for DMO.
However, and importantly, the sensitivity of the ophthalmic grader pathway to detect high-risk PDR
with pre-retinal and/or vitreous haemorrhage when using ultra-wide field fundus images was higher
(87%). The specificity of the new pathway to detect PDR was higher than that for DMO, between 49%
and 72% in pre-planned analyses, and was found to save considerable costs and ophthalmologist time.
As in the EMERALD study, patients eligible to participate in the ophthalmic grader pathway, if this
pathway were to be implemented in clinical practice in the NHS, will have previous treatment with PRP.
Hence, the risk of a recurrence and the repercussion of it would not be expected to be as high or as
severe as if active disease were to occur in a patient naive to treatment. If a vitreous haemorrhage were
to occur, patients would most likely develop floaters and could be instructed to immediately contact
hospital eye services to receive timely evaluation and further treatment, if required. In many cases, the
course of action of a vitreous haemorrhage is observation until the haemorrhage clears, especially in
patients previously treated with PRP, and then fill-in PRP, if required. Few patients previously treated
with PRP who develop a vitreous haemorrhage would be expected to require a vitrectomy. TRDs in
people previously adequately treated with PRP are infrequent. With this in mind, the ophthalmic grader
pathway for PDR may be considered justifiable at the level of sensitivity found in EMERALD, especially
in areas of the country where waiting times are preventing patients with active and severe disease from
accessing timely care, which has been highlighted to be a real problem currently in the NHS.51,52 Finally,
and importantly, a secondary planned analysis exploring the performance of the combined ophthalmic
grader assessments for both DMO and PDR (rather than of one or other) showed an overall sensitivity
of over 96% supporting, further supporting the safety of the new pathway.
Strengths and limitations
EMERALD was carried out in 13 NHS ophthalmology services, with good recruitment and adequate
power. Patients were not excluded if they had eye characteristics that would make imaging challenging
(e.g. cataracts, poor pupillary dilatation) making the results more applicable to routine care.
The photographers obtaining images were familiar with the standard ETDRS seven-field approach,
but were less experienced in taking ultra-wide field images, especially in some centres. Despite this,
few images were ungradable.
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Images of the iris and anterior chamber angle were not obtained for the evaluation of people with
PDR. In very few instances, it would be possible that new vessels could develop in these structures
but not be observed in the retina (NVE) or optic disc (NVD). However, this would be unlikely to occur
in patients previously treated with laser PRP. If it were to occur, without imaging and evaluation of
these structures, it would be missed.
In EMERALD, images were evaluated by ophthalmic graders (and by ophthalmologists undertaking the
ERS) without any information about the patient (i.e. masked to any clinical data, including previous
images). Although this was a strength in scientific design, it is likely that if clinical information were to
be available (e.g. location of previously identified new vessels), including previous images (e.g. images
of new vessels following treatment), the sensitivity and specificity of the pathway could be improved.
If the pathway were to be implemented in clinical practice, previous clinical information and images
would be available to ophthalmic graders.
Implementation of the new care pathway: matters to consider
Before implementation, careful consideration should be given to patients’ views, as elicited in our FG
discussions. The advice included providing immediate feedback to patients on the status of their disease
(i.e. stable or potentially active) using currently available media (e.g. e-mail, telephone, text message)
following the reading of the images, and maintaining periodic evaluations by an ophthalmologist,
albeit at less frequent intervals. Patients should be informed about the identity, role and function of
ophthalmic photographers and graders. Specifically, patients need to know the level of expertise of the
grader reviewing their images, and understand that ophthalmologists will still be the ones making
decisions about their treatment and care, if an ophthalmic grader pathway were to be implemented.
Data obtained in EMERALD, demonstrating that graders perform as well or even better than
ophthalmologists at grading images should be reassuring to patients.
There is no clear view on what would be the minimum required sensitivity and specificity that would
be acceptable for diagnostic or surveillance pathways. Figures of 80% for sensitivity and 95% for
specificity have been quoted in various articles on screening for DR. These seem to have come from
a 1997 British Diabetic Association document, based on a consensus conference in 1995, but the
document is no longer available (we asked Diabetes UK for access to this document) and so the
reasoning behind the figures is not known. As stated above, follow-up of previously treated patients,
especially when referring to people with PDR previously treated with PRP, is a rather different
scenario to that in DR screening, where naive-to-treatment patients are followed at less frequent
intervals. Missing a patient with PDR in a DR screening programme would be expected to have more
severe implications than missing an individual with reactivation of PDR in an eye previously treated
with PRP. Ten out of the 14 (71%) ophthalmologists in the EMERALD study group, who have extensive
expertise in DR and, specifically, PDR, believe that the 80% sensitivity of the ophthalmic grader
pathway is considered acceptable in this previously PRP treated population and that, subsequently,
the pathway for PDR could, like that of DMO, be implemented.
It may be possible to increase the diagnostic accuracy of the new pathway. To do this, it is essential to
understand that the diagnostic accuracy of the new ophthalmic grader pathway goes beyond the ability
of the graders to recognise DMO and PDR in fundus images. Thus, it is also dependent on the quality
of the images produced, which relies not only on the ophthalmic photographer/imaging technician obtaining
them but also on characteristics of the patient and the eye to be imaged. In EMERALD, however, images
could be obtained in the great majority of eyes of participants (92–97% of eyes, depending on the imaging
technology used), despite the fact that patients were not selected based on whether or not they would be
suitable for imaging (i.e. patients with e.g. small pupils, cataract, were not excluded). Furthermore, only a
small proportion of images obtained in EMERALD were considered to be ungradable (1–2% of SD-OCTs;
5–7% of seven-field ETDRS images; 4–6% of ultra-wide field images). The diagnostic accuracy of the new
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pathway may also be influenced by the platform used to make the images available to the graders, and by
the resolution of the screen on which these images were visualised. For logistic purposes (i.e. making all
imaging technologies available to each grader in the same location), EMERALD used a commercially
available platform (Ophthalsuite, BlueWorks, Coimbra, Portugal) and graders visualised images in available
computer screens and, thus, it remains unclear whether the diagnostic performance would have improved if
images had been visualised and evaluated using the software available for each of the imaging technologies
instead and/or on high resolution screens. As stated above, patients were not excluded if they had eye
characteristics that would make imaging challenging (e.g. cataracts, poor pupillary dilatation). This would be
expected to affect fundus images (seven-field ETDRS and ultra-wide field images) more so than SD-OCT
scans (the number of ungradable images in one or other modality seems to support this), which may
have contributed to the lower sensitivity observed for PDR. Currently, patients are imaged routinely with
SD-OCT and they are used to this imaging modality; they do not routinely receive ultra-wide field imaging:
seven-field ETDRS fundus images are obtained with a standard, conventional fundus camera and, thus,
patients would be accustomed to this technology. If ultra-wide field fundus imaging were to be done
routinely, it is very likely that improved collaboration could lead to improved image quality. Similarly,
many ophthalmic photographers/imaging technicians are not as used to ultra-wide field imaging as they
are to standard fundus cameras; further experience on this technology may also lead to better quality
ultra-wide field images. Further training of graders and regular feedback following grading would be
expected to improve their ability to differentiate between active and inactive disease in previously treated
patients, who constitute potentially a more challenging group than those naive to treatment. All of the
above may improve further sensitivity and specificity of the new ophthalmic grader pathway.
Potential barriers for implementation of the ophthalmic grader pathway include (1) the identification of
individuals that would wish to act as graders (i.e. grader recruitment); (2) the delivery of appropriate
training for the graders and the ability of graders to take time to undergo training; (3) the retention of
ophthalmic graders once properly trained, once in their role; and (4) efficient systems to report results
to patients, and to do so on the same day as images are read. However, the identification and training
of graders, as explained in Chapter 2, Methods, was possible in EMERALD, suggesting that it is doable.
If remunerated appropriately, retention may also be achievable.
Cost–consequences analysis
The cost–consequences analysis identified scenarios where savings could be made. In practice,
however, it is unlikely that any savings would be realised. The benefits would be the release of
ophthalmologist time to see or treat other patients. The benefits could also include that, for example,
patients with treated and stable PDR could be seen earlier (say every 3–4 months) if followed up by
ophthalmic graders than if evaluated by ophthalmologists (currently aimed to be done every 6–8 months)
although this would have implications on costs of the new ophthalmic grader pathway. We are aware that
waiting times for patients to see an ophthalmologist are very long in some places, well beyond 12 months.
In such circumstances, being followed by an ophthalmic grader at shorter intervals may be much better,
even at the sensitivity observed in EMERALD.
The potential for future automated grading of images
With the increased popularity of artificial intelligence (AI) in the field of ophthalmology and, specifically,
in DR, a question arises about whether or not AI could be used instead of graders to determine the
presence of active DMO and/or PDR on fundus images and SD-OCT scans. This concept is not new and
many groups have worked in this area. Sharp et al. proposed and undertook work, funded by the Health
Technology Assessment (HTA) programme of the National Institute for Health Research (NIHR), using
digital imaging and automated reading for the purpose of grading DR for DR screening programmes.53
Further work conducted by this group, also supported by the NIHR HTA programme, demonstrated
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excellent performance of automated detection of DMO and the value of adding OCT for this purpose.54
More recent studies undertaken by Abràmoff et al.55,56 have now demonstrated excellent sensitivity and
specificity of AI methods to determine presence of referable DR [defined as presence of moderate and
higher stages of non-proliferative DR (NPDR), PDR or DMO] in fundus images when compared with
retinal specialists. This AI system (IDx-DR; IDx Technologies Inc., Coralville, IA, USA), with 87% sensitivity,
90% specificity and 96% imageability, has been approved recently by the Food and Drug Administration
(FDA) for the automated diagnosis of DR. The studies on which this programme was developed, however,
included mostly patients with DMO and/or PDR who had not been previously treated (i.e. treatment
naive). Thus, although the programme has been shown to perform well to detect referable DR in an
untreated population, it remains to be elucidated whether high diagnostic accuracy could be achieved
through this or other AI programmes in the more complex group of previously treated patients.
Imaging modalities
EMERALD compared two different imaging technologies for the evaluation of PDR, seven-field ETDRS
and ultra-wide field fundus imaging (for details on each, see Chapter 1). For the latter, the Optos system
(Optos Inc., Dunfermline, Fife, UK) was chosen as it is the only ultra-wide field imaging technology that
allows a 200-degree field of view mode. Other wide-field imaging technologies do not reach the far
peripheral retina. The diagnostic accuracy of the new ophthalmic grader pathway to detect PDR was
very similar in both sets of images (seven-field ETDRS and ultra-wide field images) under the main
analysis (graders referring patients to ophthalmologists if they identified active disease, if they were
unsure, or if images were ungradable compared with the standard of care of ophthalmologists evaluating
patients on slit-lamp biomicroscopy). Seven-field ETDRS images led to slightly higher sensitivity than
ultra-wide field images (71%, 95% CI 61% to 79% for seven-field ETDRS, vs. 63%, 95% CI 53% to 71% for
ultra-wide field images) when referral specifically for active PDR was considered. This, however, would not
be the way in which the pathway would be running in clinical practice as graders would also be referring
patients when uncertain about the activity of the disease (as set in the main analysis). Ultra-wide field
imaging tended to have slightly higher specificity. Importantly, there was higher sensitivity and specificity
to detect people with more severe PDR (PDR with pre-retinal and vitreous haemorrhage) when ultra-wide
field imaging was used. The costs of both taking and reading ultra-wide field images were less than the
respective costs related to seven-field ETDRS photographs.
In EMERALD, images were all obtained following pupillary dilatation. It remains to be elucidated
whether comparable sensitivity and specificity of the ophthalmic grader pathway could be achieved
through multimodal imaging in the undilated eye. This could increase patient satisfaction given that
patients would be able to drive safely following the examination as their pupils would not be dilated,
and would reduce their time in clinic further, as they would not need to wait for their pupils to dilate
prior to imaging. It would also lead to some savings (dilating drops will not be required).
In EMERALD, three-field ultra-wide field imaging was obtained, with fields of the far peripheral
superior and inferior retina, in addition to the central field, which already encompasses macula,
midperipheral and most of the peripheral retina. It is uncertain whether using these three fields is
required; if results were similar using only the central field image, this could reduce time to obtain
images and to grade them and would subsequently reduce costs.
One other study compared ultra-wide field images, obtained with the same system used in EMERALD
(Optos, Dunfermline, Scotland) with seven-field ETDRS for the detection of new vessels in PDR.57
This study evaluated how often new retinal vessels were detected outside areas covered by the seven
fields of the ETDRS imaging in a consecutive series of 1562 treatment-naive eyes from the NHS DR
screening service (DRSS) referred to secondary care. After evaluation in secondary care, new vessels
were found in 102 of the 1562 eyes (6.5%) of 781 patients. In 72 eyes (71%), new vessels had been
detected in the DRSS; in 30 eyes (29%), they were found after examination in secondary care.
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In 12 of these 30 eyes, new vessels were detected by wide-angle imaging in areas outside those covered
by seven-field ETDRS. The population included in this study (treatment naive individuals), however, was
different from the group included in EMERALD (people with PDR previously treated with laser PRP).
Virtual clinics
What have been widely called ‘virtual clinics’ (evaluation of patients by looking at their images rather
than through a face-to-face consultation in clinic with an ophthalmologist) are not new to the NHS.
Published studies presented the experience of several groups throughout the UK using this form of
evaluation for people with age-related macular degeneration58 and other medical retinal diseases,59
including DR60–62 and glaucoma.63 These studies showed that implementation of virtual clinics was
feasible and reduced patients’ time in clinic, improving patients’ journey, and seemed to increase the
efficiency of the service. Most studies evaluating virtual clinics for retinal diseases were based on the
assessment of images by ophthalmologists rather than allied health-care staff (e.g. graders),58,59,63 and
included newly referred patients rather than previously treated ones, and had a selected population,
rather than evaluating all comers. In one study evaluating outcomes (proportion of people discharged,
referred for further assessment in a face to face clinic undertaken by an ophthalmologist, or continuing
care in the virtual clinic) of new referrals to virtual medical retinal clinics, images were reviewed by
ophthalmologists (consultants and medical retina fellows), an optometrist and a grader. Diagnostic
accuracy of these different members of staff, however, was not investigated. To our knowledge, there
have been no studies conducted to date, other than EMERALD, specifically addressing the diagnostic
accuracy of a new pathway involving staff other than ophthalmologists for the evaluation of people
with previously treated DMO and/or PDR using multimodal imaging.
Despite the fact that some reports on virtual clinics are available, very scarce data exist with regard
to the acceptability of virtual clinics by patients61 and health-care professionals.64 Questionnaires were
used in these studies to assess acceptability, with the inherent limitations of this method as discussed
in Chapter 3, including the fact that through questionnaires users are responding to questions previously
elaborated, which may or may not address matters that are of importance to them. Furthermore, low
ascertainment rates (46–61%) limited the generalisability of the results presented in these studies. One
study referred to the use of virtual clinics for the evaluation of patients with DR.61 A survey was sent
to 813 patients attending hospital eye services for review of their DR in Singleton Hospital, Swansea;
498 questionnaires (61%) were returned, fully or only partly filled. Patients were asked to grade their
experience with regard to delays in their appointments and waiting times while in clinic, and whether
or not they would be willing to attend virtual clinics if appointments were given timely and their time in
clinic reduced. A high proportion of patients (86%) responded that they would be happy to be seen in
virtual clinics under these circumstances. When asked how happy they would be to attend these virtual
clinics (0 being not happy at all and 10 being very happy), the average response was 8.79. A small group
of 14% of patients stated they would not be happy to attend virtual clinics at all. It is unclear what
information was given to patients with regard to what a virtual clinic involved.
The FG work showed how much patients value seeing the ophthalmologist, and if an option was chosen
that did not include the O-FTF, it is likely that patients would incur some disutility due to anxiety. Visual
loss is the most feared complication of diabetes. It is not possibly to quantify this disutility with our
current FG data. The grader FG work also suggested that if photographs showed no reactivation,
graders would be happy to reassure patients; however, they would be less happy commenting on
changes suggestive of reactivation and answering other potential questions from patients that may
follow. These matters need to be considered if the new ophthalmic grader pathway is implemented.
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Conclusion
EMERALD supports the implementation of the ophthalmic grader pathway for the evaluation of people
with DR with previously treated and stable DMO, especially those with early NPDR (i.e. those with mild
or moderate NPDR) who would be unlikely to progress to PDR in a short period of time (Figure 16).
The diagnostic accuracy of the ophthalmic grader pathway for PDR was not as good as that for DMO.
However, considering that patients going into this pathway would previously have received treatment
with PRP, this pathway may be considered safe to be implemented. A pilot phase implementation in
selected centres (e.g. those previously participating in EMERALD) prior to its widespread implementation
in the NHS could be undertaken. Measures to improve the sensitivity of this pathway (e.g. providing
continuous feed-back to graders, selecting patients entering the pathway, enhancing resolution of screens
used to view images, etc.) could be introduced and evaluated.
Recommendations for future research
Further research evaluating the performance of AI for the automated detection of DMO and active
PDR in previously treated patients would be of great value, using current available commercialised AI
methods or through the development of new ones.
It would be useful to determine, either through evidence synthesis or, if insufficient data are available,
primary research, the risk of visual loss related to recurrence of disease in people with previously
treated PDR, and hence to understand the real risk for patients if the identification of their disease
were to be missed until the next evaluation. Although the latter may not be done prospectively, due to
ethical considerations, it may be possible to obtain data retrospectively that may inform about this risk
(e.g. evaluating outcomes of people with previously treated PDR that develop reactivation of their disease).
Current pathway for treated and stable
DMO and PDR
New opthalmic grader pathway for






















































Inactive PDRNo recurrent DMO Active PDR,
‘unsure’ or
‘ungradeable’
DMO and mild/moderate NPDR
Opthalmic grader evaluation
DMO
FIGURE 16 Current standard of care and new proposed pathway for people with previously treated and stable DMO
and PDR. VA, visual acuity; SD-OCT, spectral domain optical coherence tomography; SLB, slit-lamp biomicroscopy;
F/U, follow-up; UWF, ultra-wide field. a, With current anti-VEGFs used reviews are often carried out monthly initially;
newer anti-VEGFs may only require reviews every 2 months. b, Telephone calls to patients to discuss findings by
ophthalmologist or other members of staff could be arranged in addition, for selected patients, if required.
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Studies evaluating means of further improving the sensitivity of the ophthalmic grader pathway for the
detection of PDR and the specificity of the ophthalmic grader pathway for the detection of DMO and
PDR would also be valuable.
As reported in Chapter 2, some reactivated PDR was identified by the ophthalmologists using slit-lamp
biomicroscopy but not detected by the reading of the images, and vice versa. Further work exploring
the reasons for these differences would be helpful.
If one central ultra-wide field image rather than three, as undertaken in EMERALD, would provide
comparable sensitivity and specificity, this would reduce the time taken to obtain and grade images
and, subsequently, costs. A study exploring this possibility would be helpful. In addition, a study
determining the diagnostic accuracy of the ophthalmic grader’s pathway using images obtained in
undilated eyes, rather than following pupillary dilatation, as done in EMERALD, would be of interest.
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Appendix 1 Additional tables from
Chapter 2 diagnostic accuracy
TABLE 36 Demographics of participants: active diseases based on ophthalmologist slit-lamp examination
Demographic
characteristic





Either DMO or PDR
active (N= 272)
Both DMO and PDR
active (N= 49)
Sex
Male 131 (66.16) 83 (67.48) 182 (66.91) 32 (65.31)
Female 67 (33.84) 40 (32.52) 90 (33.09) 17 (34.69)
Age (years)
18–59 83 (41.92) 81 (65.85) 134 (49.26) 30 (61.22)
≥ 60 115 (58.08) 42 (34.15) 138 (50.74) 19 (38.78)
Ethnic origin
White 171 (86.36) 106 (86.18) 235 (86.40) 42 (85.71)
Black 14 (7.07) 8 (6.50) 18 (6.62) 4 (8.16)
Asian 7 (3.54) 7 (5.69) 13 (4.78) 1 (2.04)
Middle Eastern 3 (1.52) 2 (1.63) 3 (1.10) 2 (4.08)
Other 3 (1.52) – 3 (1.10) –
TABLE 37 Findings identified by ophthalmologists (when undertaking slit-lamp biomicroscopy= reference standard) and
recorded as potential factors that could lead to inadequate image quality
Factors that could lead to
inadequate image quality Right eye (n= 397)
Left eye (n= 396)
(excluded artificial eye)
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TABLE 37 Findings identified by ophthalmologists (when undertaking slit-lamp biomicroscopy= reference standard) and
recorded as potential factors that could lead to inadequate image quality (continued )
Factors that could lead to
inadequate image quality Right eye (n= 397)







Poor patient co-operation 3 1
Ptosis 2 1
Dry eyes 1 2
Anterior synaechiae 0 1
Hyphema 0 1
Anterior capsular opacification 2 2
Posterior capsule opacification 3 2
Asteroid hyalosis 2 2
Corneal scar 0 1
TABLE 38 Other findings/comorbidities identified by the ophthalmologist when undertaking slit-lamp biomicroscopy
Other findings/comorbidities Right eye (n= 397)
Left eye (n= 396)
(excluded artificial eye)
Epiretinal membrane 10 16
Glaucoma 9 13
Amblyopia 3 3
Ocular hypertension 1 4
Macular hole 1 2
Retinal vein occlusion 3 0
Age-related macular degeneration 1 1
Choroidal naevus 1 1
High myopia 1 1
Vitreomacular traction 0 2
Macular scar 0 1
Neovascularisation of the iris 1 0
Optic atrophy 0 1
Retinal artery occlusion 1 0
Comorbidities with conditions not listeda 1 8
Total 33 53
a Comorbidities with conditions that are not listed referred to those ophthalmologists who said ‘Yes’ there is eye
comorbidities but have not stated what it is.
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
98
TABLE 39 Reason for missing eye-level assessments
Reasons for missing data











































Missing: patient needs referral 1 4 2 2 6 6 4 6 6 13
No view of fundus: cataract 1 1
No view of fundus: haemorrhage 3 1 1 1 2
No view of fundus: no reason
specified
1 1
No view of fundus: corneal graft 1 1 1
Poor pupillary dilatation 2 1 2 2
Patient unable to
co-operate with imaging
1 1 1 2
Patient unable to sit at the
camera
1 2 1 2
Media opacity: type unspecified 4 5 1 1 2 4
Missing: other reason missing – – – – 5 7 13 13 14 18
Patient did not attend 1 1 4 4 8 8
Only one eye image captured 1 1 2 3 2 3
System error 1 3 3 3 2 4
Other unknown reason 2 2 4 3 2 3
Total 396 393 396 393 396 393 396 393 396 393
TABLE 40 PDR test results using OPTOS or using ETDRS vs. reference standard or enhanced standard
Agreement regarding active PDR status n/N Estimate
G-OPTOS referrala vs. O-FTF active PDR 87/105 82.86%
G-ETDRS referral vs. O-FTF active PDR 87/102 85.29%
O-OPTOS active PDR vs. O-FTF active PDR that require treatment 62/88 70.45%
O-ETDRS active PDR vs. O-FTF active PDR that require treatment 54/79 68.35%
O-OPTOS active PDR vs. the enhanced standard 96/138 69.57%
O-ETDRS active PDR vs. the enhanced standard 85/131 64.89%
O-FTF vs. the enhanced standard 111/146 76.03%
O-FTF and O-OPTOS vs. the enhanced standard 133/146 91.10%
O-FTF and O-ETDRS vs. the enhanced standard 131/146 89.73%
G-ETDRS, grader assessment based on seven-field ETDRS fundus images; G-OPTOS, grader assessment based on
ultra-wide field fundus images using OPTOS; O-ETDRS, ophthalmologist assessment based on seven-field ETDRS
fundus images; O-FTF, reference standard for PDR; O-OPTOS, ophthalmologist assessment based on ultra-wide field
fundus images using OPTOS.
a Grader referral for PDR = ‘active’ + ‘unsure’ + ‘ungradable’.
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TABLE 41 Secondary analyses on randomly selected eyes: all patients – SECA1A
Secondary analysis Reference standard
Diagnostic
parameter n/N Estimate (95% CI)
G-OCT identified active DMO
in randomly selected eye
O-FTF +OCT active DMO
in randomly selected eye
Sensitivity 116/133 87% (80% to 92%)
Specificity 174/253 69% (63% to 74%)
Positive likelihood
ratio
– 2.79 (2.30 to 3.39)
Negative likelihood
ratio
– 0.19 (0.12 to 0.29)
G-OPTOS identified active
PDR in randomly selected eye
O-FTF active PDR in
randomly selected eye
Sensitivity 45/81 56% (45% to 66%)
Specificity 262/300 87% (83% to 91%)
Positive likelihood
ratio
– 4.39 (3.07 to 6.26)
Negative likelihood
ratio
– 0.51 (0.40 to 0.65)
G-ETDRS identified active
PDR in randomly selected eye
O-FTF active PDR in
randomly selected eye
Sensitivity 45/75 60% (49% to 70%)
Specificity 251/295 85% (81% to 89%)
Positive likelihood
ratio
– 4.02 (2.89 to 5.59)
Negative likelihood
ratio
– 0.47 (0.35 to 0.62)
G-ETDRS, grader assessment based on seven-field ETDRS fundus images; G-OCT, grader assessment based on SD-OCT
images; G-OPTOS, grader assessment based on ultra-wide field fundus images using OPTOS.
TABLE 42 Secondary analyses at eye level: all patients
Secondary
analysis Results Reference standard
Diagnostic
parameter Eye n/N Estimate (95% CI)
SECA1B G-OCT central-
involving active
DMO at eye level
O-FTF +OCT
central-involving
active DMO at eye
level
Sensitivity Right 89/106 84% (76% to 90%)
Left 79/86 92% (84% to 96%)
Specificity Right 227/279 81% (76% to 85%)
Left 229/291 79% (74% to 83%)
Positive
likelihood ratio
Right – 4.50 (3.48 to 5.84)
Left – 4.31 (3.43 to 5.42)
Negative
likelihood ratio
Right – 0.20 (0.13 to 0.31)
Left – 0.10 (0.05 to 0.21)
SECA1C G-OPTOS referrala
for PDR at eye
level
ERS at eye level Sensitivity Right 68/116 59% (50% to 67%)
Left 79/117 68% (59% to 75%)
Specificity Right 199/262 76% (70% to 81%)
Left 205/256 80% (75% to 85%)
Positive
likelihood ratio
Right – 2.44 (1.87 to 3.17)
Left – 3.39 (2.57 to 4.47)
Negative
likelihood ratio
Right – 0.54 (0.43 to 0.68)
Left – 0.41 (0.31 to 0.53)
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TABLE 42 Secondary analyses at eye level: all patients (continued )
Secondary
analysis Results Reference standard
Diagnostic
parameter Eye n/N Estimate (95% CI)
G-ETDRS referral
for PDR at eye
level
ERS at eye level Sensitivity Right 77/115 67% (58% to 75%)
Left 78/111 70% (61% to 78%)
Specificity Right 199/261 76% (71% to 81%)
Left 188/251 75% (69% to 80%)
Positive
likelihood ratio
Right – 2.82 (2.19 to 3.63)
Left – 2.80 (2.19 to 3.58)
Negative
likelihood ratio
Right – 0.43 (0.33 to 0.57)
Left – 0.40 (0.30 to 0.53)
G-ETDRS, grader assessment based on seven-field ETDRS fundus images; G-OPTOS, grader assessment based on
ultra-wide field fundus images using OPTOS; O-FTF, reference standard for PDR; O-FTF+OCT, reference standard
for DMO.
a Grader referral for PDR = ‘active’ + ‘unsure’ + ‘ungradable’.















n (%) Total, n
First 150 patients 58 (39) 52 (35) 40 (27) 150 18 (12) 87 (58) 45 (30) 150
Until 1 February 2019a 140 (41) 106 (31) 99 (29) 345 64 (19) 167 (48) 114 (33) 345
Total eligible patients 152 (38) 120 (30) 125 (31) 397 111 (28) 170 (43) 116 (29) 397
a 1 February 2019 is the time at which we stopped recruiting patients who contribute only to the inactive DMO
and/or inactive PDR groups.
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Appendix 2 Dealing with a small number
of participants
Having n = 36 (for patients) is, on the face of things, disappointing. However, it would be wrong todismiss the results of the FG research on the basis of small numbers in a world in which even
n = 1 has been known to form the basis for discoveries of lasting significance.65 More importantly,
research in a range of disciplines has repeatedly suggested that the amount of information or data
gained from the recruitment of additional cases usually declines to zero as n increases (e.g. the number
of new species discovered in sequential river water samples). Accumulation curves can be constructed
to illustrate the process, as in Figures 17–20 (using unpublished data from studies with which the
report author was previously involved).
Figure 17 traces the number of perceived barriers to increasing physical exercise according to participants of
14 FGs. The context of the research related to the provision of a 16 km linear park that was redesigned and
refurbished for an area of urban deprivation. Barriers to increasing physical exercise mentioned by the FG
participants included lack of safety, the weather, sectarianism, pollution and so forth. Figure 18 shows the
number of activities that were considered suitable for the redesigned park; these included walking, cycling
and running. The sample comprised different community-based groups (e.g. older people, young mothers and
people with disabilities) who agreed to participate in FG discussions at the research location (14 FGs were
held with 113 individuals).66 Figure 17 shows that 82% (or 19/23 barriers) were identified by the first three
groups. (Groups tended to offer an average of 10 suggestions each.) Figure 18 indicates that it took just five
FGs to identify 82% (or 28/34) of suitable activities. Therefore, the data imply that a relatively small number
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FIGURE 18 Activities for a regenerated park.
DOI: 10.3310/hta25320 Health Technology Assessment 2021 Vol. 25 No. 32
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Lois et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
103
Similar accumulation patterns are evident from other studies in which other qualitative methods, and
other forms of sampling, have been used. For example, Figure 19 tracks the number of references to
different ‘causes’ of influenza, such as coughs, sneezes and cold weather, as identified in face-to-face
interviews by a sample of older GP patients in south Wales (n = 54). The sample was randomly selected
from GP lists and stratified according to flu immunisation status (accepted, refused, lapsed or not
offered) at time of interview.67 It shows that 70% of the presumed causes of flu were mentioned in the
first 15 conversational interviews; thereafter, there was a slow accumulation of additional information
up to interview 41, after which no new causes were identified.
Figure 20 shows the consequences (e.g. memory loss, depression and loss of job or speech) of traumatic
brain injury, as identified by 32 traumatic brain injury patients in south Wales. The sample, drawn from
an outpatient clinic list, was a purposive one stratified according to the severity of injury and the time
in months since the critical incident.68 Of the 55 ‘consequences’ mentioned, 50 (90%) were cited in the
first 12 interviews. After interview 24, no new information was obtained.
One implication of these graphs is that although findings from a small n might not be good for estimating
how observations are distributed according to gender, age, ethnicity or income group, the findings can
nevertheless carry a considerable information load. It is also worth keeping in mind that in the current
study, although the participants were self-selecting, they were drawn from five geographically dispersed
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FIGURE 20 Consequences of traumatic brain injury as identified in 32 interviews with traumatic brain injury outpatients.
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